AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
56_CD
Preparation_NOMZ
of_PIN
the_DT
Financial_NN
Statements_NOMZ
and_PHC
Directors_NN
Responsibilities_NOMZ
The_DT
Directors_NN
are_VPRT [BYPA]
required_VBN [SUAV]
by_PIN
UK_NN
company_NN
law_NN
to_TO
prepare_VB
for_PIN
each_QUAN
accounting_GER
period_NN
financial_JJ
statements_NOMZ
which_WDT [WHSUB]
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
the_DT
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Group_NN
and_CC
the_DT
Company_NN
as_IN
at_PIN
the_DT
end_NN
of_PIN
the_DT
accounting_GER
period_NN
and_CC
of_PIN
the_DT
profit_NN
or_CC
loss_NN
for_PIN
that_DEMO
period_NN
._.
In_PIN
preparing_VBG
the_DT
financial_JJ
statements_NOMZ
,_,
the_DT
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
select_VB
and_PHC
apply_VB
consistently_RB
suitable_JJ
accounting_GER
policies_NN
and_CC
make_VB
reasonable_JJ
and_PHC
prudent_JJ
judgements_NOMZ
and_PHC
estimates_NN
._.
Applicable_JJ
accounting_GER
standards_NN
also_RB
have_VPRT
to_TO
be_VB [PASS]
followed_VBN
and_CC
a_DT
statement_NOMZ
made_VBD
to_PIN
that_DEMO
effect_NN
in_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
subject_JJ
to_PIN
any_QUAN
material_NN
departures_NN
being_VBG [WZPRES] [PASS]
disclosed_VBN [PUBV]
and_PHC
explained_VBN [PUBV]
in_PIN
the_DT
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
The_DT
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
prepare_VB
the_DT
financial_JJ
statements_NOMZ
on_PIN
a_DT
going_VBG
concern_NN
basis_NN
unless_COND
it_PIT
is_VPRT [BEMA]
inappropriate_PRED
to_TO
presume_VB [PRIV]
that_THVC
the_DT
Group_NN
will_PRMD
continue_VB
in_PIN
business_NOMZ
._.
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
ensuring_VBG [SUAV] [PRIV]
proper_JJ
accounting_GER
records_NN
are_VPRT [PASS]
kept_VBN
which_WDT
disclose_VPRT [PUBV]
with_PIN
reasonable_JJ
accuracy_NN
at_PIN
any_QUAN
time_NN
the_DT
financial_JJ
position_NOMZ
of_PIN
the_DT
Company_NN
and_CC
enable_VB
them_TPP3
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
financial_JJ
statements_NOMZ
comply_VPRT
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
They_TPP3
are_VPRT [BEMA]
also_RB
responsible_PRED
for_PIN
taking_VBG
reasonable_JJ
steps_NN
to_TO
safeguard_VB
the_DT
assets_NN
of_PIN
the_DT
Company_NN
and_CC
prevent_VB
and_PHC
detect_VB
fraud_NN
and_CC
other_JJ
irregularities_NOMZ
._.
com_NN
57_CD
Independent_NN
Auditors_NN
Report_NN
to_PIN
the_DT
Members_NN
of_PIN
AstraZeneca_NN
PLC_NN
We_FPP1
have_VPRT [PEAS]
audited_VBN
the_DT
Financial_NN
Statements_NOMZ
on_PIN
We_FPP1
review_VPRT
whether_IN
the_DT
statement_NOMZ
on_PIN
page_NN
46_CD
Opinion_NN
pages_NN
58_CD
to_PIN
122_CD
._.
We_FPP1
have_VPRT [SPAU] [PEAS]
also_RB
audited_VBN
the_DT
reflects_VPRT [PRIV]
the_DT
Companys_NN
compliance_NN
with_PIN
the_DT
In_PIN
our_FPP1
opinion_NN
information_NOMZ
in_PIN
the_DT
Directors_NN
Remuneration_NOMZ
seven_CD
provisions_NN
of_PIN
the_DT
Combined_NN
Code_NN
Report_NN
that_DEMP
is_VPRT [PASS]
described_VBN
as_IN
having_VBG [PEAS]
been_VBN [PASS]
specified_VBN
for_PIN
our_FPP1
review_NN
by_PIN
the_DT
Listing_GER
Rules_NN
,_,
the_DT
Financial_NN
Statements_NOMZ
give_VB
a_DT
true_JJ
and_PHC
audited_JJ
._.
and_ANDC
we_FPP1
report_VPRT [PUBV]
if_COND
it_PIT
does_VPRT
not_XX0
._.
We_FPP1
are_VPRT [BEMA]
not_XX0
fair_JJ
view_NN
of_PIN
the_DT
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
required_VBN [SUAV]
to_TO
consider_VB [PRIV]
whether_IN [WHCL]
the_DT
Boards_NN
Company_NN
and_CC
the_DT
Group_NN
as_IN
at_PIN
This_DEMO
report_NN
is_VPRT [PASS]
made_VBN
solely_RB
to_PIN
the_DT
Companys_NN
statements_NOMZ
on_PIN
internal_JJ
control_NN
cover_VB
all_QUAN
risks_NN
31_CD
December_NN
2002_CD
and_CC
of_PIN
the_DT
profit_NN
of_PIN
members_NN
,_,
as_IN
a_DT
body_NN
,_,
in_PIN
accordance_NN
with_PIN
and_CC
controls_NN
,_,
or_CC
form_VB
an_DT
opinion_NN
on_PIN
the_DT
the_DT
Group_NN
for_PIN
the_DT
year_NN
then_RB
ended_VBD
:_:
and_ANDC
section_NOMZ
235_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Our_FPP1
effectiveness_NOMZ
of_PIN
the_DT
Groups_NN
corporate_JJ
governance_NN
procedures_NN
or_CC
its_PIT
risk_NN
and_CC
control_VB
the_DT
Financial_NN
Statements_NOMZ
and_CC
the_DT
part_NN
of_PIN
audit_NN
work_NN
has_VPRT [PEAS]
been_VBN [PASS]
undertaken_VBN
so_OSUB
that_NULL
we_FPP1
procedures_NN
._.
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
to_TO
be_VB
might_POMD
state_VB [PUBV]
to_PIN
the_DT
Companys_NN
members_NN
audited_VBN
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
properly_RB
prepared_VBN
in_PIN
those_DEMO
matters_NN
we_FPP1
are_VPRT [PASS]
required_VBN [SUAV]
to_PIN
state_NN
to_PIN
We_FPP1
read_VPRT
the_DT
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
them_TPP3
in_PIN
an_DT
auditors_NN
report_NN
and_CC
for_PIN
no_SYNE
other_JJ
the_DT
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_NN
,_,
including_VBG [PRESP]
1985_CD
._.
purpose_NN
._.
To_PIN
the_DT
fullest_JJ
extent_NN
permitted_VBN [WZPAST]
by_PIN
the_DT
corporate_JJ
governance_NN
statement_NOMZ
and_PHC
law_NN
,_,
we_FPP1
do_VPRT
not_XX0
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
consider_VB [PRIV]
whether_IN [WHCL]
it_PIT
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
responsibility_NOMZ
to_PIN
anyone_QUPR
other_JJ
than_PIN
the_DT
audited_JJ
Financial_NN
Statements_NOMZ
._.
We_FPP1
consider_VPRT [PRIV]
30_CD
January_NN
2003_CD
Company_NN
and_CC
the_DT
Companys_NN
members_NN
as_IN
a_DT
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
body_NN
,_,
for_PIN
our_FPP1
audit_NN
work_NN
,_,
for_PIN
this_DEMO
report_NN
,_,
or_CC
for_PIN
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
KPMG_NN
Audit_NN
Plc_NN
the_DT
opinions_NN
we_FPP1
have_VPRT [PEAS]
formed_VBN
._.
material_NN
inconsistencies_NN
with_PIN
the_DT
Financial_NN
Chartered_NN
Accountants_NN
Statements_NOMZ
._.
Registered_NN
Auditor_NN
Respective_NN
responsibilities_NOMZ
of_PIN
Directors_NN
8_CD
Salisbury_NN
Square_NN
and_PHC
Auditor_NN
Basis_NN
of_PIN
audit_NN
opinion_NN
London_NN
EC4Y_NN
8BB_NN
The_NN
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
We_FPP1
conducted_VBD
our_FPP1
audit_NN
in_PIN
accordance_NN
with_PIN
the_DT
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_NN
and_CC
the_DT
Auditing_GER
Standards_NN
issued_VBN [WZPAST]
by_PIN
the_DT
Auditing_GER
Directors_NN
Remuneration_NOMZ
Report_NN
._.
An_DT
audit_NN
includes_VPRT
The_DT
above_PLACE
opinion_NN
is_VPRT [PASS]
provided_VBN
in_PIN
compliance_NN
described_VBN [WZPAST]
on_PIN
page_NN
56_CD
this_DEMP
includes_VPRT
examination_NOMZ
,_,
on_PIN
a_DT
test_NN
basis_NN
,_,
of_PIN
evidence_NN
with_PIN
UK_NN
requirements_NOMZ
._.
An_DT
opinion_NN
complying_VBG [WZPRES]
responsibility_NOMZ
for_PIN
preparing_VBG
the_DT
Financial_NN
relevant_JJ
to_PIN
the_DT
amounts_NN
and_PHC
disclosures_NN
in_PIN
the_DT
with_PIN
auditing_GER
standards_NN
generally_RB
accepted_VBN [PRIV]
in_PIN
Statements_NOMZ
in_PIN
accordance_NN
with_PIN
applicable_JJ
UK_NN
law_NN
and_PHC
accounting_GER
standards_NN
:_:
the_DT
Directors_NN
Financial_NN
Statements_NOMZ
and_CC
the_DT
part_NN
of_PIN
the_DT
the_DT
US_FPP1
will_PRMD
be_VB [PASS]
included_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
have_VPRT [SPAU] [PEAS]
also_RB
presented_VBN
additional_JJ
information_NOMZ
Directors_NN
Remuneration_NOMZ
Report_NN
to_TO
be_VB [BEMA]
on_PIN
Form_NN
20-F_NN
filed_VBN [WZPAST]
with_PIN
the_DT
US_FPP1
Securities_NOMZ
and_CC
under_IN
US_FPP1
requirements_NOMZ
._.
It_PIT
also_RB
includes_VPRT
an_DT
assessment_NOMZ
of_PIN
the_DT
Exchange_NN
Commission_NN
._.
as_IN
independent_JJ
auditor_NN
,_,
are_VPRT [PASS]
established_VBN [PRIV]
in_PIN
the_DT
significant_JJ
estimates_NN
and_PHC
judgements_NOMZ
made_VBD
UK_NN
by_PIN
statute_NN
,_,
the_DT
Auditing_GER
Practices_NN
Board_NN
,_,
by_PIN
the_DT
Directors_NN
in_PIN
the_DT
preparation_NOMZ
of_PIN
the_DT
Generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
in_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Financial_NN
Statements_NOMZ
and_CC
of_PIN
whether_IN
the_DT
the_DT
UK_NN
vary_VPRT
in_PIN
certain_JJ
significant_JJ
respects_NN
Authority_NOMZ
,_,
and_ANDC
by_PIN
our_FPP1
professions_NN
ethical_JJ
accounting_GER
policies_NN
are_VPRT [BEMA]
appropriate_PRED
to_PIN
the_DT
from_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
guidance_NN
._.
Groups_NN
circumstances_NN
,_,
consistently_RB
applied_VBN
principles_NN
in_PIN
the_DT
US_FPP1
._.
Application_NOMZ
of_PIN
generally_RB
and_PHC
adequately_RB
disclosed_VBN [PUBV]
._.
accepted_VBN [PRIV]
accounting_GER
principles_NN
in_PIN
the_DT
US_FPP1
We_FPP1
report_VPRT [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
as_IN
to_PIN
whether_IN
would_PRMD
have_VB [PEAS]
affected_VBN
results_NN
of_PIN
operations_NOMZ
for_PIN
the_DT
Financial_NN
Statements_NOMZ
give_VB
a_DT
true_JJ
and_PHC
fair_JJ
We_FPP1
planned_VBD
and_PHC
performed_VBD
our_FPP1
audit_NN
so_RB
as_IN
to_PIN
each_QUAN
of_PIN
the_DT
years_NN
in_PIN
the_DT
three-year_JJ
period_NN
view_NN
and_ANDC
whether_IN
the_DT
Financial_NN
Statements_NOMZ
obtain_VB
all_QUAN
the_DT
information_NOMZ
and_PHC
explanations_NOMZ
ended_VBD
31_CD
December_NN
2002_CD
and_CC
consolidated_JJ
and_CC
the_DT
part_NN
of_PIN
the_DT
Directors_NN
Remuneration_NOMZ
which_WDT [WHOBJ]
we_FPP1
considered_VBD [PRIV]
necessary_JJ
in_PIN
order_NN
to_PIN
shareholders_NN
equity_NOMZ
at_PIN
31_CD
December_NN
2002_CD
Report_NN
to_TO
be_VB [PASS]
audited_VBN
have_VPRT [PEAS]
been_VBN [SPAU]
properly_RB
provide_VB
us_FPP1
with_PIN
sufficient_JJ
evidence_NN
to_TO
give_VB
and_CC
2001_CD
,_,
to_PIN
the_DT
extent_NN
summarised_VBN [WZPAST]
on_PIN
prepared_JJ
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
reasonable_JJ
assurance_NN
that_TOBJ
the_DT
Financial_NN
pages_NN
113_CD
to_PIN
122_CD
._.
We_FPP1
also_RB
report_VPRT [PUBV]
to_PIN
you_SPP2
if_COND
,_,
in_PIN
our_FPP1
Statements_NOMZ
and_CC
the_DT
part_NN
of_PIN
the_DT
Directors_NN
opinion_NN
,_,
the_DT
Directors_NN
Report_NN
is_VPRT
not_XX0
Remuneration_NOMZ
Report_NN
to_TO
be_VB [PASS]
audited_VBN
are_VPRT [BEMA]
free_JJ
consistent_JJ
with_PIN
the_DT
Financial_NN
Statements_NOMZ
,_,
if_COND
from_PIN
material_NN
misstatement_NOMZ
,_,
whether_IN
caused_VBN
the_DT
Company_NN
has_VPRT [PEAS]
not_XX0
kept_VBN
proper_JJ
accounting_GER
by_PIN
fraud_NN
or_CC
other_JJ
irregularity_NOMZ
or_CC
error_NN
._.
In_PIN
records_NN
,_,
if_COND
we_FPP1
have_VPRT [PEAS]
not_XX0
received_VBN
all_QUAN
the_DT
forming_VBG
our_FPP1
opinion_NN
we_FPP1
also_RB
evaluated_VBD
the_DT
information_NOMZ
and_PHC
explanations_NOMZ
we_FPP1
require_VPRT [SUAV]
for_PIN
overall_JJ
adequacy_NN
of_PIN
the_DT
presentation_NOMZ
of_PIN
our_FPP1
audit_NN
,_,
or_CC
if_COND
information_NOMZ
specified_VBN [WZPAST]
by_PIN
law_NN
information_NOMZ
in_PIN
the_DT
Financial_NN
Statements_NOMZ
and_CC
regarding_VBG
Directors_NN
remuneration_NOMZ
and_CC
the_DT
part_NN
of_PIN
the_DT
Directors_NN
Remuneration_NOMZ
transactions_NOMZ
with_PIN
the_DT
Group_NN
is_VPRT [PASS]
not_XX0
disclosed_VBN [PUBV]
._.
com_NN
58_CD
Group_NN
Profit_NN
and_PHC
Loss_NN
Account_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
Continuing_GER
Exceptional_NN
2002_CD
operations_NOMZ
items_NN
Total_JJ
Notes_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Turnover_NN
:_:
Group_NN
and_PHC
share_NN
of_PIN
joint_JJ
ventures_NN
18,032_CD
18,032_CD
Less_RB
:_:
Share_NN
of_PIN
joint_JJ
venture_NN
turnover_NN
191_CD
191_CD
Group_NN
turnover_NN
3_CD
17,841_CD
17,841_CD
Operating_GER
costs_NN
3_CD
13,728_CD
350_CD
14,078_CD
Other_JJ
operating_GER
income_NN
3_CD
243_CD
243_CD
Group_NN
operating_GER
profit_NN
3_CD
4,356_CD
350_CD
4,006_CD
Share_NN
of_PIN
operating_VBG
loss_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
4_CD
Profits_NN
less_RB
losses_NN
on_PIN
sale_NN
,_,
closure_NN
,_,
or_CC
demerger_NN
of_PIN
operations_NOMZ
5_CD
Profits_NN
on_PIN
sale_NN
of_PIN
fixed_JJ
assets_NN
5_CD
Dividend_NN
income_NN
1_CD
1_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
interest_NN
4,357_CD
350_CD
4,007_CD
Net_JJ
interest_NN
630_CD
30_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
4,387_CD
350_CD
4,037_CD
Taxation_NOMZ
7_CD
1,177_CD
1,177_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
3,210_CD
350_CD
2,860_CD
Attributable_JJ
to_PIN
minorities_NOMZ
24_CD
24_CD
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
3,186_CD
350_CD
2,836_CD
Dividends_NN
to_PIN
shareholders_NN
Cash_NN
8_CD
1,206_CD
Dividend_NN
in_PIN
specie_NN
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
8_CD
Profit_NN
loss_NN
retained_VBN [WZPAST]
for_PIN
the_DT
financial_JJ
year_NN
1,630_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
9_CD
$_$
1.84_CD
$_$
1.84_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
basic_JJ
9_CD
$_$
1.84_CD
$_$
0.20_CD
$_$
1.64_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
diluted_VBD
9_CD
$_$
1.84_CD
$_$
0.20_CD
$_$
1.64_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
9_CD
1,733_CD
Group_NN
Statement_NOMZ
of_PIN
Total_NN
Recognised_NN
Gains_NN
and_PHC
Losses_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
Notes_NN
$_$
m_CD [BEMA]
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
2,836_CD
Exchange_NN
adjustments_NOMZ
on_PIN
net_JJ
assets_NN
22_CD
1,106_CD
Translation_NOMZ
differences_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
22_CD
6_CD
Tax_NN
on_PIN
translation_NOMZ
differences_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
22_CD
2_CD
Total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
financial_JJ
year_NN
3,946_CD
Prior_RB
year_NN
adjustment_NOMZ
page_NN
62_CD
200_CD
Total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
since_OSUB
the_DT
last_JJ
annual_JJ
report_NN
3,746_CD
$_$
m_JJ
means_NN
millions_NN
of_PIN
US_FPP1
dollars_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
60_CD
Group_NN
Balance_NN
Sheet_NN
at_PIN
31_CD
December_NN
2002_CD
2001_CD
restated_VBN
Notes_NN
$_$
m_CD
$_$
m_CD [PASS]
Fixed_VBN
assets_NN
Tangible_JJ
fixed_VBN
assets_NN
11_CD
6,597_CD
5,409_CD
Goodwill_NN
and_CC
intangible_JJ
assets_NN
12_CD
2,807_CD
2,700_CD
Fixed_VBN
asset_NN
investments_NOMZ
13_CD
46_CD
23_CD
9,450_CD
8,132_CD
Current_JJ
assets_NN
Stocks_NN
14_CD
2,593_CD
2,402_CD
Debtors_NN
15_CD
4,845_CD
4,139_CD
Short_JJ
term_NN
investments_NOMZ
16_CD
3,962_CD
3,118_CD
Cash_NN
30 726 705_CD
12,126_CD
10,364_CD
Total_JJ
assets_NN
21,576_CD
18,496_CD
Creditors_NN
due_JJ
within_PIN
one_CD
year_NN
Short_JJ
term_NN
borrowings_GER
17 202 214_CD
Current_JJ
instalments_NOMZ
of_PIN
loans_NN
19 314 107_CD
Other_JJ
creditors_NN
18_CD
7,699_CD
6,159_CD
8,215_CD
6,480_CD
Net_JJ
current_JJ
assets_NN
3,911_CD
3,884_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
13,361_CD
12,016_CD
Creditors_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Loans_NN
19 328 635_CD
Other_JJ
creditors_NN
18 34 152 362_CD
787_CD
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
21_CD
1,773_CD
1,600_CD
Net_JJ
assets_NN
11,226_CD
9,629_CD
Capital_NN
and_PHC
reserves_NN
Called-up_JJ
share_NN
capital_NN
38 429 436_CD
Share_NN
premium_NN
account_NN
23 403 334_CD
Capital_NN
redemption_NOMZ
reserve_NN
23_CD
16_CD
9_CD
Merger_NN
reserve_NN
23 433 433_CD
Other_JJ
reserves_NN
23_CD
1,440_CD
1,470_CD
Profit_NN
and_PHC
loss_NN
account_NN
23_CD
8,451_CD
6,904_CD
Shareholders_NN
funds_NN
equity_NOMZ
interests_NN
22_CD
11,172_CD
9,586_CD
Minority_NOMZ
equity_NOMZ
interests_NN
54_CD
43_CD
Shareholders_NN
funds_NN
and_PHC
minority_NOMZ
interests_NN
11,226_CD
9,629_CD
The_DT
Financial_NN
Statements_NOMZ
on_PIN
pages_NN
58_CD
to_PIN
122_CD
were_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
on_PIN
30_CD
January_NN
2003_CD
and_CC
were_VBD [PASS]
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
Sir_NN
Tom_NN
McKillop_NN
Jonathan_NN
Symonds_NN
Director_NN
Director_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
61_CD
Statement_NOMZ
of_PIN
Group_NN
Cash_NN
Flow_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002 2001 2000_CD
Notes_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cash_NN
flow_NN
from_PIN
operating_VBG
activities_NOMZ
Net_JJ
cash_NN
inflow_NN
from_PIN
trading_GER
operations_NOMZ
24_CD
5,686_CD
4,130_CD
4,992_CD
Outflow_NN
related_VBN [WZPAST]
to_PIN
exceptional_JJ
items_NN
25 93 368 809_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
5,593_CD
3,762_CD
4,183_CD
Dividends_NN
received_VBN [WZPAST]
from_PIN
joint_JJ
ventures_NN
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
Interest_NN
received_VBD
142 232 180_CD
Interest_NN
paid_VBN
96_CD
84_CD
145_CD
Dividends_NN
received_VBD
8_CD
Dividends_NN
paid_VBN [WZPAST]
by_PIN
subsidiaries_NN
to_PIN
minority_NOMZ
interests_NN
11_CD
16_CD
35_CD
156_CD
19_CD
Tax_NN
paid_VBD
795 792 648_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
Cash_NN
expenditure_NN
on_PIN
tangible_JJ
fixed_JJ
assets_NN
11_CD
1,340_CD
1,385_CD
1,347_CD
Cash_NN
expenditure_NN
on_PIN
intangible_JJ
assets_NN
and_PHC
goodwill_NN
268 197 113_CD
Cash_NN
expenditure_NN
on_PIN
fixed_JJ
asset_NN
investments_NOMZ
1_CD
5_CD
3_CD
Disposals_NN
of_PIN
fixed_JJ
assets_NN
66_CD
44_CD
37_CD
1,543_CD
1,543_CD
1,426_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
Acquisitions_NOMZ
of_PIN
subsidiaries_NN
and_PHC
purchases_NN
of_PIN
minority_NOMZ
interests_NN
26_CD
44_CD
167_CD
Net_JJ
repayment_NOMZ
of_PIN
debt_NN
by_PIN
Zeneca_NN
Agrochemicals_NN
27_CD
909_CD
Disposals_NN
of_PIN
business_NOMZ
operations_NOMZ
28_CD
Disposals_NN
of_PIN
investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
2_CD
44_CD
740_CD
Equity_NOMZ
dividends_NN
paid_VBD
to_PIN
Shareholders_NN
1,234_CD
1,236_CD
1,220_CD
Net_JJ
cash_NN
inflow_NN
before_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
30_CD
2,056_CD
303_CD
1,648_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
Movement_NOMZ
in_PIN
short_JJ
term_NN
investments_NOMZ
and_CC
fixed_VBN
deposits_NN
net_JJ
806 260 608_CD
Financing_GER
31_CD
118_CD
35_CD
66_CD
Net_JJ
share_NN
re-purchases_VPRT
1,154_CD
994_CD
334_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
in_PIN
the_DT
year_NN
29 22 396 640_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
62_CD
Basis_NN
of_PIN
Consolidation_NOMZ
and_PHC
Presentation_NOMZ
of_PIN
Financial_NN
Information_NOMZ
The_NN
preparation_NOMZ
of_PIN
the_DT
Financial_NN
Statements_NOMZ
in_PIN
have_VPRT [PEAS]
fallen_VBN
from_PIN
$_$
1.77_CD
to_TO
$_$
1.73_CD
2000_CD
$_$
1.76_CD
conformity_NOMZ
with_PIN
generally_RB
accepted_VBN [PRIV]
to_TO
$_$
1.62_CD
._.
Comparative_JJ
periods_NN
have_VPRT [PEAS]
been_VBN
accounting_VBG
principles_NN
requires_VPRT [SUAV] [THATD]
management_NOMZ
restated_VBN
._.
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
assets_NN
and_ANDC
In_CONJ
addition_NULL
,_,
the_DT
following_VBG
new_JJ
accounting_GER
liabilities_NOMZ
and_PHC
disclosure_NN
of_PIN
contingent_JJ
assets_NN
standard_NN
had_VBD [PEAS]
been_VBN [PASS]
issued_VBN
but_CC
has_VPRT
not_XX0
yet_RB
and_CC
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
the_DT
Financial_NN
been_VBN [WZPAST] [SPAU] [PASS]
fully_AMP
adopted_VBN
:_:
Statements_NOMZ
and_CC
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
UK_NN
Financial_NN
Reporting_GER
Standard_NN
17_CD
FRS_NN
17_CD
period_NN
._.
Actual_JJ
results_NN
could_POMD
differ_VB
from_PIN
those_DEMO
Retirement_NOMZ
Benefits_NN
becomes_VPRT
fully_AMP
estimates_NN
._.
effective_JJ
for_PIN
accounting_GER
periods_NN
beginning_VBG [WZPRES]
on_PIN
or_CC
after_IN
1_CD
January_NN
2005_CD
,_,
with_PIN
increasing_VBG
levels_NN
As_IN
part_NN
of_PIN
AstraZenecas_NN
objective_NN
to_TO
align_VB
of_PIN
disclosure_NN
required_VBN [SUAV] [WZPAST]
for_PIN
each_QUAN
accounting_GER
with_PIN
accounting_GER
best_JJ
practice_NN
,_,
cash_NN
period_NN
ending_VBG [WZPRES]
on_PIN
or_CC
after_IN
22_CD
June_NN
2001_CD
._.
It_PIT
discounts_VPRT
arising_VBG
from_PIN
prompt_JJ
payment_NOMZ
of_PIN
sets_NN
out_PIN
the_DT
requirements_NOMZ
for_PIN
accounting_GER
for_PIN
invoices_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
from_PIN
cost_NN
of_PIN
retirement_NOMZ
benefits_NN
,_,
including_VBG [PRESP]
the_DT
fair_JJ
value_NN
of_PIN
sales_NN
to_PIN
sales_NN
._.
Comparatives_NN
have_VPRT [SPAU] [PEAS]
also_RB
been_VBN
assets_NN
and_PHC
liabilities_NOMZ
arising_VBG [WZPRES]
from_PIN
employers_NN
reclassified_VBN [WZPAST]
for_PIN
consistency_NN
of_PIN
presentation_NOMZ
._.
obligations_NOMZ
,_,
the_DT
treatment_NOMZ
of_PIN
related_JJ
costs_NN
and_CC
Both_DT
sales_NN
and_PHC
cost_NN
of_PIN
sales_NN
have_VPRT [PEAS]
been_VBN
level_NN
of_PIN
disclosure_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
adopted_VBN
reduced_VBN
by_PIN
$_$
287m_CD
in_PIN
the_DT
current_JJ
year_NN
2001_CD
FRS_NN
17_CD
to_PIN
the_DT
extent_NN
of_PIN
the_DT
mandated_VBN
disclosure_NN
requirements_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
$_$
258m_CD
,_,
2000_CD
$_$
221m_CD
._.
The_DT
change_NN
has_VPRT
31_CD
December_NN
2002_CD
and_CC
these_DEMP
are_VPRT [PASS]
included_VBN
in_PIN
minimal_JJ
impact_NN
on_PIN
previously_TIME
stated_VBN [PUBV] [THATD]
sales_NN
Note_VPRT [PRIV]
32_CD
to_PIN
the_DT
Financial_NN
Statements_NOMZ
._.
Furthermore_CONJ
,_,
neither_SYNE
profits_NN
nor_SYNE
net_JJ
assets_NN
have_VPRT [PEAS]
been_VBN [PASS]
affected_VBN
._.
Discontinued_VBN
operations_NOMZ
Following_VBG [WZPRES]
the_DT
demerger_NN
of_PIN
the_DT
Zeneca_NN
Agrochemicals_NN
business_NOMZ
on_PIN
13_CD
November_NN
2000_CD
and_CC
its_PIT
subsequent_JJ
merger_NN
with_PIN
Novartis_NN
agribusiness_NOMZ
to_TO
form_VB
Syngenta_NN
AG_NN
,_,
Zeneca_NN
Agrochemicals_NN
results_NN
have_VPRT [PEAS]
been_VBN [PASS]
reported_VBN [PUBV]
as_IN
discontinued_VBN
operations_NOMZ
._.
New_NN
accounting_GER
standards_NN
The_DT
following_JJ
new_JJ
accounting_GER
standard_NN
was_VBD [PASS]
adopted_VBN
during_PIN
the_DT
year_NN
:_:
UK_NN
Financial_NN
Reporting_GER
Standard_NN
19_CD
FRS_NN
19_CD
Deferred_NN
Tax_NN
is_VPRT [BEMA]
applicable_PRED
for_PIN
accounting_GER
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
after_IN
23_CD
January_NN
2002_CD
._.
It_PIT
requires_VPRT [SUAV]
full_JJ
provision_NN
to_TO
be_VB [PASS]
made_VBN
for_PIN
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
arising_VBG [WZPRES]
from_PIN
timing_VBG
differences_NN
between_PIN
the_DT
recognition_NOMZ
of_PIN
gains_NN
and_PHC
losses_NN
in_PIN
the_DT
Financial_NN
Statements_NOMZ
and_CC
their_TPP3
recognition_NOMZ
in_PIN
a_DT
tax_NN
computation_NOMZ
except_PIN
for_PIN
certain_JJ
exemptions_NOMZ
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
standard_NN
._.
The_DT
impact_NN
of_PIN
adoption_NOMZ
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
has_VPRT [PEAS]
been_VBN
to_TO
reduce_VB
net_JJ
profit_NN
by_PIN
$_$
19m_CD
._.
Compliance_NN
with_PIN
FRS_NN
19_CD
at_PIN
31_CD
December_NN
2001_CD
reduced_VBD
net_JJ
assets_NN
by_PIN
$_$
193m_CD
,_,
being_VBG [PRESP] [BEMA]
an_DT
increase_NN
in_PIN
assets_NN
of_PIN
$_$
511m_CD
and_CC
an_DT
increase_NN
in_PIN
liabilities_NOMZ
of_PIN
$_$
704m_CD
._.
The_DT
net_JJ
profit_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2001_CD
decreased_VBN
by_PIN
$_$
61m_CD
2000_CD
$_$
261m_CD
,_,
resulting_VBG [PRESP]
in_PIN
an_DT
effective_JJ
tax_NN
rate_NN
of_PIN
28.5_CD
%_NN
2000_CD
40.6_CD
%_NN
compared_VBN [WZPAST]
with_PIN
the_DT
previously_TIME
reported_VBN [PUBV]
27_CD
%_NN
2000_CD
33.8_CD
%_NN
._.
The_DT
adjustments_NOMZ
did_VBD
not_XX0
change_VB
the_DT
tax_NN
effects_NN
on_PIN
exceptional_JJ
items_NN
._.
Basic_JJ
earnings_GER
per_PIN
share_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2001_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
from_PIN
$_$
1.69_CD
to_TO
$_$
1.65_CD
2000_CD
$_$
1.44_CD
to_TO
$_$
1.30_CD
whilst_OSUB
earnings_GER
per_PIN
share_NN
before_IN
exceptional_JJ
items_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
63_CD
Accounting_GER
Policies_NN
Basis_NN
of_PIN
accounting_VBG
up_RP
to_TO
and_CC
including_VBG
1997_CD
was_VBD
to_TO
eliminate_VB
ventures_NN
and_PHC
associates_NN
together_RB
with_PIN
those_DEMO
The_DT
Financial_NN
Statements_NOMZ
are_VPRT [PASS]
prepared_VBN
under_IN
goodwill_NN
arising_VBG [WZPRES]
upon_PIN
acquisitions_NOMZ
against_PIN
on_PIN
relevant_JJ
foreign_JJ
currency_NN
loans_NN
are_VPRT [PASS]
taken_VBN
the_DT
historical_JJ
cost_NN
convention_NOMZ
,_,
modified_VBN [PASTP]
to_PIN
reserves_NN
._.
Such_JJ
goodwill_NN
will_PRMD
remain_VB
eliminated_VBN
directly_RB
to_PIN
reserves_NN
via_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
include_VPRT
the_DT
revaluation_NOMZ
to_PIN
market_NN
value_NN
of_PIN
against_PIN
reserves_NN
until_IN
disposal_NN
or_CC
termination_NOMZ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
certain_JJ
current_JJ
asset_NN
investments_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
of_PIN
the_DT
previously_TIME
acquired_VBN
business_NOMZ
including_VBG [WZPRES]
Group_NN
subsidiaries_NN
as_IN
described_VBN
below_PLACE
,_,
in_PIN
the_DT
planned_VBN
disposal_NN
or_CC
termination_NOMZ
when_RB
Taxation_NOMZ
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
there_EX
are_VPRT
indications_NOMZ
that_TOBJ
the_DT
value_NN
of_PIN
the_DT
The_DT
charge_NN
for_PIN
taxation_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
profits_NN
and_PHC
UK_NN
generally_RB
accepted_VBD [PRIV]
accounting_GER
goodwill_NN
has_VPRT [PEAS]
been_VBN [SPAU] [PASS]
permanently_RB
impaired_VBN
,_,
for_PIN
the_DT
year_NN
and_CC
takes_VPRT
into_PIN
account_NN
taxation_NOMZ
principles_NN
UK_NN
GAAP_NN
._.
Where_RB
there_EX
are_VPRT
when_RB
the_DT
profit_NN
or_CC
loss_NN
on_PIN
disposal_NN
or_CC
deferred_VBN
because_CAUS
of_PIN
timing_NN
differences_NN
significant_JJ
differences_NN
to_PIN
US_FPP1
GAAP_NN
these_DEMO
termination_NOMZ
will_PRMD
be_VB [PASS]
calculated_VBN [PRIV]
after_IN
charging_VBG
between_PIN
the_DT
treatment_NOMZ
of_PIN
certain_JJ
items_NN
for_PIN
have_VPRT [PEAS]
been_VBN [PASS]
described_VBN
in_PIN
the_DT
US_FPP1
GAAP_NN
section_NOMZ
the_DT
gross_JJ
amount_NN
,_,
at_PIN
current_JJ
exchange_NN
rates_NN
,_,
taxation_NOMZ
and_CC
for_PIN
accounting_GER
purposes_NN
._.
The_DT
following_GER
of_PIN
any_QUAN
such_JJ
goodwill_NN
._.
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
the_DT
tax_NN
effects_NN
of_PIN
these_DEMO
paragraphs_NN
describe_VPRT
the_DT
main_JJ
accounting_GER
differences_NN
._.
No_SYNE
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
policies_NN
under_IN
UK_NN
GAAP_NN
._.
The_DT
accounting_GER
Post-retirement_NOMZ
benefits_NN
unremitted_JJ
earnings_GER
of_PIN
foreign_JJ
subsidiaries_NN
policies_NN
of_PIN
some_QUAN
overseas_PLACE
subsidiaries_NN
and_CC
The_DT
pension_NN
costs_NN
relating_VBG [WZPRES]
to_PIN
UK_NN
retirement_NOMZ
where_RB
there_EX
is_VPRT
no_SYNE
commitment_NOMZ
to_TO
remit_VB
such_JJ
associated_VBN
undertakings_GER
do_VPRT
not_XX0
conform_VB
with_PIN
plans_NN
are_VPRT [PASS]
assessed_VBN
in_PIN
accordance_NN
with_PIN
the_DT
earnings_GER
,_,
nor_SYNE
is_VPRT [PASS]
provision_NN
made_VBN [WZPAST]
for_PIN
rolled_VBN
over_IN
UK_NN
GAAP_NN
and_CC
,_,
where_RB
appropriate_JJ
,_,
advice_NN
of_PIN
independent_JJ
qualified_JJ
actuaries_NN
._.
The_DT
deferred_JJ
tax_NN
balances_NN
are_VPRT
adjustments_NOMZ
are_VPRT [PASS]
made_VBN
on_PIN
consolidation_NOMZ
in_PIN
amounts_NN
so_EMPH
determined_JJ
include_VPRT
the_DT
regular_JJ
not_XX0
discounted_VBN
._.
order_NN
to_TO
present_VB
the_DT
Group_NN
Financial_NN
cost_NN
of_PIN
providing_VBG
the_DT
benefits_NN
under_IN
the_DT
plans_NN
Statements_NOMZ
on_PIN
a_DT
consistent_JJ
basis_NN
._.
which_WDT [SERE]
it_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
should_NEMD
remain_VB
as_IN
a_DT
level_NN
Fixed_VBN
assets_NN
,_,
depreciation_NOMZ
and_PHC
percentage_NN
of_PIN
current_JJ
and_PHC
expected_JJ
future_JJ
amortisation_NOMZ
On_PIN
13_CD
November_NN
2000_CD
,_,
AstraZeneca_NN
earnings_GER
of_PIN
the_DT
employees_NN
covered_VBN
under_IN
the_DT
AstraZenecas_NN
policy_NN
is_VPRT
to_TO
write_VB [PUBV]
off_PIN
the_DT
demerged_JJ
Zeneca_NN
Agrochemicals_NN
,_,
which_WDT [SERE]
plans_VPRT
._.
Variations_NOMZ
from_PIN
the_DT
regular_JJ
pension_NN
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
each_QUAN
tangible_JJ
was_VBD [PASS]
merged_VBN
with_PIN
the_DT
Novartis_NN
agribusiness_NOMZ
to_PIN
cost_NN
are_VPRT [PASS]
spread_VBN
on_PIN
a_DT
systematic_JJ
basis_NN
over_IN
fixed_JJ
asset_NN
and_CC
its_PIT
residual_JJ
value_NN
evenly_RB
over_IN
form_NN
Syngenta_NN
AG_NN
._.
The_DT
impact_NN
of_PIN
the_DT
the_DT
estimated_VBN [PRIV]
average_JJ
remaining_VBG
service_NN
lives_VPRT
its_PIT
estimated_VBN [PRIV]
remaining_VBG
life_NN
._.
Reviews_NN
are_VPRT
demerger_NN
on_PIN
the_DT
AstraZeneca_NN
Financial_NN
of_PIN
current_JJ
employees_NN
in_PIN
the_DT
plans_NN
._.
Retirement_NOMZ
made_VBD
periodically_RB
of_PIN
the_DT
estimated_VBN [PRIV]
remaining_VBG
Statements_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
plans_NN
of_PIN
non-UK_JJ
subsidiaries_NN
are_VPRT [PASS]
accounted_VBN
lives_NN
of_PIN
individual_JJ
productive_JJ
assets_NN
,_,
taking_VBG [PRESP]
2000_CD
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
Note_NN
27_CD
._.
for_PIN
in_PIN
accordance_NN
with_PIN
local_JJ
conditions_NOMZ
and_PHC
account_NN
of_PIN
commercial_JJ
and_PHC
technological_JJ
practice_NN
._.
With_PIN
minor_JJ
exceptions_NOMZ
,_,
these_DEMO
obsolescence_NN
as_RB
well_RB
as_IN
normal_JJ
wear_NN
and_CC
Critical_JJ
accounting_GER
policies_NN
subsidiaries_NN
recognize_VPRT [PRIV]
the_DT
expected_VBN [PRIV]
cost_NN
of_PIN
tear_VB
._.
Under_IN
this_DEMO
policy_NN
it_PIT
becomes_VPRT
AstraZenecas_NN
management_NOMZ
considers_VPRT [PRIV]
the_DT
providing_VBG
pensions_NN
on_PIN
a_DT
systematic_JJ
basis_NN
impracticable_JJ
to_TO
calculate_VB [PRIV] [THATD]
average_JJ
asset_NN
lives_VPRT
following_VBG
to_TO
be_VB [BEMA]
the_DT
most_EMPH
important_JJ
over_IN
the_DT
average_JJ
remaining_VBG
service_NN
lives_NN
of_PIN
exactly_RB
._.
However_CONJ
,_,
the_DT
total_JJ
lives_NN
range_VPRT
from_PIN
accounting_VBG
policies_NN
in_PIN
the_DT
context_NN
of_PIN
the_DT
employees_NN
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
approximately_RB
13_CD
to_PIN
50_CD
years_NN
for_PIN
buildings_GER
,_,
Groups_NN
operations_NOMZ
._.
The_DT
impact_NN
of_PIN
these_DEMO
independent_JJ
qualified_JJ
actuaries_NN
._.
The_DT
costs_NN
of_PIN
and_CC
3_CD
to_PIN
15_CD
years_NN
for_PIN
plant_NN
and_PHC
equipment_NOMZ
._.
policies_NN
and_PHC
management_NOMZ
judgements_NOMZ
made_VBD
providing_VBG
post-retirement_JJ
benefits_NN
other_JJ
than_PIN
Intangible_JJ
assets_NN
,_,
including_VBG
patents_NN
acquired_VBN
,_,
when_RB
applying_VBG
them_TPP3
are_VPRT [PASS]
discussed_VBN
in_PIN
the_DT
pensions_NN
,_,
principally_RB
healthcare_NN
,_,
are_VPRT [PASS]
charged_VBN
are_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
their_TPP3
Financial_JJ
Review_NN
._.
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
a_DT
consistent_JJ
estimated_VBN [PRIV]
useful_JJ
lives_NN
generally_RB
not_XX0
basis_NN
over_IN
the_DT
average_JJ
service_NN
lives_NN
of_PIN
exceeding_VBG
20_CD
years_NN
,_,
in_PIN
line_NN
with_PIN
the_DT
benefits_NN
Turnover_NN
employees_NN
._.
Such_JJ
costs_NN
are_VPRT [PASS]
assessed_VBN
in_PIN
accruing_VBG
._.
If_COND
related_JJ
products_NN
fail_VPRT
,_,
the_DT
Turnover_NN
excludes_VPRT
intercompany_NN
turnover_NN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
independent_JJ
remaining_VBG
unamortised_JJ
amounts_NN
are_VPRT
and_PHC
value_VPRT
added_VBN [PUBV]
taxes_NN
and_CC
represents_VPRT
net_JJ
qualified_VBN
actuaries_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
adopted_VBN
immediately_TIME
written_VBN [PUBV]
off_PIN
to_PIN
revenue_NN
expense_NN
._.
invoice_NN
value_NN
less_RB
estimated_JJ
rebates_NN
,_,
returns_VPRT
the_DT
disclosure_NN
requirements_NOMZ
of_PIN
FRS_NN
17_CD
._.
Finance_NN
costs_NN
and_CC
internally_RB
developed_VBN
and_CC
settlement_NOMZ
discounts_NN
._.
Revenue_NN
is_VPRT [BEMA]
intangible_JJ
assets_NN
are_VPRT [PASS]
not_XX0
capitalized_VBN
._.
All_QUAN
fixed_VBN
recognized_VBN [PRIV]
at_PIN
the_DT
point_NN
at_PIN
which_WDT [PIRE]
title_NN
passes_VPRT
._.
Other_JJ
accounting_GER
policies_NN
assets_NN
are_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
when_RB
there_EX
are_VPRT
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
value_NN
Research_NN
and_PHC
development_NOMZ
Foreign_JJ
currencies_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
Research_NN
and_PHC
development_NOMZ
expenditure_NN
is_VPRT
Profit_NN
and_PHC
loss_NN
accounts_NN
in_PIN
foreign_JJ
currencies_NN
charged_VBN
to_TO
profit_VB
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT
are_VPRT [PASS]
translated_VBN
into_PIN
US_FPP1
dollars_NN
at_PIN
average_JJ
rates_NN
Leases_VPRT
incurred_VBN
._.
for_PIN
the_DT
relevant_JJ
accounting_GER
periods_NN
._.
Assets_NN
Assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
are_VPRT
and_CC
liabilities_NOMZ
are_VPRT [PASS]
translated_VBN
at_PIN
exchange_NN
rates_NN
capitalized_VBN
and_PHC
included_VBN
in_PIN
tangible_JJ
fixed_VBN
Goodwill_NN
prevailing_VBG [WZPRES]
at_PIN
the_DT
date_NN
of_PIN
the_DT
Group_NN
balance_NN
assets_NN
at_PIN
fair_JJ
value_NN
._.
Each_QUAN
asset_NN
is_VPRT [PASS]
depreciated_VBN
On_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
fair_JJ
values_NN
sheet_NN
._.
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
lease_NN
term_NN
or_CC
its_PIT
useful_JJ
are_VPRT [PASS]
attributed_VBN
to_PIN
the_DT
net_JJ
assets_NN
acquired_VBN
._.
The_DT
obligations_NOMZ
related_VBN
to_TO
finance_VB
leases_NN
,_,
Goodwill_NN
arises_VPRT
where_RB
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Exchange_NN
gains_NN
and_PHC
losses_NN
on_PIN
short_JJ
term_NN
net_NN
of_PIN
finance_NN
charges_NN
in_PIN
respect_NN
of_PIN
future_JJ
consideration_NOMZ
given_VBN [WZPAST]
for_PIN
a_DT
business_NOMZ
exceeds_VPRT
foreign_JJ
currency_NN
borrowings_GER
and_PHC
deposits_NN
are_VPRT
periods_NN
,_,
are_VPRT [PASS]
included_VBN
,_,
as_IN
appropriate_JJ
,_,
the_DT
fair_JJ
value_NN
of_PIN
such_JJ
net_JJ
assets_NN
._.
Goodwill_NN
included_VBD
within_PIN
net_JJ
interest_NN
payable_JJ
._.
under_IN
creditors_NN
due_JJ
within_PIN [STPR]
,_,
or_CC
creditors_NN
due_RB
arising_VBG
on_PIN
acquisitions_NOMZ
since_OSUB
1998_CD
is_VPRT
Exchange_NN
differences_NN
on_PIN
all_QUAN
other_JJ
after_IN
,_,
one_CD
year_NN
._.
The_DT
interest_NN
element_NOMZ
of_PIN
the_DT
capitalized_JJ
and_PHC
amortised_JJ
over_IN
its_PIT
estimated_JJ
transactions_NOMZ
,_,
except_PIN
relevant_JJ
foreign_JJ
currency_NN
rental_JJ
obligation_NOMZ
is_VPRT [PASS]
allocated_VBN
to_TO
accounting_VBG
useful_JJ
life_NN
generally_RB
not_XX0
exceeding_VBG
20_CD
years_NN
._.
loans_NN
,_,
are_VPRT [PASS]
taken_VBN
to_TO
operating_VBG
profit_NN
._.
In_PIN
the_DT
periods_NN
during_PIN
the_DT
lease_NN
term_NN
to_TO
reflect_VB [PRIV] [THATD]
a_DT
Goodwill_NN
is_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
when_RB
consolidated_JJ
Financial_NN
Statements_NOMZ
exchange_NN
constant_JJ
rate_NN
of_PIN
interest_NN
on_PIN
the_DT
remaining_VBG
there_EX
are_VPRT
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
value_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
consolidation_NOMZ
of_PIN
the_DT
net_JJ
balance_NN
of_PIN
the_DT
obligation_NOMZ
for_PIN
each_QUAN
accounting_GER
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
The_DT
Groups_NN
policy_NN
investments_NOMZ
in_PIN
overseas_PLACE
subsidiaries_NN
,_,
joint_JJ
period_NN
._.
Rentals_NN
under_IN
operating_VBG
leases_NN
are_VPRT
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
64_CD
Accounting_GER
Policies_NN
continued_VBD
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
AstraZeneca_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
environmental_JJ
incurred_VBN
._.
liabilities_NOMZ
relating_VBG [WZPRES]
to_PIN
its_PIT
past_JJ
operations_NOMZ
,_,
principally_RB
in_PIN
respect_NN
of_PIN
soil_NN
and_PHC
groundwater_NN
Investments_NOMZ
remediation_NOMZ
costs_NN
._.
Provisions_NN
for_PIN
these_DEMO
costs_NN
An_DT
associate_NN
is_VPRT [BEMA]
an_DT
undertaking_GER
,_,
not_XX0
being_VBG [BEMA]
a_DT
are_VPRT [PASS]
made_VBN
when_RB
there_EX
is_VPRT
a_DT
present_JJ
obligation_NOMZ
,_,
it_PIT
subsidiary_NN
or_CC
joint_JJ
venture_NN
,_,
in_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
probable_PRED
that_THAC
expenditure_NN
on_PIN
remedial_JJ
work_NN
AstraZeneca_NN
has_VPRT
a_DT
participating_VBG
interest_NN
and_CC
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
and_CC
a_DT
reliable_JJ
estimate_NN
can_POMD
be_VB
over_IN
whose_WPS
commercial_JJ
and_PHC
financial_JJ
policy_NN
made_VBN [WZPAST]
of_PIN
the_DT
cost_NN
._.
decisions_NN
AstraZeneca_NN
exercises_VPRT
significant_JJ
influence_NN
._.
Stock_NN
valuation_NOMZ
Finished_VBN
goods_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
A_DT
joint_JJ
venture_NN
is_VPRT [BEMA]
an_DT
entity_NOMZ
in_PIN
which_WDT [PIRE]
or_CC
net_JJ
realisable_JJ
value_NN
and_CC
raw_JJ
materials_NN
and_PHC
AstraZeneca_NN
holds_VPRT [PRIV]
an_DT
interest_NN
on_PIN
a_DT
long_JJ
term_NN
other_JJ
stocks_NN
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
or_CC
basis_NN
and_ANDC
which_WDT
is_VPRT [SPAU] [BYPA]
jointly_RB
controlled_VBN
by_PIN
replacement_NOMZ
price_NN
._.
The_DT
first_JJ
in_PIN [STPR]
,_,
first_RB
out_PIN
or_CC
an_DT
AstraZeneca_NN
and_CC
one_CD
or_CC
more_EMPH
other_JJ
venturers_NN
average_JJ
method_NN
of_PIN
valuation_NOMZ
is_VPRT [PASS]
used_VBN
._.
determining_VBG [SUAV] [PRIV]
cost_NN
,_,
depreciation_NOMZ
is_VPRT [PASS]
included_VBN
but_CC
selling_VBG
expenses_NN
and_CC
certain_JJ
overhead_JJ
AstraZenecas_NN
share_NN
of_PIN
the_DT
profits_NN
less_RB
losses_NN
expenses_NN
principally_RB
central_JJ
administration_NOMZ
of_PIN
all_QUAN
significant_JJ
joint_JJ
ventures_NN
and_PHC
associates_NN
costs_NN
are_VPRT [PASS]
excluded_VBN
._.
Net_JJ
realisable_JJ
value_NN
is_VPRT
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
determined_VBN [SUAV] [PRIV]
as_IN
estimated_VBN [PRIV]
selling_GER
price_NN
less_JJ
account_NN
on_PIN
the_DT
equity_NOMZ
accounting_GER
basis_NN
or_CC
,_,
in_PIN
costs_NN
of_PIN
disposal_NN
._.
the_DT
case_NN
of_PIN
joint_JJ
ventures_NN
,_,
the_DT
gross_JJ
equity_NOMZ
accounting_GER
basis_NN
._.
The_DT
holding_GER
value_NN
of_PIN
Principal_NN
financial_JJ
instruments_NOMZ
significant_JJ
associates_NN
and_CC
joint_JJ
ventures_NN
in_PIN
the_DT
Forward_NN
foreign_JJ
exchange_NN
contracts_NN
for_PIN
Group_NN
balance_NN
sheet_NN
is_VPRT [BYPA]
calculated_VBN [PRIV]
by_PIN
existing_VBG
transactions_NOMZ
are_VPRT [PASS]
revalued_VBN
to_PIN
year_NN
end_NN
reference_NN
to_PIN
AstraZenecas_NN
equity_NOMZ
in_PIN
the_DT
net_JJ
spot_NN
rates_NN
and_CC
the_DT
gains_NN
losses_NN
arising_VBG [WZPRES]
are_VPRT
assets_NN
of_PIN
such_JJ
associates_NN
and_CC
joint_JJ
ventures_NN
,_,
recognized_VBN [PRIV] [PASTP]
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
as_IN
shown_VBN [PRIV]
by_PIN
the_DT
most_EMPH
recent_JJ
accounts_NN
account_VPRT
._.
Interest_NN
differentials_NN
are_VPRT [PASS]
amortised_VBN
available_JJ
,_,
adjusted_VBN
where_RB
appropriate_JJ
and_CC
on_PIN
a_DT
straight_JJ
line_NN
basis_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
including_VBG
goodwill_NN
on_PIN
acquisitions_NOMZ
made_VBN
since_OSUB
contract_NN
._.
The_DT
gains_NN
losses_NN
on_PIN
forward_RB
foreign_JJ
Fixed_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
exchange_NN
contracts_NN
and_PHC
currency_NN
option_NOMZ
and_CC
reviewed_VBN
for_PIN
impairment_NOMZ
if_COND
there_EX
are_VPRT
contracts_NN
hedging_VBG [WZPRES]
anticipated_JJ
exposures_NN
are_VPRT
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
value_NN
may_POMD
not_XX0
be_VB [PASS]
deferred_VBN
until_IN
the_DT
date_NN
the_DT
underlying_VBG
recoverable_JJ
._.
transaction_NOMZ
being_VBG [WZPRES] [PASS]
hedged_VBN
is_VPRT [PASS]
completed_VBN
._.
Current_JJ
asset_NN
investments_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Interest_NN
rate_NN
swaps_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
on_PIN
an_DT
Groups_NN
insurance_NN
company_NN
subsidiaries_NN
,_,
to_PIN
accruals_NN
basis_NN
._.
Cross-currency_NN
swaps_NN
are_VPRT [BEMA]
the_DT
extent_NN
that_TOBJ
they_TPP3
are_VPRT [SPAU] [PASS]
actively_RB
matched_VBN
translated_VBN
at_PIN
year_NN
end_NN
exchange_NN
rates_NN
:_:
against_PIN
insurance_NN
liabilities_NOMZ
,_,
are_VPRT [PASS]
valued_VBN
at_PIN
gains_NN
losses_NN
arising_VBG [WZPRES]
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
market_NN
value_NN
and_CC
unrealised_JJ
gains_NN
and_PHC
losses_NN
measurement_NOMZ
of_PIN
the_DT
related_JJ
liabilities_NOMZ
and_CC
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
via_PIN
the_DT
dealt_VBN
with_PIN
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_CC
or_CC
reserves_NN
as_IN
appropriate_JJ
._.
Realised_VBN [PRIV]
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
taken_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Contingent_JJ
liabilities_NOMZ
Through_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
,_,
AstraZeneca_NN
is_VPRT [PASS]
involved_VBN
in_PIN
legal_JJ
disputes_NN
the_DT
settlement_NOMZ
of_PIN
which_WDT [PIRE]
may_POMD
involve_VB
cost_NN
to_PIN
the_DT
Group_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
where_RB
the_DT
outcome_NN
and_CC
associated_VBN
costs_NN
can_POMD
be_VB [PASS]
estimated_VBN [PRIV]
reliably_RB
._.
com_NN
65_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
1_CD
Composition_NOMZ
of_PIN
the_DT
Group_NN
The_NN
Group_NN
Financial_NN
Statements_NOMZ
consolidate_VB
the_DT
financial_JJ
statements_NOMZ
of_PIN
AstraZeneca_NN
PLC_NN
and_CC
its_PIT
subsidiaries_NN
,_,
of_PIN
which_WDT [PIRE]
there_EX
were_VBD
235_CD
,_,
at_PIN
31_CD
December_NN
2002_CD
._.
Owing_VBG [PRESP]
to_PIN
local_JJ
conditions_NOMZ
and_CC
to_TO
avoid_VB
undue_JJ
delay_NN
in_PIN
the_DT
presentation_NOMZ
of_PIN
the_DT
Group_NN
Financial_NN
Statements_NOMZ
,_,
Salick_NN
Health_NN
Care_NN
prepares_VPRT
its_PIT
financial_JJ
statements_NOMZ
to_PIN
30_CD
November_NN
._.
2_CD
Note_NN
of_PIN
historical_JJ
cost_NN
profits_NN
and_PHC
losses_NN
There_EX
were_VBD
no_SYNE
material_NN
differences_NN
between_PIN
reported_VBN [PUBV]
profits_NN
and_PHC
losses_NN
and_CC
historical_JJ
cost_NN
profits_NN
and_PHC
losses_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
._.
com_NN
66_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
3_CD
Group_NN
operating_GER
profit_NN
Continuing_VBG [WZPRES]
operations_NOMZ
Pre_NN
exceptional_JJ
Exceptional_JJ
2002_CD
items_NN
items_NN
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
Group_NN
turnover_NN
17,841_CD
17,841_CD
Operating_GER
costs_NN
Cost_NN
of_PIN
sales_NN
4,520_CD
4,520_CD
Distribution_NOMZ
costs_NN
141_CD
141_CD
Research_NN
and_PHC
development_NOMZ
3,069_CD
3,069_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
5,998_CD
350_CD
6,348_CD
13,728_CD
350_CD
14,078_CD
Other_JJ
operating_GER
income_NN
Royalties_NN
113_CD
113_CD
Other_JJ
income_NN
130 130 243 243_CD
Other_JJ
income_NN
includes_VPRT
gains_NN
arising_VBG [WZPRES]
from_PIN
disposals_NN
under_IN
ongoing_JJ
product_NN
rationalisation_NOMZ
programs_NN
._.
Group_NN
operating_GER
profit_NN
4,356_CD
350_CD
4,006_CD
Charges_NN
included_VBD
above_PLACE
for_PIN
depreciation_NOMZ
705_CD
705_CD
for_PIN
amortisation_NOMZ
255_CD
255_CD
for_PIN
impairment_NOMZ
Gross_NN
profit_NN
,_,
as_IN
defined_VBN
by_PIN
the_DT
Companies_NN
Act_NN
1985_CD
13,321_CD
13,321_CD
4_CD
Share_NN
of_PIN
operating_VBG
profits_NN
losses_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
Continuing_VBG [WZPRES]
operations_NOMZ
Pre_NN
exceptional_JJ
Exceptional_JJ
2002_CD
items_NN
items_NN
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
Share_NN
of_PIN
operating_VBG
loss_NN
profit_NN
of_PIN
joint_JJ
ventures_NN
Share_NN
of_PIN
operating_GER
profit_NN
of_PIN
associates_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
68_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
5_CD
Exceptional_JJ
items_NN
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Accrual_NN
related_VBN [WZPAST]
to_PIN
Zoladex_NN
investigation_NOMZ
350_CD
Integration_NOMZ
and_PHC
synergy_NN
costs_NN
202_CD
322_CD
Exceptional_JJ
items_NN
included_VBN [WZPAST]
in_PIN
operating_VBG
profits_NN
350 202 322_CD
Continuing_VBG
operations_NOMZ
Provision_NN
of_PIN
impairment_NOMZ
of_PIN
investment_NOMZ
in_PIN
Advanta_NN
BV_NN
after_IN
charging_VBG
$_$
49m_CD
of_PIN
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
137_CD
Share_NN
of_PIN
operating_GER
losses_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
137_CD
Discontinued_VBN
operations_NOMZ
Costs_NN
related_VBN [WZPAST]
to_PIN
the_DT
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
and_PHC
formation_NOMZ
of_PIN
Syngenta_NN
AG_NN
150_CD
Profits_NN
less_RB
losses_NN
on_PIN
sale_NN
,_,
closure_NN
,_,
or_CC
demerger_NN
of_PIN
operations_NOMZ
150_CD
Profit_NN
on_PIN
sale_NN
of_PIN
fixed_JJ
assets_NN
10_CD
Total_JJ
exceptional_JJ
items_NN
before_IN
taxation_NOMZ
350 192 609_CD
Net_JJ
taxation_NOMZ
credit_NN
54_CD
28_CD
Total_JJ
exceptional_JJ
items_NN
after_IN
taxation_NOMZ
350 138 581_CD
The_DT
US_FPP1
Department_NOMZ
of_PIN
Justice_NN
has_VPRT [PEAS]
been_VBN
conducting_VBG
an_DT
investigation_NOMZ
into_PIN
the_DT
sale_NN
and_PHC
marketing_GER
of_PIN
Zoladex_NN
goserelin_NN
acetate_NN
implant_VPRT
._.
This_DEMO
investigation_NOMZ
was_VBD [BYPA]
prompted_VBN
by_PIN
the_DT
filing_NN
of_PIN
a_DT
qui_FW
tam_FW
complaint_NN
by_PIN
a_DT
private_JJ
party_NN
in_PIN
1997_CD
and_CC
involves_VPRT
allegations_NOMZ
of_PIN
improper_JJ
submissions_NN
of_PIN
claims_NN
to_PIN
the_DT
Medicare_NN
and_PHC
Medicaid_NN
programs_NN
._.
The_DT
Company_NN
and_CC
federal_JJ
and_CC
state_NN
authorities_NOMZ
are_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
negotiating_VBG
a_DT
potential_JJ
settlement_NOMZ
of_PIN
the_DT
civil_JJ
and_PHC
criminal_JJ
claims_NN
at_PIN
issue_NN
in_PIN
the_DT
investigation_NOMZ
._.
As_CONJ
a_NULL
result_NULL
,_,
although_CONC
no_SYNE
final_JJ
agreement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
concluded_VBN [PRIV]
,_,
the_DT
Company_NN
believes_VPRT [PRIV]
it_PIT
appropriate_JJ
to_TO
accrue_VB
$_$
350m_CD
to_TO
cover_VB
estimated_VBN [PRIV]
settlement_NOMZ
costs_NN
._.
The_DT
integration_NOMZ
and_PHC
synergy_NN
program_NN
initiated_VBN [WZPAST]
in_PIN
1999_CD
was_VBD [PASS]
completed_VBN
during_PIN
2001_CD
,_,
with_PIN
further_JJ
exceptional_JJ
charges_NN
of_PIN
$_$
202m_CD
2000_CD
$_$
322m_CD
,_,
principally_RB
for_PIN
manpower_NN
related_VBN
costs_NN
,_,
IT_PIT
costs_VPRT
,_,
and_ANDC
contractors_NN
._.
The_DT
Group_NN
took_VBD
an_DT
exceptional_JJ
charge_NN
of_PIN
$_$
137m_CD
in_PIN
2000_CD
to_TO
provide_VB
for_PIN
impairment_NOMZ
of_PIN
its_PIT
50_CD
%_NN
interest_NN
in_PIN
the_DT
seeds_NN
company_NN
Advanta_NN
BV_NN
,_,
including_VBG [PRESP]
a_DT
write_VB [PUBV]
off_PIN
of_PIN
$_$
49m_CD
of_PIN
related_JJ
goodwill_NN
previously_TIME
taken_VBN
to_PIN
reserves_NN
._.
The_DT
costs_NN
related_VBN [WZPAST]
to_PIN
the_DT
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
and_PHC
formation_NOMZ
of_PIN
Syngenta_NN
AG_NN
included_VBD
advisors_NN
fees_NN
,_,
the_DT
costs_NN
of_PIN
separating_VBG
computer_NN
systems_NN
,_,
employee_NN
related_VBN
costs_NN
and_CC
environmental_JJ
and_PHC
occupational_JJ
health_NN
provisions_NN
._.
The_DT
exceptional_JJ
charge_NN
was_VBD [BYPA]
reduced_VBN
by_PIN
the_DT
gain_NN
on_PIN
disposal_NN
of_PIN
products_NN
whose_WPS [WHOBJ]
sale_NN
was_VBD [BYPA]
required_VBN [SUAV]
by_PIN
the_DT
competition_NOMZ
authorities_NOMZ
as_IN
a_DT
condition_NOMZ
of_PIN
the_DT
creation_NOMZ
of_PIN
Syngenta_NN
AG_NN
._.
Tax_NN
relief_NN
on_PIN
the_DT
net_JJ
exceptional_JJ
costs_NN
was_VBD [BEMA]
more_EMPH
than_PIN
offset_VBN
by_PIN
the_DT
provision_NN
for_PIN
capital_NN
taxes_NN
arising_VBG [WZPRES]
out_PIN
of_PIN
the_DT
restructuring_GER
of_PIN
the_DT
business_NOMZ
in_PIN
preparation_NOMZ
for_PIN
demerger_NN
,_,
resulting_VBG [PRESP]
in_PIN
a_DT
net_JJ
tax_NN
cost_NN
of_PIN
$_$
50m_CD
._.
com_NN
69_CD
6_CD
Net_JJ
interest_NN
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Interest_NN
receivable_NN
and_CC
similar_JJ
income_NN
from_PIN
investments_NOMZ
Securities_NOMZ
21_CD
19_CD
30_CD
Short_JJ
term_NN
deposits_NN
90 179 192_CD
Exchange_NN
gain_NN
6_CD
146_CD
Joint_NN
ventures_NN
1_CD
117 199 269_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
Loan_NN
interest_NN
10_CD
32_CD
50_CD
Interest_NN
on_PIN
short_JJ
term_NN
borrowings_GER
and_CC
other_JJ
financing_GER
costs_NN
51_CD
35_CD
62_CD
Discount_NN
on_PIN
liability_NOMZ
10_CD
15_CD
19_CD
Exchange_NN
losses_NN
16_CD
12_CD
Joint_NN
ventures_NN
3_CD
87_CD
94_CD
134_CD
Net_JJ
interest_NN
receivable_NN
30 105 135_CD
The_DT
discounting_GER
charge_NN
above_PLACE
relates_VPRT
to_PIN
amounts_NN
owed_VBN [WZPAST]
in_PIN
respect_NN
of_PIN
the_DT
re-acquisition_NOMZ
of_PIN
certain_JJ
distribution_NOMZ
rights_NN
,_,
the_DT
final_JJ
instalment_NOMZ
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
payable_PRED
in_PIN
2003_CD
._.
In_PIN
prior_JJ
years_NN
,_,
all_QUAN
interest_NN
has_VPRT [PEAS]
been_VBN [PASS]
classified_VBN
within_PIN
continuing_VBG
operations_NOMZ
as_IN
the_DT
management_NOMZ
of_PIN
the_DT
Groups_NN
liquidity_NOMZ
and_PHC
funding_GER
is_VPRT [PASS]
carried_VBN
out_PIN
by_PIN
the_DT
central_JJ
treasury_NN
function_NOMZ
and_CC
it_PIT
is_VPRT [BEMA]
not_XX0
practicable_PRED
to_TO
allocate_VB
interest_NN
to_PIN
the_DT
different_JJ
reporting_GER
segments_NOMZ
._.
com_NN
70_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
7_CD
Taxation_NOMZ
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
,_,
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
,_,
was_VBD
as_IN
follows_VPRT
:_:
2002 2001 2000_CD
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
UK_NN
741 618 808_NN
Overseas_NN
3,296_CD
3,459_CD
3,039_CD
4,037_CD
4,077_CD
3,847_CD
Taxes_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
UK_NN
taxation_NOMZ
Corporation_NOMZ
tax_NN
165 147 130_CD
Double_RB
taxation_NOMZ
relief_NN
29_CD
37_CD
42_CD
Deferred_JJ
taxation_NOMZ
24_CD
53_CD
3_CD
160_CD
163_CD
85_CD
Overseas_PLACE
taxation_NOMZ
Overseas_PLACE
taxes_NN
929_CD
739_CD
1,066_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
51_CD
17_CD
4_CD
Deferred_VBN
taxation_NOMZ
139 275 402_CD
1,017_CD
997_CD
1,472_CD
Share_NN
of_PIN
taxation_NOMZ
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
3_CD
Tax_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
1,177_CD
1,160_CD
1,560_CD
In_PIN
prior_JJ
years_NN
,_,
the_DT
charge_NN
for_PIN
taxation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
between_PIN
continuing_VBG
operations_NOMZ
and_CC
discontinued_VBN
operations_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
effective_JJ
tax_NN
rates_NN
for_PIN
the_DT
Group_NN
in_PIN
the_DT
territories_NN
in_PIN
which_WDT [PIRE]
these_DEMO
operations_NOMZ
are_VPRT [PASS]
based_VBN
._.
UK_NN
and_CC
overseas_PLACE
taxation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
at_PIN
current_JJ
rates_NN
on_PIN
the_DT
profits_NN
earned_VBN [WZPAST]
for_PIN
the_DT
periods_NN
covered_VBN [WZPAST]
by_PIN
the_DT
Group_NN
financial_JJ
statements_NOMZ
._.
To_PIN
the_DT
extent_NN
that_TOBJ
dividends_NN
remitted_VBN [WZPAST]
from_PIN
overseas_PLACE
subsidiaries_NN
,_,
joint_JJ
ventures_NN
and_PHC
associates_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
result_VB
in_PIN
additional_JJ
taxes_NN
,_,
appropriate_JJ
amounts_NN
have_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
._.
No_SYNE
deferred_JJ
tax_NN
has_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
for_PIN
unremitted_JJ
earnings_GER
of_PIN
Group_NN
companies_NN
overseas_PLACE
as_IN
these_DEMP
are_VPRT
,_,
in_PIN
the_DT
main_JJ
,_,
considered_VBN [PRIV] [PASTP]
permanently_RB
employed_VBN
in_PIN
the_DT
businesses_NOMZ
of_PIN
these_DEMO
companies_NN
and_CC
,_,
in_PIN
the_DT
case_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
,_,
the_DT
taxes_NN
would_PRMD
not_XX0
be_VB
material_NN
._.
Cumulative_JJ
unremitted_JJ
earnings_GER
of_PIN
overseas_PLACE
subsidiaries_NN
and_CC
related_VBN
undertakings_GER
totalled_VBD
approximately_RB
$_$
9,141_CD
m_NN [BEMA]
at_PIN
31_CD
December_NN
2002_CD
._.
Unremitted_JJ
earnings_GER
may_POMD
be_VB [BEMA]
liable_PRED
to_PIN
overseas_PLACE
taxes_NN
and_CC
or_CC
UK_NN
taxation_NOMZ
after_IN
allowing_VBG [SUAV]
for_PIN
double_JJ
taxation_NOMZ
relief_NN
if_COND
they_TPP3
were_VBD
to_TO
be_VB [PASS]
distributed_VBN
as_IN
dividends_NN
._.
Exceptional_JJ
items_NN
included_VBN [WZPAST]
in_PIN
tax_NN
on_PIN
ordinary_JJ
activities_NOMZ
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Tax_NN
credit_NN
on_PIN
exceptional_JJ
items_NN
54_CD
28_CD
Includes_VPRT
deferred_JJ
tax_NN
relief_NN
of_PIN
$_$
nil_JJ
2001_CD
$_$
23m_CD
,_,
2000_CD
$_$
66m_CD
._.
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
In_PIN
certain_JJ
circumstances_NN
,_,
tax_NN
charges_NN
or_CC
credits_NN
on_PIN
currency_NN
differences_NN
on_PIN
borrowings_GER
are_VPRT [PASS]
taken_VBN
to_PIN
reserves_NN
via_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
The_DT
tax_NN
charge_NN
on_PIN
such_JJ
currency_NN
translation_NOMZ
differences_NN
amounted_VBD
to_TO
$_$
2m_CD
in_PIN
2002_CD
2001_CD
$_$
6m_CD
,_,
2000_CD
$_$
42m_CD
,_,
and_ANDC
has_VPRT [PEAS]
been_VBN [PASS]
reported_VBN [PUBV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
Factors_NN
affecting_VBG [WZPRES]
future_JJ
tax_NN
charges_NN
As_IN
a_DT
group_NN
involved_VBN [WZPAST]
in_PIN
worldwide_JJ
operations_NOMZ
,_,
AstraZeneca_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
several_QUAN
factors_NN
that_TSUB
may_POMD
affect_VB
future_JJ
tax_NN
charges_NN
,_,
principally_RB
the_DT
levels_NN
and_PHC
mix_NN
of_PIN
profitability_NOMZ
in_PIN
different_JJ
jurisdictions_NOMZ
,_,
transfer_NN
pricing_GER
policies_NN
and_PHC
tax_NN
levels_NN
imposed_VBN
._.
com_NN
71_CD
7_CD
Taxation_NOMZ
continued_VBD
Tax_NN
reconciliation_NOMZ
to_PIN
UK_NN
statutory_JJ
rate_NN
The_DT
table_NN
shown_VBN [PRIV]
below_PLACE
reconciles_NN
the_DT
UK_NN
statutory_JJ
tax_NN
charge_NN
to_PIN
the_DT
Groups_NN
current_JJ
tax_NN
charge_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
._.
2002 2001 2000_CD
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
4,037_CD
4,077_CD
3,847_CD
Notional_NN
taxation_NOMZ
charge_NN
at_PIN
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
30_CD
%_NN
for_PIN
2001_CD
,_,
30_CD
%_NN
for_PIN
2000_CD
1,211_CD
1,223_CD
1,154_CD
Differences_NN
in_PIN
effective_JJ
overseas_PLACE
tax_NN
rates_NN
141 108 215_CD
Capital_NN
allowances_NN
tax_NN
reliefs_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
291 401 235_CD
Other_JJ
timing_NN
differences_NN
40_CD
99_CD
134_CD
Items_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
49_CD
48_CD
37_CD
Items_NN
not_XX0
chargeable_JJ
for_PIN
tax_NN
purposes_NN
110_CD
58_CD
54_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
51_CD
17_CD
4_CD
Exceptional_JJ
items_NN
105_CD
28_CD
171_CD
Current_JJ
ordinary_JJ
tax_NN
charge_NN
for_PIN
the_DT
year_NN
1,014_CD
832_CD
1,158_CD
Balance_NN
sheet_NN
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Deferred_VBN
taxation_NOMZ
liability_NOMZ
asset_NN
movement_NOMZ
At_PIN
beginning_GER
of_PIN
year_NN
212_CD
96_CD
369_CD
Prior_RB
year_NN
adjustment_NOMZ
page_NN
62_CD
33_CD
212_CD
96_CD
336_CD
Profit_NN
and_PHC
loss_NN
account_NN
163 328 399_CD
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
155_CD
19_CD
83_CD
Exchange_NN
139_CD
39_CD
76_CD
At_PIN
end_NN
of_PIN
year_NN
359_CD
212_CD
96_CD
Debtors_NN
amount_NN
due_JJ
within_PIN
one_CD
year_NN
Note_NN
15 625 550 541_CD
Debtors_NN
amount_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Note_NN
15 226 146 189_CD
Provisions_NN
Note_VPRT [PRIV]
21_CD
1,210_CD
908 634 359 212_CD
96_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
72_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
7_CD
Taxation_NOMZ
continued_VBD
Deferred_JJ
taxation_NOMZ
The_DT
amounts_NN
of_PIN
deferred_VBN
taxation_NOMZ
accounted_VBD
for_PIN
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
comprised_VBD
the_DT
following_JJ
deferred_JJ
tax_NN
liabilities_NOMZ
and_PHC
assets_NN
:_:
2002_CD
2001_CD
restated_VBN
$_$
m_CD
$_$
m_CD [PASS]
Deferred_VBN
tax_NN
liabilities_NOMZ
UK_NN
fixed_VBN
assets_NN
429_CD
332_CD
Non-UK_JJ
fixed_JJ
assets_NN
570_CD
455_CD
Interest_NN
accruals_VPRT
13_CD
72_CD
Untaxed_JJ
reserves_NN
86_CD
11_CD
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
46_CD
Other_JJ
53_CD
150_CD
1,197_CD
1,020_CD
Deferred_JJ
tax_NN
assets_NN
Intercompany_NN
inventory_NN
transfers_NN
496_CD
413_CD
Merger_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
charges_NN
16_CD
121_CD
Accrued_VBN
expenses_NN
243_CD
161_CD
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
26_CD
91_CD
Other_JJ
57 22 838 808_CD
Deferred_JJ
tax_NN
liability_NOMZ
359_CD
212_CD
No_SYNE
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
,_,
in_PIN
accordance_NN
with_PIN
FRS19_CD
,_,
for_PIN
rolled_VBN
over_IN
gains_NN
amounting_VBG [WZPRES]
to_TO
$_$
126m_CD
2001_CD
$_$
75m_CD
,_,
2000_CD
$_$
79m_CD
._.
com_NN
73_CD
8_CD
Dividends_NN
2002 2001 2000 2002_CD
2001_CD
2000_CD
Per_PIN
Per_PIN
Per_PIN
Share_NN
Share_NN
Share_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Interim_NN
,_,
paid_VBN [PASTP]
on_PIN
7_CD
October_NN
2002_CD
$_$
0.23_CD
$_$
0.23_CD
$_$
0.23_CD
398 405 406_CD
Second_JJ
interim_NN
,_,
to_TO
be_VB [PASS]
confirmed_VBN [PUBV]
as_IN
final_JJ
,_,
payable_JJ
7_CD
April_NN
2003_CD
$_$
0.47_CD
$_$
0.47_CD
$_$
0.47_CD
808 820 830_CD
$_$
0.70_CD
$_$
0.70_CD
$_$
0.70_CD
1,206_CD
1,225_CD
1,236_CD
Dividend_NN
in_PIN
specie_NN
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
1,669_CD
The_DT
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
in_PIN
2000_CD
was_VBD [PASS]
recorded_VBN
in_PIN
the_DT
Group_NN
accounts_NN
at_PIN
the_DT
book_NN
value_NN
of_PIN
the_DT
net_JJ
assets_NN
which_WDT [WHSUB]
were_VBD [PASS]
deconsolidated_VBN
,_,
$_$
2,059_CD
m_NN
net_NN
of_PIN
minority_NOMZ
interest_NN
,_,
together_RB
with_PIN
$_$
813m_CD
of_PIN
related_JJ
goodwill_NN
which_WDT [WHSUB]
had_VBD [SPAU] [PEAS]
previously_TIME
been_VBN [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
,_,
less_JJ
debt_NN
and_PHC
liabilities_NOMZ
assumed_VBN [PRIV] [WZPAST]
by_PIN
Zeneca_NN
Agrochemicals_NN
,_,
$_$
1,203_CD
m_NN
,_,
giving_VBG [PRESP]
a_DT
dividend_NN
in_PIN
specie_NN
of_PIN
$_$
1,669_CD
m._NN
9_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
2002 2001 2000_CD
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
before_IN
exceptional_JJ
items_NN
$_$
m_CD [BEMA]
3,186_CD
3,044_CD
2,858_CD
Exceptional_JJ
items_NN
after_IN
tax_NN
$_$
m_CD
see_VPRT [PRIV]
Note_NN
5_CD
350 138 581_CD
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
$_$
m_CD [BEMA]
2,836_CD
2,906_CD
2,277_CD
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
$_$
$_$
1.84_CD
$_$
1.73_CD
$_$
1.62_CD
Loss_NN
per_PIN
Ordinary_NN
Share_NN
on_PIN
exceptional_JJ
items_NN
$_$
$_$
0.20_CD
$_$
0.08_CD
$_$
0.32_CD
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
$_$
$_$
1.64_CD
$_$
1.65_CD
$_$
1.30_CD
Diluted_VBN
earnings_GER
per_PIN
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
$_$
$_$
1.84_CD
$_$
1.73_CD
$_$
1.62_CD
Diluted_VBN
loss_NN
per_PIN
Ordinary_NN
Share_NN
on_PIN
exceptional_JJ
items_NN
$_$
$_$
0.20_CD
$_$
0.08_CD
$_$
0.32_CD
Diluted_VBN
earnings_GER
per_PIN
Ordinary_NN
Share_NN
$_$
$_$
1.64_CD
$_$
1.65_CD
$_$
1.30_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
issue_NN
for_PIN
basic_JJ
earnings_GER
millions_NN
1,733_CD
1,758_CD
1,768_CD
Dilutive_JJ
impact_NN
of_PIN
share_NN
options_NOMZ
outstanding_JJ
millions_NN
2_CD
32_CD
Diluted_VBN
average_JJ
number_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
1,735_CD
1,761_CD
1,770_CD
There_EX
are_VPRT
no_SYNE
options_NOMZ
,_,
warrants_NN
or_CC
rights_NN
outstanding_JJ
in_PIN
respect_NN
of_PIN
unissued_JJ
shares_NN
except_PIN
for_PIN
employee_NN
share_NN
option_NOMZ
schemes_NN
._.
The_DT
number_NN
of_PIN
options_NOMZ
outstanding_JJ
and_CC
the_DT
weighted_JJ
average_JJ
exercise_NN
price_NN
of_PIN
these_DEMO
options_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
Note_NN
33_CD
._.
The_DT
earnings_GER
figures_NN
used_VBN [WZPAST]
in_PIN
the_DT
calculations_NOMZ
above_PLACE
are_VPRT [BEMA]
unchanged_PRED
for_PIN
diluted_JJ
earnings_GER
per_PIN
Ordinary_NN
Share_NN
._.
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
have_VPRT [PEAS]
been_VBN [PASS]
calculated_VBN [PRIV]
to_TO
eliminate_VB
the_DT
impact_NN
of_PIN
exceptional_JJ
items_NN
on_PIN
the_DT
results_NN
of_PIN
the_DT
business_NOMZ
._.
com_NN
74_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
10_CD
Segment_NOMZ
information_NOMZ
Classes_NN
of_PIN
Business_NOMZ
Turnover_NN
2002 2001 2000_CD
reclassified_VBD
reclassified_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Continuing_VBG
operations_NOMZ
17,841_CD
16,222_CD
15,583_CD
Discontinued_VBN
operations_NOMZ
Agrochemicals_NN
2,299_CD
Group_NN
turnover_NN
17,841_CD
16,222_CD
17,882_CD
Share_NN
of_PIN
joint_JJ
venture_NN
turnover_NN
191 183 195_CD
Group_NN
turnover_NN
and_PHC
share_NN
of_PIN
joint_JJ
venture_NN
turnover_NN
18,032_CD
16,405_CD
18,077_CD
The_DT
Groups_NN
policy_NN
is_VPRT
to_TO
transfer_VB
products_NN
internally_RB
at_PIN
external_JJ
market_NN
prices_NN
._.
Operating_GER
profit_NN
Profit_NN
loss_NN
before_IN
after_IN
exceptionals_NN
interest_NN
and_PHC
taxation_NOMZ
2002 2001 2000 2002_CD
2001_CD
2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Profit_NN
arising_VBG [WZPRES]
in_PIN
Continuing_VBG
operations_NOMZ
4,006_CD
3,954_CD
3,662_CD
4,007_CD
3,972_CD
3,665_CD
Discontinued_VBN
operations_NOMZ
Agrochemicals_NN
346_CD
196_CD
4,006_CD
3,954_CD
4,008_CD
4,007_CD
3,972_CD
3,861_CD
Share_NN
of_PIN
operating_VBG
loss_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
149_CD
4,007_CD
3,972_CD
3,712_CD
In_PIN
prior_JJ
years_NN
,_,
corporate_JJ
overheads_NN
have_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
to_PIN
each_QUAN
business_NOMZ
segment_NOMZ
on_PIN
a_DT
consistent_JJ
basis_NN
._.
The_DT
effect_NN
of_PIN
these_DEMO
allocations_NOMZ
was_VBD
not_XX0
material_NN
._.
Net_JJ
assets_NN
liabilities_NOMZ
Total_JJ
assets_NN
2002 2001 2000 2002_CD
2001_CD
2000_CD
restated_VBN
restated_VBN
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Continuing_VBG
operations_NOMZ
9,868_CD
8,808_CD
7,604_CD
16,212_CD
14,158_CD
13,658_CD
Discontinued_VBN
operations_NOMZ
Specialties_NN
126_CD
3_CD
9,868_CD
8,808_CD
7,478_CD
16,212_CD
14,158_CD
13,661_CD
Intra-Group_NN
eliminations_NOMZ
12_CD
Non-operating_JJ
assets_NN
1,358_CD
821_CD
1,938_CD
5,364_CD
4,338_CD
5,208_CD
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
11,226_CD
9,629_CD
9,416_CD
21,576_CD
18,496_CD
18,857_CD
Non-operating_JJ
assets_NN
include_VPRT
short_JJ
term_NN
investments_NOMZ
and_PHC
cash_NN
,_,
short_JJ
term_NN
borrowings_GER
,_,
loans_NN
,_,
and_ANDC
non-operating_JJ
debtors_NN
and_PHC
creditors_NN
not_XX0
attributable_JJ
to_PIN
individual_JJ
business_NOMZ
segments_NOMZ
._.
Depreciation_NOMZ
,_,
amortisation_NOMZ
Capital_NN
expenditure_NN
and_PHC
impairment_NOMZ
2002 2001 2000 2002_CD
2001_CD
2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Continuing_VBG
operations_NOMZ
1,463_CD
1,501_CD
1,248_CD
960 872 890_CD
Discontinued_VBN
operations_NOMZ
Agrochemicals_NN
153_CD
121_CD
1,463_CD
1,501_CD
1,401_CD
960_CD
872_CD
1,011_CD
Capital_NN
expenditure_NN
includes_VPRT
expenditure_NN
on_PIN
goodwill_NN
and_CC
intangible_JJ
assets_NN
._.
com_NN
75_CD
10_CD
Segment_NOMZ
information_NOMZ
continued_VBD
Geographic_JJ
areas_NN
The_DT
tables_NN
below_PLACE
show_NN
information_NOMZ
by_PIN
geographic_JJ
area_NN
and_CC
,_,
for_PIN
turnover_NN
and_CC
tangible_JJ
fixed_VBN
assets_NN
,_,
material_NN
countries_NN
._.
The_DT
figures_NN
for_PIN
each_QUAN
area_NN
show_VPRT [PRIV]
the_DT
turnover_NN
,_,
operating_VBG
profit_NN
and_PHC
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
interest_NN
and_PHC
taxation_NOMZ
made_VBN [WZPAST]
by_PIN
companies_NN
located_VBN [WZPAST]
in_PIN
that_DEMO
area_NN
country_NN
,_,
together_RB
with_PIN
net_JJ
operating_GER
assets_NN
and_CC
tangible_JJ
fixed_VBN
assets_NN
owned_VBN [WZPAST]
by_PIN
the_DT
same_JJ
companies_NN
:_:
export_NN
sales_NN
and_CC
the_DT
related_JJ
profit_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
areas_NN
from_PIN
which_WDT [PIRE]
those_DEMO
sales_NN
were_VBD [PASS]
made_VBN
._.
com_NN
77_CD
10_CD
Segment_NOMZ
information_NOMZ
continued_VBD
2002 2001 2000_CD
reclassified_VBN
reclassified_VBD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Geographic_JJ
markets_NN
Turnover_NN
in_PIN
each_QUAN
geographic_JJ
market_NN
in_PIN
which_WDT [PIRE]
customers_NN
located_VBN
UK_NN
623 759 787_CD
Continental_NN
Europe_NN
5,072_CD
4,477_CD
4,359_CD
The_DT
Americas_NN
10,287_CD
9,353_CD
8,799_CD
Asia_NN
,_,
Africa_NN
&_CC
Australasia_NN
1,859_CD
1,633_CD
1,638_CD
Continuing_VBG
operations_NOMZ
17,841_CD
16,222_CD
15,583_CD
Discontinued_VBN
operations_NOMZ
Agrochemicals_NN
2,299_CD
17,841_CD
16,222_CD
17,882_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
78_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
11_CD
Tangible_JJ
fixed_VBN
assets_NN
Capital_NN
expenditure_NN
and_PHC
assets_NN
in_PIN
Total_JJ
Land_NN
and_PHC
Plant_NN
and_PHC
course_NN
of_PIN
tangible_JJ
buildings_GER
equipment_NOMZ
construction_NOMZ
assets_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cost_NN
At_PIN
beginning_GER
of_PIN
year_NN
2,490_CD
5,295_CD
1,119_CD
8,904_CD
Exchange_NN
adjustments_NOMZ
292 612 139_CD
1,043_CD
Capital_NN
expenditure_NN
48_CD
212_CD
1,082_CD
1,342_CD
Transfer_NN
of_PIN
assets_NN
into_PIN
use_NN
387_CD
631_CD
1,018_CD
Disposals_NN
and_CC
other_JJ
movements_NOMZ
72_CD
150_CD
24_CD
246_CD
At_PIN
end_NN
of_PIN
year_NN
3,145_CD
6,600_CD
1,298_CD
11,043_CD
Depreciation_NOMZ
At_PIN
beginning_GER
of_PIN
year_NN
753_CD
2,742_CD
3,495_CD
Exchange_NN
adjustments_NOMZ
87 354 441_CD
Charge_NN
for_PIN
year_NN
104 601 705_CD
Disposals_NN
and_CC
other_JJ
movements_NOMZ
49 146 195_CD
At_PIN
end_NN
of_PIN
year_NN
895_CD
3,551_CD
4,446_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2002_CD
2,250_CD
3,049_CD
1,298_CD
6,597_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2001_CD
1,737_CD
2,553_CD
1,119_CD
5,409_CD
Capital_NN
expenditure_NN
in_PIN
the_DT
year_NN
of_PIN
$_$
1,342_CD
m_NN [BEMA]
2001_CD
$_$
1,393_CD
m_NN [PASS]
did_VBD
not_XX0
include_VB
any_QUAN
capitalized_VBN
finance_NN
leases_NN
2001_CD
$_$
nil_JJ
._.
Cash_NN
expenditure_NN
on_PIN
tangible_JJ
fixed_JJ
assets_NN
was_VBD
$_$
1,340_CD
m_NN [BEMA]
2001_CD
$_$
1,385_CD
m_NN
,_,
2000_CD
$_$
1,347_CD
m._FW
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD [BEMA]
The_DT
net_JJ
book_NN
value_NN
of_PIN
land_NN
and_PHC
buildings_GER
comprised_VBD
Freeholds_NN
2,220_CD
1,690_CD
Long_NN
leases_NN
over_IN
50_CD
years_NN
unexpired_JJ
29_CD
45_CD
Short_JJ
leases_NN
1_CD
2_CD
2,250_CD
1,737_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
79_CD
12_CD
Goodwill_NN
and_CC
intangible_JJ
assets_NN
Intangible_NN
Goodwill_NN
assets_NN
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cost_NN
At_PIN
beginning_GER
of_PIN
year_NN
1,000_CD
2,727_CD
3,727_CD
Exchange_NN
adjustments_NOMZ
85 311 396_CD
Additions_NOMZ
17 104 121_CD
Disposals_NN
and_CC
other_JJ
movements_NOMZ
25_CD
25_CD
At_PIN
end_NN
of_PIN
year_NN
1,102_CD
3,117_CD
4,219_CD
Amortisation_NOMZ
At_PIN
beginning_GER
of_PIN
year_NN
166_CD
861_CD
1,027_CD
Exchange_NN
adjustments_NOMZ
28 128 156_CD
Charge_NN
for_PIN
year_NN
55 200 255_CD
Disposals_NN
and_CC
other_JJ
movements_NOMZ
26_CD
26_CD
At_PIN
end_NN
of_PIN
year_NN
249_CD
1,163_CD
1,412_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2002_CD
853_CD
1,954_CD
2,807_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2001_CD
834_CD
1,866_CD
2,700_CD
13_CD
Fixed_VBN
asset_NN
investments_NOMZ
Joint_NN
Other_JJ
ventures_NN
investments_NOMZ
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cost_NN
At_PIN
beginning_GER
of_PIN
year_NN
134_CD
23_CD
157_CD
Additions_NOMZ
25_CD
25_CD
Disposals_NN
and_CC
other_JJ
movements_NOMZ
,_,
including_VBG
exchange_NN
2_CD
2_CD
At_PIN
end_NN
of_PIN
year_NN
134_CD
46_CD
180_CD
Share_NN
of_PIN
post-acquisition_JJ
reserves_NN
At_PIN
beginning_GER
and_PHC
end_NN
of_PIN
year_NN
134_CD
134_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2002_CD
46_CD
46_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2001_CD
23_CD
23_CD
The_DT
fair_JJ
values_NN
of_PIN
other_JJ
investments_NOMZ
are_VPRT
not_XX0
materially_RB
different_PRED
from_PIN
their_TPP3
carrying_VBG
values_NN
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Companys_NN
share_NN
ownership_NN
trust_NN
held_VBD [PRIV]
885,425_CD
Ordinary_NN
Shares_NN
._.
Share_NN
of_PIN
joint_JJ
venture_NN
assets_NN
and_PHC
liabilities_NOMZ
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD
Gross_NN
assets_NN
107_CD
99_CD
Gross_NN
liabilities_NOMZ
107_CD
99_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
80_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
14_CD
Stocks_NN
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD
Raw_NN
materials_NN
and_PHC
consumables_NN
992_CD
796_CD
Stocks_NN
in_PIN
process_NN
1,062_CD
720_CD
Finished_VBN
goods_NN
and_PHC
goods_NN
for_PIN
resale_NN
539_CD
886_CD
2,593_CD
2,402_CD
15_CD
Debtors_NN
2002_CD
2001_CD
restated_VBN
$_$
m_CD
$_$
m_CD
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
Trade_NN
debtors_NN
2,701_CD
2,430_CD
Less_RB
:_:
Amounts_NN
provided_VBN [WZPAST]
for_PIN
doubtful_JJ
debts_NN
56_CD
42_CD
2,645_CD
2,388_CD
Deferred_JJ
taxation_NOMZ
Note_NN
7_CD
625_CD
550_CD
Other_JJ
debtors_NN
658_CD
641_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
519_CD
274_CD
4,447_CD
3,853_CD
Amounts_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Deferred_VBN
taxation_NOMZ
Note_NN
7_CD
226_CD
146_CD
Other_JJ
debtors_NN
16_CD
23_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
156 117 398 286_CD
4,845_CD
4,139_CD
Figures_NN
include_VPRT
prepaid_VBN
pension_NN
costs_NN
Note_VPRT [PRIV]
32_CD
._.
Provisions_NN
for_PIN
doubtful_JJ
debts_NN
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Balance_NN
at_PIN
beginning_GER
of_PIN
year_NN
42_CD
39_CD
118_CD
Profit_NN
and_PHC
loss_NN
account_NN
charge_NN
11_CD
434_CD
Amounts_NN
utilised_JJ
and_PHC
other_JJ
movements_NOMZ
incl_NN
._.
Agrochemicals_NN
demerger_VPRT
in_PIN
2000_CD
3_CD
1_CD
113_CD
Balance_NN
at_PIN
end_NN
of_PIN
year_NN
56_CD
42_CD
39_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
81_CD
16_CD
Short_JJ
term_NN
investments_NOMZ
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD [PASS]
Listed_VBN
debt_NN
securities_NOMZ
144_CD
288_CD
Other_JJ
listed_VBN
investments_NOMZ
46_CD
45_CD
Investment_NOMZ
securities_NOMZ
190_CD
333_CD
Fixed_VBN
deposits_NN
3,772_CD
2,785_CD
3,962_CD
3,118_CD
The_DT
Groups_NN
insurance_NN
subsidiaries_NN
hold_VPRT [PRIV]
cash_NN
and_CC
short_JJ
term_NN
investments_NOMZ
totalling_VBG [WZPRES]
$_$
173m_CD
2001_CD
$_$
186m_CD
,_,
of_PIN
which_WDT [PIRE]
$_$
120m_CD
2001_CD
$_$
105m_CD
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
meet_VB
insurance_NN
solvency_NN
requirements_NOMZ
and_ANDC
which_WDT
,_,
as_CONJ
a_NULL
result_NULL
,_,
is_VPRT
not_XX0
readily_RB
available_PRED
for_PIN
the_DT
general_JJ
purposes_NN
of_PIN
the_DT
Group_NN
._.
In_CONJ
addition_NULL
,_,
some_QUAN
$_$
126m_CD
2001_CD
$_$
236m_CD
of_PIN
short_JJ
term_NN
investments_NOMZ
shown_VBN [PRIV]
above_PLACE
are_VPRT [PASS]
committed_VBN
as_IN
security_NOMZ
against_PIN
deferred_VBN
payments_NOMZ
due_JJ
under_IN
a_DT
contractual_JJ
obligation_NOMZ
of_PIN
the_DT
Group_NN
see_VB [PRIV]
Note_VB [PRIV]
34_CD
._.
The_DT
market_NN
value_NN
of_PIN
other_JJ
listed_VBN
investments_NOMZ
was_VBD
$_$
137m_CD
2001_CD
$_$
145m_CD
at_PIN
the_DT
year_NN
end_NN
._.
17_CD
Short_JJ
term_NN
borrowings_GER
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD
Bank_NN
borrowings_GER
Fixed_VBN
securities_NOMZ
11_CD
22_CD
Secured_JJ
by_PIN
floating_VBG
charge_NN
8_CD
Unsecured_NN
191 183 202 213_CD
Other_JJ
borrowings_GER
unsecured_JJ
1_CD
202_CD
214_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
82_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
18_CD
Other_JJ
creditors_NN
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
Trade_NN
creditors_NN
3,171_CD
2,385_CD
Corporate_JJ
taxation_NOMZ
1,191_CD
1,018_CD
Value_NN
added_VBD [PUBV]
and_CC
payroll_NN
taxes_NN
and_CC
social_JJ
security_NOMZ
167_CD
173_CD
Other_JJ
creditors_NN
1,507_CD
1,219_CD
Accruals_NN
855_CD
544_CD
Dividends_NN
to_PIN
shareholders_NN
808_CD
820_CD
7,699_CD
6,159_CD
Amounts_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Other_JJ
creditors_NN
34_CD
152_CD
Included_VBN
in_PIN
other_JJ
creditors_NN
are_VPRT
amounts_NN
totalling_VBG [WZPRES]
$_$
189m_CD
2001_CD
$_$
104m_CD
to_TO
meet_VB
insurance_NN
obligations_NOMZ
of_PIN
the_DT
Groups_NN
insurance_NN
subsidiaries_NN
._.
Also_RB
included_VBN
in_PIN
other_JJ
creditors_NN
are_VPRT
amounts_NN
due_JJ
within_PIN
one_CD
year_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
Groups_NN
exceptional_JJ
charges_NN
as_IN
detailed_VBN
in_PIN
Note_NN
5_CD
._.
The_DT
amounts_NN
comprise_VPRT
$_$
350m_CD
2001_CD
$_$
nil_CD
in_PIN
respect_NN
of_PIN
the_DT
accrual_NN
related_VBN [WZPAST]
to_PIN
the_DT
Zoladex_NN
investigation_NOMZ
in_PIN
the_DT
US_FPP1
,_,
$_$
36m_CD
2001_CD
$_$
116m_CD
in_PIN
respect_NN
of_PIN
synergy_NN
and_PHC
integration_NOMZ
costs_NN
,_,
$_$
14m_CD
2001_CD
$_$
21m_CD
in_PIN
respect_NN
of_PIN
the_DT
Agrochemicals_NN
demerger_NN
and_CC
$_$
48m_CD
2001_CD
$_$
64m_CD
in_PIN
respect_NN
of_PIN
the_DT
Specialties_NN
disposal_NN
and_CC
other_JJ
minor_JJ
restructurings_GER
._.
19_CD
Loans_NN
Repayment_NOMZ
2002_CD
2001_CD
Dates_NN
$_$
m_CD
$_$
m_CD [BEMA]
Secured_JJ
loans_NN
Secured_JJ
by_PIN
fixed_JJ
charge_NN
2003_CD
2007_CD
19_CD
48_CD
Total_JJ
secured_VBN
19_CD
48_CD
Unsecured_JJ
loans_NN
US_FPP1
dollars_NN
6.3_CD
%_NN
Guaranteed_VBN [PUBV]
notes_NN
2003 284 284_CD
7_CD
%_NN
Guaranteed_VBN [PUBV]
debentures_NN
2023 295 295_CD
Others_NN
2003_CD
2013_CD
44_CD
115_CD
Total_JJ
unsecured_JJ
623_CD
694_CD
Total_JJ
loans_NN
642_CD
742_CD
Less_RB
:_:
current_JJ
instalments_NOMZ
of_PIN
loans_NN
314_CD
107_CD
Loans_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
328_CD
635_CD
In_PIN
the_DT
above_PLACE
table_NN
loans_NN
are_VPRT [PASS]
shown_VBN [PRIV]
after_IN
taking_VBG
account_NN
of_PIN
associated_VBN
cross-currency_NN
swaps_NN
see_VPRT [PRIV]
Note_VB [PRIV]
20_CD
._.
Loans_NN
from_PIN
banks_NN
included_VBD
in_PIN
the_DT
table_NN
above_PLACE
amounted_VBD
to_TO
$_$
61m_CD
2001_CD
$_$
156m_CD
of_PIN
which_WDT [PIRE]
$_$
40m_CD
2001_CD
$_$
48m_CD
was_VBD [PASS]
secured_VBN
._.
com_NN
83_CD
20_CD
Financial_NN
instruments_NOMZ
A_DT
discussion_NN
of_PIN
the_DT
Groups_NN
objective_NN
,_,
policy_NN
and_PHC
strategy_NN
in_PIN
respect_NN
of_PIN
risk_NN
management_NOMZ
and_CC
the_DT
use_NN
of_PIN
financial_JJ
instruments_NOMZ
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
Financial_NN
Review_NN
on_PIN
pages_NN
30_CD
to_PIN
43_CD
._.
The_DT
following_JJ
disclosures_NN
exclude_VPRT
all_QUAN
short_JJ
term_NN
trade_NN
related_VBN
debtors_NN
and_PHC
creditors_NN
._.
Interest_NN
rate_NN
risks_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
The_DT
interest_NN
rate_NN
profile_NN
,_,
after_IN
taking_VBG
account_NN
of_PIN
interest_NN
and_PHC
currency_NN
swaps_NN
,_,
of_PIN
the_DT
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
Group_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
was_VBD
:_:
Financial_NN
Weighted_NN
Weighted_NN
assets_NN
liabilities_NOMZ
average_JJ
average_NN
on_PIN
which_WDT [PIRE]
fixed_JJ
period_NN
for_PIN
Floating_VBG
Fixed_VBN
no_SYNE
interest_NN
is_VPRT
interest_NN
which_WDT [WHOBJ]
rate_NN
rate_NN
rate_NN
paid_VBD
received_VBN
Total_JJ
rate_NN
is_VPRT [PASS]
fixed_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
%_NN
Years_NN
Financial_NN
liabilities_NOMZ
US_FPP1
dollar_NN
782_CD
8_CD
126_CD
916_CD
12.8_CD
9.6_CD
Sterling_GER
Euro_NN
Other_JJ
35_CD
19_CD
54_CD
6.3_CD
2.2_CD
817 27 126 970_CD
Financial_NN
assets_NN
US_FPP1
dollar_NN
4,354_CD
4,354_CD
Euro_NN
71_CD
71_CD
Sterling_GER
114_CD
46_CD
160_CD
SEK_NN
33_CD
33_CD
Other_JJ
70_CD
22_CD
92_CD
4,642_CD
68_CD
4,710_CD
Financial_NN
liabilities_NOMZ
on_PIN
which_WDT [PIRE]
no_SYNE
interest_NN
is_VPRT [PASS]
paid_VBN
comprise_VPRT
deferred_VBN
payments_NOMZ
due_JJ
relating_VBG
to_PIN
the_DT
reacquisition_NOMZ
of_PIN
certain_JJ
marketing_GER
rights_NN
._.
The_DT
floating_VBG
rate_NN
financial_JJ
liabilities_NOMZ
comprise_VPRT
largely_RB
of_PIN
fixed_JJ
rate_NN
debt_NN
that_TSUB
has_VPRT [PEAS]
been_VBN [PASS]
swapped_VBN
into_PIN
floating_VBG
rate_NN
debt_NN
._.
One_CD
long_JJ
dated_JJ
$_$
300m_CD
USD_NN
bond_NN
reverts_VPRT
back_RB
to_PIN
a_DT
fixed_JJ
rate_NN
in_PIN
2009_CD
._.
The_DT
financial_JJ
liabilities_NOMZ
also_RB
include_VPRT
$_$
202m_CD
of_PIN
short_JJ
term_NN
bank_NN
borrowings_GER
and_PHC
overdrafts_NN
,_,
bearing_VBG
interest_NN
at_PIN
rates_NN
fixed_VBN [WZPAST]
by_PIN
reference_NN
to_PIN
local_JJ
interbank_NN
rates_NN
._.
Financial_JJ
assets_NN
on_PIN
which_WDT [PIRE]
no_SYNE
interest_NN
is_VPRT [PASS]
received_VBN
comprise_VPRT
equity_NOMZ
investments_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Group_NN
._.
The_DT
financial_JJ
assets_NN
principally_RB
comprise_VPRT
cash_NN
on_PIN
overnight_JJ
deposit_NN
and_CC
short_JJ
term_NN
investments_NOMZ
with_PIN
an_DT
average_JJ
maturity_NOMZ
of_PIN
67_CD
days_NN
._.
These_DEMP
include_VPRT
deposits_NN
where_RB
the_DT
interest_NN
rate_NN
is_VPRT [PASS]
fixed_VBN
until_IN
maturity_NOMZ
but_CC
,_,
as_IN
the_DT
original_JJ
maturity_NOMZ
is_VPRT [BEMA]
less_PRED
than_PIN
one_CD
year_NN
,_,
they_TPP3
are_VPRT [PASS]
classified_VBN
as_IN
floating_VBG
rate_NN
financial_JJ
instruments_NOMZ
._.
The_DT
benchmark_NN
rates_NN
for_PIN
financial_JJ
assets_NN
are_VPRT [BEMA]
the_DT
LIBID_NN
rate_NN
for_PIN
euro_NN
and_PHC
US_FPP1
dollar_NN
liquidity_NOMZ
balances_NN
and_CC
the_DT
average_JJ
Federal_NN
Funds_NN
effective_JJ
rate_NN
for_PIN
US_FPP1
dollar_NN
overnight_JJ
balances_NN
._.
Financial_JJ
assets_NN
include_VPRT
$_$
46m_CD
of_PIN
other_JJ
fixed_JJ
asset_NN
investments_NOMZ
on_PIN
which_WDT [PIRE]
no_SYNE
interest_NN
is_VPRT [PASS]
received_VBN
._.
com_NN
84_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
20_CD
Financial_NN
instruments_NOMZ
continued_VBD
Currency_NN
exposures_NN
100_CD
%_NN
of_PIN
the_DT
Groups_NN
transactional_JJ
currency_NN
exposures_NN
on_PIN
working_VBG
capital_NN
balances_NN
,_,
which_WDT [SERE]
typically_RB
extend_VPRT
for_PIN
up_RB
to_PIN
three_CD
months_NN
,_,
are_VPRT [PASS]
hedged_VBN
using_VBG
forward_RB
foreign_JJ
exchange_NN
contracts_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
as_RB
at_PIN
31_CD
December_NN
2002_CD
,_,
there_EX
were_VBD
no_SYNE
material_NN
monetary_JJ
assets_NN
or_CC
liabilities_NOMZ
in_PIN
currencies_NN
other_JJ
than_PIN
the_DT
functional_JJ
currencies_NN
of_PIN
the_DT
Group_NN
companies_NN
concerned_VBN
,_,
having_VBG [PEAS]
taken_VBN
into_PIN
account_NN
the_DT
effect_NN
of_PIN
forward_RB
exchange_NN
currency_NN
contracts_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
utilised_VBN
to_TO
match_VB
foreign_JJ
currency_NN
exposures_NN
._.
Additionally_RB
,_,
approximately_RB
50_CD
%_NN
of_PIN
forecast_NN
future_JJ
foreign_JJ
currency_NN
transaction_NOMZ
exposures_NN
extending_VBG [WZPRES]
for_PIN
12_CD
months_NN
are_VPRT [SPAU] [PASS]
selectively_RB
hedged_VBN
._.
The_DT
principal_JJ
currency_NN
exposures_NN
sterling_GER
,_,
Swedish_JJ
kronor_NN
,_,
euro_NN
,_,
Australian_JJ
dollars_NN
,_,
Canadian_JJ
dollars_NN
and_PHC
yen_NN
are_VPRT [PASS]
hedged_VBN
using_VBG
a_DT
mixture_NN
of_PIN
purchased_JJ
currency_NN
options_NOMZ
and_CC
forward_RB
foreign_JJ
exchange_NN
contracts_NN
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
the_DT
Group_NN
held_VBD [PRIV]
forward_RB
and_CC
option_NOMZ
contracts_NN
to_TO
hedge_VB
the_DT
following_JJ
forecast_NN
foreign_JJ
currency_NN
transaction_NOMZ
exposures_NN
:_:
2002_CD
2001_CD
Hedged_NN
Hedged_NN
amount_NN
amount_NN
$_$
m_CD
$_$
m_CD
Sterling_GER
payables_NN
1,316_CD
1,324_CD
SEK_NN
payables_NN
503_CD
401_CD
Euro_NN
receivables_NN
713_CD
591_CD
Yen_NN
receivables_NN
153_CD
89_CD
AUD_NN
receivables_NN
81_CD
73_CD
CAD_NN
receivables_NN
168_CD
128_CD
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
The_DT
maturity_NOMZ
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
,_,
other_JJ
than_PIN
short_JJ
term_NN
creditors_NN
such_JJ
as_IN
trade_NN
creditors_NN
and_PHC
accruals_NN
,_,
at_PIN
31_CD
December_NN
2002_CD
was_VBD
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Analysis_NN
by_PIN
year_NN
of_PIN
repayment_NOMZ
Loans_NN
Other_JJ
Total_NN
Loans_NN
Other_JJ
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
After_IN
five_CD
years_NN
308 308 314 314_CD
From_PIN
five_CD
to_PIN
four_CD
years_NN
13_CD
13_CD
14_CD
14_CD
From_PIN
four_CD
to_PIN
three_CD
years_NN
9_CD
9_CD
From_PIN
three_CD
to_PIN
two_CD
years_NN
7_CD
7_CD
From_PIN
two_CD
to_PIN
one_CD
years_NN
7_CD
7_CD
291 120 411_CD
Due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
328 328 635 120_CD
755_CD
Due_JJ
within_PIN
one_CD
year_NN
314 328 642 107_CD
356 463 642 328_CD
970 742 476_CD
1,218_CD
Other_JJ
financial_JJ
liabilities_NOMZ
comprise_VPRT
deferred_VBN
payments_NOMZ
to_PIN
re-acquire_JJ
certain_JJ
distribution_NOMZ
rights_NN
,_,
short_JJ
term_NN
borrowings_GER
and_PHC
finance_NN
leases_NN
._.
Borrowing_GER
facilities_NOMZ
The_DT
Group_NN
has_VPRT
various_JJ
borrowing_GER
facilities_NOMZ
available_JJ
to_PIN
it_PIT
,_,
the_DT
majority_NOMZ
of_PIN
which_WDT [PIRE]
offer_VPRT
a_DT
currency_NN
option_NOMZ
of_PIN
US_FPP1
dollars_NN
,_,
euros_NN
or_CC
sterling_GER
._.
Unused_JJ
short_JJ
term_NN
credit_NN
facilities_NOMZ
both_DT
committed_JJ
and_PHC
uncommitted_JJ
totalled_JJ
approximately_RB
$_$
0.5_CD
bn_NN
at_PIN
31_CD
December_NN
2002_CD
._.
Included_VBN [PASTP]
in_PIN
this_DEMP
were_VBD [BEMA]
undrawn_JJ
committed_JJ
facilities_NOMZ
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
all_QUAN
conditions_NOMZ
precedent_NN
had_VBD [PEAS]
been_VBN [PASS]
met_VBN
at_PIN
that_DEMO
date_NN
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD
Expiring_GER
in_PIN
one_CD
year_NN
or_CC
less_JJ
75_CD
375_CD
Expiring_GER
in_PIN
more_EMPH
than_PIN
one_CD
year_NN
but_CC
not_XX0
more_EMPH
than_PIN
two_CD
years_NN
Expiring_VBG [WZPRES]
in_PIN
more_EMPH
than_PIN
two_CD
years_NN
75_CD
375_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
85_CD
20_CD
Financial_NN
instruments_NOMZ
continued_VBD
Fair_NN
values_NN
of_PIN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
Set_VPRT
out_PIN
below_PLACE
is_VPRT [BEMA]
a_DT
comparison_NN
by_PIN
category_NN
of_PIN
carrying_VBG
values_NN
and_CC
fair_JJ
values_NN
of_PIN
all_QUAN
the_DT
Groups_NN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
as_IN
at_PIN
31_CD
December_NN
2002_CD
and_CC
2001_CD
._.
2002 2002 2001 2001_CD
Carrying_VBG
Fair_NN
Carrying_VBG [WZPRES]
Fair_NN
value_NN
value_NN
value_NN
value_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Primary_JJ
financial_JJ
instruments_NOMZ
Short_JJ
term_NN
borrowings_GER
202 202 214 214_CD
Loans_NN
657 733 759 805_CD
Cash_NN
726 726 705 705_CD
Short_JJ
term_NN
investments_NOMZ
3,962_CD
4,067_CD
3,118_CD
3,192_CD
Fixed_VBN
asset_NN
investments_NOMZ
46_CD
46_CD
23_CD
23_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
to_TO
manage_VB
the_DT
interest_NN
rate_NN
and_PHC
currency_NN
profile_NN
Cross-currency_NN
swaps_NN
and_PHC
interest_NN
rate_NN
swaps_NN
15_CD
82_CD
17_CD
70_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
or_CC
issued_VBN
to_TO
hedge_VB
the_DT
currency_NN
exposure_NN
on_PIN
existing_VBG
transactions_NOMZ
Forward_RB
foreign_JJ
exchange_NN
contracts_NN
9_CD
9_CD
11_CD
9_CD
Foreign_JJ
currency_NN
option_NOMZ
contracts_NN
1_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
or_CC
issued_VBN
to_TO
hedge_VB
the_DT
currency_NN
exposure_NN
on_PIN
expected_JJ
future_JJ
transactions_NOMZ
Forward_RB
foreign_JJ
exchange_NN
contracts_NN
1_CD
Foreign_JJ
currency_NN
option_NOMZ
contracts_NN
56_CD
97_CD
82_CD
81_CD
In_CONJ
addition_NULL
to_PIN
the_DT
primary_JJ
financial_JJ
instruments_NOMZ
above_PLACE
,_,
the_DT
Group_NN
has_VPRT
financial_JJ
liabilities_NOMZ
of_PIN
$_$
126m_CD
comprising_VBG
deferred_JJ
payments_NOMZ
due_JJ
$_$
129m_CD
before_IN
discounting_VBG
._.
The_DT
Group_NN
has_VPRT
a_DT
standby_JJ
letter_NN
of_PIN
credit_NN
covering_VBG [WZPRES]
these_DEMO
financial_JJ
liabilities_NOMZ
which_WDT [WHSUB]
is_VPRT [BYPA]
collateralised_VBN
by_PIN
high_JJ
grade_NN
government_NOMZ
securities_NOMZ
._.
The_DT
methods_NN
and_PHC
assumptions_NOMZ
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
values_NN
of_PIN
financial_JJ
instruments_NOMZ
are_VPRT
as_IN
follows_VPRT
:_:
a._VB
Short_JJ
term_NN
investments_NOMZ
the_DT
fair_JJ
value_NN
of_PIN
listed_VBN
investments_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
year_NN
end_NN
quoted_VBN
market_NN
prices_NN
._.
For_PIN
unlisted_JJ
investments_NOMZ
carrying_VBG [WZPRES]
values_NN
approximate_JJ
fair_JJ
value_NN
._.
Fixed_JJ
asset_NN
investments_NOMZ
excluding_VBG [WZPRES]
equity_NOMZ
investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
the_DT
fair_JJ
value_NN
of_PIN
listed_VBN
investments_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
year_NN
end_NN
quoted_VBN
market_NN
prices_NN
._.
c._FW
Loans_NN
the_DT
fair_JJ
value_NN
of_PIN
publicly_RB
traded_VBN
debt_NN
is_VPRT [PASS]
based_VBN
on_PIN
year_NN
end_NN
quoted_VBN
market_NN
prices_NN
:_:
the_DT
fair_JJ
value_NN
of_PIN
floating_VBG
rate_NN
debt_NN
is_VPRT [BEMA]
nominal_JJ
value_NN
,_,
as_IN
market_NN
to_PIN
market_NN
differences_NN
would_PRMD
be_VB [BEMA]
minimal_PRED
given_VBN
frequency_NN
of_PIN
resets_NN
:_:
the_DT
fair_JJ
value_NN
of_PIN
remaining_VBG
debt_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
using_VBG
appropriate_JJ
zero_CD
coupon_NN
valuation_NOMZ
techniques_NN
based_VBN [WZPAST]
on_PIN
rates_NN
current_JJ
at_PIN
year_NN
end_NN
._.
d._FW
Forward_RB
foreign_JJ
exchange_NN
contracts_NN
the_DT
Group_NN
has_VPRT
forward_RB
foreign_JJ
exchange_NN
contracts_NN
to_TO
sell_VB
currency_NN
for_PIN
the_DT
purpose_NN
of_PIN
hedging_VBG
nondollar_JJ
commercial_JJ
transaction_NOMZ
exposures_NN
which_WDT [WHSUB]
existed_VBD
at_PIN
the_DT
date_NN
of_PIN
the_DT
balance_NN
sheet_NN
and_CC
to_TO
hedge_VB
anticipated_VBN [PRIV]
,_,
but_CC
not_XX0
firmly_RB
committed_VBN
,_,
non-dollar_JJ
commercial_JJ
transactions_NOMZ
for_PIN
2003_CD
._.
The_DT
majority_NOMZ
of_PIN
the_DT
contracts_NN
for_PIN
existing_VBG
transactions_NOMZ
had_VBD
a_DT
maturity_NOMZ
of_PIN
six_CD
months_NN
or_CC
less_JJ
from_PIN
year_NN
end_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
forward_RB
foreign_JJ
exchange_NN
contracts_NN
is_VPRT [PASS]
based_VBN
on_PIN
market_NN
forward_RB
foreign_JJ
exchange_NN
rates_NN
at_PIN
year_NN
end_NN
._.
e._FW
Foreign_JJ
currency_NN
option_NOMZ
contracts_NN
the_DT
Group_NN
has_VPRT
foreign_JJ
currency_NN
option_NOMZ
contracts_NN
to_TO
hedge_VB
anticipated_VBN [PRIV]
,_,
but_CC
not_XX0
firmly_RB
committed_VBN
,_,
nondollar_JJ
commercial_JJ
transactions_NOMZ
for_PIN
2003_CD
._.
The_DT
fair_JJ
value_NN
of_PIN
option_NOMZ
contracts_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
using_VBG
Black-Scholes_NN
valuation_NOMZ
techniques_NN
as_IN
adapted_VBN
by_PIN
Garman_NN
and_PHC
Kohlhagen_NN
._.
f._FW
Interest_NN
rate_NN
and_PHC
cross-currency_NN
swaps_NN
AstraZeneca_NN
uses_VPRT
interest_NN
rate_NN
and_PHC
cross-currency_NN
swaps_NN
to_TO
hedge_VB
the_DT
Groups_NN
exposure_NN
to_PIN
fluctuations_NOMZ
in_PIN
interest_NN
rates_NN
and_CC
foreign_JJ
exchange_NN
movements_NOMZ
on_PIN
borrowings_GER
in_PIN
accordance_NN
with_PIN
a_DT
formal_JJ
risk_NN
management_NOMZ
strategy_NN
._.
The_DT
fair_JJ
value_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
using_VBG
appropriate_JJ
zero_CD
coupon_NN
valuation_NOMZ
techniques_NN
based_VBN [WZPAST]
on_PIN
rates_NN
current_JJ
at_PIN
year_NN
end_NN
._.
com_NN
86_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
20_CD
Financial_NN
instruments_NOMZ
continued_VBD
The_DT
above_PLACE
financial_JJ
instruments_NOMZ
are_VPRT [BEMA]
subject_PRED
to_PIN
credit_NN
and_PHC
market_NN
risk_NN
._.
AstraZeneca_NN
contains_VPRT
credit_NN
risk_NN
through_PIN
the_DT
use_NN
of_PIN
counterparty_NN
and_PHC
product_NN
specific_JJ
credit_NN
limits_NN
and_CC
by_PIN
ongoing_JJ
review_NN
procedures_NN
._.
All_QUAN
financial_JJ
instruments_NOMZ
except_PIN
the_DT
letter_NN
of_PIN
credit_NN
are_VPRT [PASS]
transacted_VBN
with_PIN
commercial_JJ
banks_NN
and_CC
,_,
in_PIN
line_NN
with_PIN
standard_JJ
market_NN
practice_NN
,_,
are_VPRT [PASS]
not_XX0
backed_VBN
with_PIN
cash_NN
collateral_NN
._.
The_DT
notional_JJ
principal_NN
values_NN
of_PIN
off_PIN
balance_NN
sheet_NN
financial_JJ
instruments_NOMZ
do_VPRT
not_XX0
represent_VB
amounts_NN
exchanged_VBN [WZPAST]
by_PIN
the_DT
parties_NN
and_CC
are_VPRT [BEMA]
not_XX0
a_DT
measure_NN
of_PIN
the_DT
credit_NN
risk_NN
to_PIN
the_DT
Group_NN
of_PIN
these_DEMO
instruments_NOMZ
._.
The_DT
credit_NN
risk_NN
of_PIN
these_DEMO
instruments_NOMZ
is_VPRT [PASS]
limited_VBN
to_PIN
the_DT
positive_JJ
fair_JJ
values_NN
of_PIN
such_JJ
contracts_NN
._.
Market_NN
risk_NN
is_VPRT [BEMA]
the_DT
sensitivity_NOMZ
of_PIN
the_DT
value_NN
of_PIN
financial_JJ
instruments_NOMZ
to_PIN
changes_NN
in_PIN
related_JJ
currency_NN
and_PHC
interest_NN
rates_NN
._.
The_DT
Group_NN
is_VPRT [PASS]
not_XX0
exposed_VBN
to_PIN
material_NN
market_NN
risk_NN
because_CAUS
gains_NN
and_PHC
losses_NN
on_PIN
the_DT
derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [SPAU] [BYPA]
largely_RB
offset_VBN
by_PIN
gains_NN
and_PHC
losses_NN
on_PIN
the_DT
underlying_VBG
assets_NN
,_,
liabilities_NOMZ
and_PHC
transactions_NOMZ
subject_JJ
to_TO
hedge_VB
._.
Hedges_NN
The_NN
Groups_NN
policy_NN
is_VPRT
to_TO
hedge_VB
100_CD
%_NN
of_PIN
transactional_JJ
currency_NN
exposures_NN
and_CC
50_CD
%_NN
of_PIN
forecast_NN
future_JJ
transaction_NOMZ
exposures_NN
using_VBG [WZPRES]
forward_RB
foreign_JJ
exchange_NN
contracts_NN
and_CC
foreign_JJ
currency_NN
option_NOMZ
contracts_NN
._.
It_PIT
also_RB
uses_VPRT
cross-currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
to_TO
manage_VB
its_PIT
borrowings_GER
profile_VPRT
._.
Gains_NN
and_PHC
losses_NN
on_PIN
instruments_NOMZ
used_VBN [WZPAST]
for_PIN
hedging_VBG
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
until_IN
the_DT
exposure_NN
that_DEMP
is_VPRT
being_VBG [PASS]
hedged_VBN
is_VPRT [BEMA] [PASS]
itself_PIT
recognized_VBN [PRIV]
._.
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
on_PIN
instruments_NOMZ
used_VBN [WZPAST]
for_PIN
hedging_VBG
are_VPRT
as_IN
follows_VPRT
:_:
Total_JJ
net_JJ
Gains_NN
Losses_NN
gains_VPRT
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
on_PIN
hedges_NN
at_PIN
1_CD
January_NN
2002_CD
54_CD
4_CD
50_CD
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
previous_JJ
years_NN
that_TSUB
were_VBD [PASS]
recognized_VBN [PRIV]
in_PIN
2002_CD
31_CD
4_CD
27_CD
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
previous_JJ
years_NN
that_TSUB
were_VBD [PASS]
not_XX0
recognized_VBN [PRIV]
in_PIN
2002_CD
23_CD
23_CD
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
on_PIN
hedges_NN
at_PIN
31_CD
December_NN
2002 108 108_CD
Gains_NN
and_PHC
losses_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
2003_CD
56_CD
56_CD
Gains_NN
and_PHC
losses_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
2004_CD
or_CC
later_TIME
52_CD
52_CD
21_CD
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
Environmental_NN
,_,
litigation_NOMZ
Integration_NOMZ
Employee_NN
and_CC
other_JJ
Deferred_JJ
and_CC
synergies_NN
benefits_NN
provisions_NN
taxation_NOMZ
Total_JJ
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
At_PIN
1_CD
January_NN
2001_CD
as_IN
previously_TIME
reported_VBN [PUBV]
25 754 204_CD
85_CD
1,068_CD
Prior_RB
year_NN
adjustment_NOMZ
page_NN
62 549 549_CD
25 754 204 634_CD
1,617_CD
Profit_NN
and_PHC
loss_NN
account_NN
156_CD
103 14 329 602_CD
Net_JJ
amounts_NN
paid_VBN
or_CC
becoming_VBG
current_JJ
148_CD
306_CD
55_CD
509_CD
Acquisitions_NOMZ
1_CD
1_CD
Other_JJ
movements_NOMZ
,_,
including_VBG
exchange_NN
18_CD
23_CD
15_CD
55_CD
111_CD
At_PIN
31_CD
December_NN
2001_CD
restated_VBN
15 529 148 908_CD
1,600_CD
Profit_NN
and_PHC
loss_NN
account_NN
89 43 305 437_CD
Net_JJ
amounts_NN
paid_VBN
or_CC
becoming_VBG
current_JJ
11_CD
279_CD
31_CD
321_CD
Other_JJ
movements_NOMZ
,_,
including_VBG
exchange_NN
10_CD
34_CD
16_CD
3_CD
57_CD
At_PIN
31_CD
December_NN
2002 14 373 176_CD
1,210_CD
1,773_CD
Employee_NN
benefit_NN
provisions_NN
comprise_VPRT
pension_NN
,_,
post-retirement_NOMZ
and_CC
other_JJ
employee_NN
benefit_NN
provisions_NN
._.
These_DEMP
will_PRMD
crystallise_VB
,_,
in_PIN
the_DT
main_JJ
,_,
over_IN
the_DT
estimated_VBN [PRIV]
working_VBG
lives_NN
of_PIN
the_DT
employees_NN
concerned_VBN
._.
The_DT
environmental_JJ
provisions_NN
are_VPRT [BEMA]
principally_RB
in_PIN
respect_NN
of_PIN
sites_NN
in_PIN
the_DT
US_FPP1
,_,
further_JJ
details_NN
of_PIN
which_WDT [PIRE]
are_VPRT [PASS]
given_VBN
in_PIN
Note_NN
34_CD
._.
No_SYNE
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
released_VBN
or_CC
applied_VBN
for_PIN
any_QUAN
purpose_NN
other_JJ
than_PIN
that_DEMO
for_PIN
which_WDT [PIRE]
it_PIT
was_VBD [PASS]
established_VBN [PRIV]
._.
com_NN
87_CD
22_CD
Reconciliation_NOMZ
of_PIN
movements_NOMZ
in_PIN
shareholders_NN
funds_NN
2002 2001 2000_CD
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Shareholders_NN
funds_NN
at_PIN
beginning_GER
of_PIN
year_NN
9,586_CD
9,389_CD
10,302_CD
Prior_RB
year_NN
adjustment_NOMZ
page_NN
62_CD
39_CD
9,586_CD
9,389_CD
10,263_CD
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
2,836_CD
2,906_CD
2,277_CD
Dividends_NN
Cash_NN
1,206_CD
1,225_CD
1,236_CD
Dividend_NN
in_PIN
specie_NN
1,669_CD
1,630_CD
1,681_CD
628_CD
Issues_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
36_CD
86_CD
19_CD
Re-purchase_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
1,190_CD
1,080_CD
353_CD
Astra_NN
AB_NN
minority_NOMZ
interest_NN
buyout_NN
8_CD
Goodwill_NN
written_VBN [PUBV] [WZPAST]
back_RB
862_CD
Exchange_NN
adjustments_NOMZ
on_PIN
net_JJ
assets_NN
1,106_CD
502_CD
870_CD
Translation_NOMZ
differences_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
6_CD
18_CD
154_CD
Tax_NN
on_PIN
translation_NOMZ
differences_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
2_CD
6_CD
42_CD
Other_JJ
movements_NOMZ
8_CD
Net_JJ
addition_NOMZ
to_PIN
reduction_NOMZ
in_PIN
shareholders_NN
funds_NN
1,586_CD
197_CD
874_CD
Shareholders_NN
funds_NN
at_PIN
end_NN
of_PIN
year_NN
11,172_CD
9,586_CD
9,389_CD
Shareholders_NN
funds_NN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
year_NN
were_VBD
originally_TIME
$_$
9,786_CD
m_NN
before_IN
deducting_VBG
the_DT
prior_JJ
year_NN
adjustment_NOMZ
of_PIN
$_$
200m_CD
in_PIN
respect_NN
of_PIN
deferred_JJ
tax_NN
under_IN
FRS_NN
19_CD
2001_CD
$_$
9,521_CD
m_NN
before_IN
deduction_NOMZ
of_PIN
$_$
132m_CD
._.
23_CD
Reserves_NN
Share_NN
Capital_NN
Joint_NN
Profit_NN
premium_NN
redemption_NOMZ
Merger_NN
Other_JJ
ventures_NN
and_CC
and_CC
loss_NN
account_NN
reserve_NN
reserve_NN
reserves_NN
associates_NN
account_VPRT
Total_JJ
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
At_PIN
31_CD
December_NN
1999_CD
as_IN
previously_TIME
reported_VBN [PUBV]
202_CD
1_CD
441_CD
703_CD
27_CD
8,538_CD
9,858_CD
Prior_RB
year_NN
adjustment_NOMZ
page_NN
62_CD
39_CD
39_CD
202_CD
1_CD
441_CD
703_CD
27_CD
8,499_CD
9,819_CD
Loss_NN
retained_VBN [WZPAST]
for_PIN
year_NN
157 471 628_CD
Share_NN
premiums_NN
19_CD
19_CD
Transfer_NN
between_PIN
reserves_NN
14_CD
14_CD
Re-purchase_NN
of_PIN
shares_NN
2_CD
353_CD
351_CD
Astra_NN
AB_NN
minority_NOMZ
interest_NN
buyout_NN
8_CD
8_CD
Goodwill_NN
written_VBN [PUBV] [WZPAST]
back_RB
862_CD
862_CD
Exchange_NN
adjustments_NOMZ
:_:
Goodwill_NN
67_CD
67_CD
Net_JJ
assets_NN
1_CD
871_CD
870_CD
On_PIN
foreign_JJ
currency_NN
borrowings_GER
154_CD
154_CD
Foreign_JJ
currency_NN
borrowings_GER
tax_NN
effect_NN
42_CD
42_CD
67_CD
1_CD
826_CD
758_CD
Other_JJ
movements_NOMZ
2_CD
10_CD
8_CD
Net_NN
movements_NOMZ
33_CD
2_CD
8_CD
931_CD
156_CD
1,674_CD
872_CD
At_PIN
31_CD
December_NN
2000_CD
restated_VBN
235_CD
3_CD
433_CD
1,634_CD
183_CD
6,825_CD
8,947_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
88_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
23_CD
Reserves_NN
continued_VBN
Share_NN
Capital_NN
Joint_NN
Profit_NN
premium_NN
redemption_NOMZ
Merger_NN
Other_JJ
ventures_NN
and_CC
and_CC
loss_NN
account_NN
reserve_NN
reserve_NN
reserves_NN
associates_NN
account_VPRT
Total_JJ
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
At_PIN
31_CD
December_NN
2000_CD
restated_VBN
235_CD
3_CD
433_CD
1,634_CD
183_CD
6,825_CD
8,947_CD
Profit_NN
retained_VBN [WZPAST]
for_PIN
year_NN
1,681_CD
1,681_CD
Share_NN
premiums_NN
86_CD
86_CD
Transfer_NN
between_PIN
reserves_NN
13_CD
13_CD
Re-purchase_NN
of_PIN
shares_NN
6_CD
1,080_CD
1,074_CD
Exchange_NN
adjustments_NOMZ
:_:
Goodwill_NN
19_CD
19_CD
Net_JJ
assets_NN
502_CD
502_CD
On_PIN
foreign_JJ
currency_NN
borrowings_GER
18_CD
18_CD
Foreign_JJ
currency_NN
borrowings_GER
tax_NN
effect_NN
6_CD
6_CD
19 509 490_CD
Net_JJ
movements_NOMZ
99_CD
6_CD
19_CD
79_CD
203_CD
At_PIN
31_CD
December_NN
2001_CD
restated_VBN
334_CD
9_CD
433_CD
1,653_CD
183_CD
6,904_CD
9,150_CD
Profit_NN
retained_VBN [WZPAST]
for_PIN
year_NN
1,630_CD
1,630_CD
Share_NN
premiums_NN
36_CD
36_CD
Transfer_NN
between_PIN
reserves_NN
33_CD
33_CD
Re-purchase_NN
of_PIN
shares_NN
7_CD
1,190_CD
1,183_CD
Exchange_NN
adjustments_NOMZ
:_:
Goodwill_NN
30_CD
30_CD
Net_JJ
assets_NN
1,106_CD
1,106_CD
On_PIN
foreign_JJ
currency_NN
borrowings_GER
66_CD
Foreign_JJ
currency_NN
borrowings_GER
tax_NN
effect_NN
2_CD
2_CD
30_CD
1,140_CD
1,110_CD
Net_JJ
movements_NOMZ
69_CD
7_CD
30_CD
1,547_CD
1,593_CD
At_PIN
31_CD
December_NN
2002_CD
403_CD
16_CD
433_CD
1,623_CD
183_CD
8,451_CD
10,743_CD
The_DT
prior_JJ
year_NN
adjustment_NOMZ
arises_VPRT
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
adoption_NOMZ
of_PIN
FRS19_NN
Deferred_NN
Tax_NN
,_,
as_IN
explained_VBN [PUBV]
in_PIN
more_EMPH
detail_NN
on_PIN
page_NN
62_CD
._.
The_DT
movement_NOMZ
in_PIN
other_JJ
reserves_NN
in_PIN
2000_CD
relates_VPRT
to_PIN
the_DT
realisation_NOMZ
of_PIN
goodwill_NN
in_PIN
respect_NN
of_PIN
the_DT
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
$_$
813m_CD
and_CC
the_DT
impairment_NOMZ
of_PIN
the_DT
Advanta_NN
seeds_NN
business_NOMZ
goodwill_NN
$_$
49m_CD
._.
The_DT
cumulative_JJ
amount_NN
of_PIN
goodwill_NN
resulting_VBG [WZPRES]
from_PIN
acquisitions_NOMZ
,_,
net_NN
of_PIN
disposals_NN
,_,
prior_RB
to_PIN
the_DT
adoption_NOMZ
of_PIN
FRS_NN
10_CD
in_PIN
1998_CD
,_,
amounted_VBD
to_TO
$_$
617m_CD
2001_CD
$_$
587m_CD
,_,
2000_CD
$_$
606m_CD
using_VBG
year_NN
end_NN
rates_NN
of_PIN
exchange_NN
._.
There_EX
are_VPRT
no_SYNE
significant_JJ
statutory_JJ
or_CC
contractual_JJ
restrictions_NOMZ
on_PIN
the_DT
distribution_NOMZ
of_PIN
current_JJ
profits_NN
of_PIN
subsidiaries_NN
,_,
joint_JJ
ventures_NN
or_CC
associates_NN
:_:
undistributed_JJ
profits_NN
of_PIN
prior_JJ
years_NN
are_VPRT
,_,
in_PIN
the_DT
main_JJ
,_,
permanently_RB
employed_VBN
in_PIN
the_DT
businesses_NOMZ
of_PIN
these_DEMO
companies_NN
._.
The_DT
undistributed_JJ
income_NN
of_PIN
AstraZeneca_NN
companies_NN
overseas_PLACE
may_POMD
be_VB [BEMA]
liable_PRED
to_PIN
overseas_PLACE
taxes_NN
and_CC
or_CC
UK_NN
taxation_NOMZ
after_IN
allowing_VBG [SUAV]
for_PIN
double_JJ
taxation_NOMZ
relief_NN
if_COND
they_TPP3
were_VBD
to_TO
be_VB [PASS]
distributed_VBN
as_IN
dividends_NN
see_VPRT [PRIV]
Note_NN
7_CD
._.
com_NN
89_CD
24_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
trading_GER
operations_NOMZ
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Operating_GER
profit_NN
before_IN
exceptional_JJ
items_NN
4,356_CD
4,156_CD
4,330_CD
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
960 860 988_CD
Stocks_NN
decrease_VPRT
increase_NN
101 417 670_CD
Debtors_NN
increase_NN
decrease_NN
198 138 987_CD
Creditors_NN
increase_NN
decrease_NN
402_CD
727_CD
1,317_CD
Other_JJ
non-cash_JJ
movements_NOMZ
65_CD
120_CD
14_CD
5,686_CD
4,130_CD
4,992_CD
25_CD
Cash_NN
flows_VPRT
related_VBN
to_PIN
exceptional_JJ
items_NN
Current_JJ
period_NN
cash_NN
flow_NN
related_VBN [WZPAST]
to_PIN
exceptional_JJ
items_NN
and_PHC
merger_NN
2002 2001 2000_CD
related_JJ
payments_NOMZ
,_,
before_IN
associated_VBN
tax_NN
charge_NN
relief_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Merck_NN
trigger_NN
event_NN
payment_NOMZ
93_CD
Merger_NN
,_,
integration_NOMZ
and_PHC
synergy_NN
costs_NN
68 312 532_CD
Salick_NN
Health_NN
Care_NN
rationalisation_NOMZ
11_CD
Agrochemicals_NN
restructuring_VBG [WZPRES]
46_CD
Costs_NN
relating_VBG [WZPRES]
to_PIN
the_DT
disposal_NN
of_PIN
Specialties_NN
business_NOMZ
21_CD
22_CD
62_CD
Demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
and_PHC
formation_NOMZ
of_PIN
Syngenta_NN
AG_NN
4_CD
34_CD
65_CD
Outflow_NN
related_VBN [WZPAST]
to_PIN
exceptional_JJ
charges_NN
93 368 809_CD
Repayment_NOMZ
of_PIN
debt_NN
by_PIN
Zeneca_NN
Agrochemicals_NN
included_VBD
in_PIN
Acquisitions_NOMZ
and_PHC
disposals_NN
909_CD
Proceeds_NN
from_PIN
disposal_NN
of_PIN
fixed_JJ
assets_NN
accounted_VBD
for_PIN
as_IN
exceptional_JJ
10_CD
Exceptional_JJ
item_NN
cash_NN
flow_NN
93 358 100_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
90_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
26_CD
Acquisitions_NOMZ
of_PIN
subsidiaries_NN
and_PHC
purchases_NN
of_PIN
minority_NOMZ
interests_NN
There_EX
were_VBD
no_SYNE
significant_JJ
business_NOMZ
acquisitions_NOMZ
in_PIN
any_QUAN
of_PIN
the_DT
years_NN
presented_VBN
._.
All_QUAN
acquisitions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
by_PIN
the_DT
acquisition_NOMZ
method_NN
of_PIN
accounting_GER
._.
2002 2001 2000_CD
Total_JJ
Total_JJ
Total_JJ
fair_JJ
value_NN
fair_JJ
value_NN
fair_JJ
value_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Fixed_VBN
assets_NN
4_CD
Current_JJ
assets_NN
26_CD
Creditors_NN
due_JJ
within_PIN
one_CD
year_NN
16_CD
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
1_CD
Fair_NN
value_NN
of_PIN
net_JJ
assets_NN
acquired_VBN
13_CD
Goodwill_NN
acquired_VBD
41_CD
32_CD
Consideration_NOMZ
for_PIN
subsidiaries_NN
and_PHC
operations_NOMZ
acquired_VBD
54_CD
32_CD
Purchases_NN
of_PIN
minority_NOMZ
interests_NN
7_CD
135_CD
47_CD
167_CD
Less_RB
:_:
Cash_NN
included_VBD
in_PIN
undertaking_VBG
acquired_VBN
3_CD
Net_JJ
cash_NN
consideration_NOMZ
44_CD
167_CD
Assets_NN
and_PHC
liabilities_NOMZ
were_VBD [PASS]
adjusted_VBN
to_PIN
their_TPP3
fair_JJ
values_NN
based_VBN [WZPAST]
on_PIN
external_JJ
valuations_NOMZ
and_CC
internal_JJ
assessments_NOMZ
._.
There_EX
were_VBD
no_SYNE
significant_JJ
differences_NN
between_PIN
book_NN
and_CC
fair_JJ
values_NN
in_PIN
respect_NN
of_PIN
the_DT
acquisitions_NOMZ
made_VBN [WZPAST]
in_PIN
any_QUAN
of_PIN
the_DT
years_NN
presented_VBN
._.
com_NN
91_CD
27_CD
Zeneca_NN
Agrochemicals_NN
demerger_NN
On_PIN
13_CD
November_NN
2000_CD
Zeneca_NN
Agrochemicals_NN
was_VBD [PASS]
demerged_VBN
from_PIN
the_DT
Group_NN
and_CC
merged_VBD
with_PIN
the_DT
agribusiness_NOMZ
of_PIN
Novartis_NN
to_TO
form_VB
Syngenta_NN
AG_NN
._.
The_DT
Zeneca_NN
Agrochemicals_NN
results_NN
for_PIN
the_DT
period_NN
to_PIN
13_CD
November_NN
2000_CD
have_VPRT [PEAS]
been_VBN [PASS]
reported_VBN [PUBV]
as_IN
discontinued_VBN
in_PIN
the_DT
AstraZeneca_NN
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
._.
The_DT
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
dividend_NN
in_PIN
specie_NN
._.
The_DT
impact_NN
of_PIN
the_DT
demerger_NN
on_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
$_$
m_CD [PASS]
Fixed_VBN
assets_NN
1,491_CD
Current_JJ
assets_NN
2,130_CD
Creditors_NN
due_JJ
within_PIN
one_CD
year_NN
1,306_CD
Creditors_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
and_PHC
provisions_NN
246_CD
Book_NN
value_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
net_JJ
assets_NN
disposed_VBD
2,069_CD
Minority_NOMZ
interest_NN
share_NN
of_PIN
net_JJ
assets_NN
10_CD
Goodwill_NN
previously_TIME
charged_VBD
to_PIN
reserves_NN
written_VBN [PUBV] [WZPAST]
back_RB
813_CD
2,872_CD
Repayment_NOMZ
of_PIN
debt_NN
by_PIN
Zeneca_NN
Agrochemicals_NN
Net_JJ
repayment_NOMZ
of_PIN
debt_NN
per_PIN
Cash_NN
Flow_NN
Statement_NOMZ
909_CD
Net_JJ
financial_JJ
liabilities_NOMZ
demerged_VBD
294_CD
1,203_CD
Dividend_NN
in_PIN
specie_NN
1,669_CD
In_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2000_CD
,_,
prior_RB
to_PIN
its_PIT
demerger_NN
,_,
the_DT
Agrochemicals_NN
business_NOMZ
contributed_VBD
$_$
173m_CD
to_TO
operating_VBG
cash_NN
flows_NN
before_IN
exceptional_JJ
items_NN
,_,
and_ANDC
absorbed_VBD
$_$
78m_CD
in_PIN
respect_NN
of_PIN
exceptional_JJ
items_NN
and_CC
$_$
149m_CD
in_PIN
respect_NN
of_PIN
capital_NN
expenditure_NN
._.
28_CD
Disposals_NN
There_EX
were_VBD
no_SYNE
significant_JJ
disposals_NN
in_PIN
any_QUAN
of_PIN
the_DT
years_NN
presented_VBN
._.
29_CD
Reconciliation_NOMZ
of_PIN
net_JJ
cash_NN
flow_NN
to_PIN
movement_NOMZ
in_PIN
net_JJ
funds_NN
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
22 396 640_CD
Cash_NN
outflow_NN
inflow_NN
from_PIN
decrease_NN
increase_NN
in_PIN
loans_NN
and_CC
short_JJ
term_NN
borrowings_GER
118_CD
35_CD
66_CD
Cash_NN
outflow_NN
inflow_NN
from_PIN
increase_NN
decrease_NN
in_PIN
short_JJ
term_NN
investments_NOMZ
806 260 608_CD
Change_NN
in_PIN
net_JJ
funds_NN
resulting_VBG [WZPRES]
from_PIN
cash_NN
flows_NN
902_CD
691_CD
1,314_CD
Debt_NN
released_VBN [WZPAST]
on_PIN
disposals_NN
127_CD
Other_JJ
non-cash_JJ
changes_NN
48_CD
Exchange_NN
movements_NOMZ
75_CD
47_CD
53_CD
Movement_NOMZ
in_PIN
net_JJ
funds_NN
977_CD
738_CD
1,436_CD
Net_JJ
funds_NN
at_PIN
1_CD
January_NN
2,867_CD
3,605_CD
2,169_CD
Net_JJ
funds_NN
at_PIN
31_CD
December_NN
3,844_CD
2,867_CD
3,605_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
92_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
30_CD
Analysis_NN
of_PIN
net_JJ
funds_NN
At_PIN
1_CD
Jan_NN
Cash_NN
Other_NN
Exchange_NN
At_PIN
31_CD
Dec_NN
2002_CD
flow_NN
non-cash_JJ
movements_NOMZ
2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Loans_NN
due_JJ
after_IN
one_CD
year_NN
635 28 279 328_CD
Current_JJ
instalments_NOMZ
of_PIN
loans_NN
107_CD
77_CD
279_CD
5_CD
314_CD
Total_JJ
loans_NN
742_CD
105_CD
5_CD
642_CD
Short_JJ
term_NN
investments_NOMZ
3,118_CD
806_CD
38_CD
3,962_CD
Cash_NN
705_CD
18_CD
39_CD
726_CD
Overdrafts_NN
195_CD
4_CD
3_CD
202_CD
Short_JJ
term_NN
borrowings_GER
,_,
excluding_VBG
overdrafts_NN
19_CD
13_CD
6_CD
3,609_CD
797_CD
80_CD
4,486_CD
Net_JJ
funds_NN
2,867_CD
902_CD
75_CD
3,844_CD
Financing_GER
items_NN
included_VBD
in_PIN
cash_NN
movements_NOMZ
above_PLACE
:_:
Issue_NN
of_PIN
shares_NN
36_CD
Re-purchase_NN
of_PIN
shares_NN
1,190_CD
Net_JJ
cash_NN
inflow_NN
before_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
2,056_CD
31_CD
Financing_GER
2002 2001 2000_CD
Notes_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Issues_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
30_CD
36_CD
86_CD
19_CD
Re-purchase_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
30_CD
1,190_CD
1,080_CD
353_CD
1,154_CD
994_CD
334_CD
Repayment_NOMZ
of_PIN
lease_NN
finance_NN
2_CD
New_NN
loans_NN
220_CD
39_CD
Loans_NN
repaid_VBN
105_CD
192_CD
36_CD
Net_JJ
decrease_NN
increase_NN
in_PIN
short_JJ
term_NN
borrowings_GER
30_CD
13_CD
7_CD
67_CD
118_CD
35_CD
64_CD
Net_JJ
cash_NN
outflow_NN
from_PIN
financing_VBG
1,272_CD
959_CD
400_CD
There_EX
were_VBD
no_SYNE
major_JJ
non-cash_JJ
financing_GER
transactions_NOMZ
in_PIN
any_QUAN
year_NN
._.
com_NN
93_CD
32_CD
Post-retirement_NOMZ
benefits_NN
Pensions_NN
Background_NN
The_NN
Group_NN
continues_VPRT
to_TO
account_VB
for_PIN
pension_NN
costs_NN
in_PIN
its_PIT
primary_JJ
Financial_NN
Statements_NOMZ
in_PIN
accordance_NN
with_PIN
the_DT
UK_NN
Statement_NOMZ
of_PIN
Standard_NN
Accounting_GER
Practice_NN
No._NN
._.
In_CONJ
addition_NULL
,_,
disclosures_NN
have_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
below_PLACE
in_PIN
accordance_NN
with_PIN
Financial_NN
Reporting_GER
Standard_NN
No._NN
._.
The_DT
Company_NN
and_CC
most_EMPH
of_PIN
its_PIT
subsidiaries_NN
offer_VPRT
retirement_NOMZ
plans_NN
which_WDT [WHSUB]
cover_VPRT
the_DT
majority_NOMZ
of_PIN
employees_NN
in_PIN
the_DT
Group_NN
._.
Many_QUAN
of_PIN
these_DEMO
plans_NN
are_VPRT [PASS]
defined_VBN
contribution_NOMZ
where_RB
the_DT
company_NN
contribution_NOMZ
and_CC
resulting_VBG
profit_NN
and_PHC
loss_NN
account_NN
charge_NN
is_VPRT [PASS]
fixed_VBN
at_PIN
a_DT
set_VBN
level_NN
or_CC
is_VPRT [BEMA]
a_DT
set_NN
percentage_NN
of_PIN
employees_NN
pay_VPRT
._.
However_CONJ
,_,
several_QUAN
plans_NN
,_,
mainly_RB
in_PIN
the_DT
UK_NN
,_,
US_FPP1
and_PHC
Sweden_NN
,_,
are_VPRT [PASS]
defined_VBN
benefit_NN
,_,
where_RB
benefits_NN
are_VPRT [PASS]
based_VBN
on_PIN
employees_NN
length_NN
of_PIN
service_NN
and_CC
final_JJ
pensionable_JJ
pay_NN
._.
All_QUAN
of_PIN
the_DT
major_JJ
plans_NN
are_VPRT [PASS]
funded_VBN
through_PIN
legally_RB
separate_JJ
trustee_NN
administered_VBN
funds_NN
._.
The_DT
major_JJ
defined_VBN
benefit_NN
plans_NN
,_,
apart_RB
from_PIN
the_DT
Swedish_NN
plan_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
closed_VBN
to_PIN
new_JJ
entrants_NN
since_OSUB
2000_CD
._.
The_DT
cash_NN
funding_GER
of_PIN
the_DT
plans_NN
,_,
which_WDT [SERE]
may_POMD
from_PIN
time_NN
to_PIN
time_NN
involve_VB
special_JJ
payments_NOMZ
,_,
is_VPRT [PASS]
designed_VBN
,_,
in_PIN
consultation_NOMZ
with_PIN
independent_JJ
qualified_JJ
actuaries_NN
,_,
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
present_JJ
and_PHC
future_JJ
contributions_NOMZ
should_NEMD
be_VB [BEMA]
sufficient_PRED
to_TO
meet_VB
future_JJ
liabilities_NOMZ
._.
SSAP_NN
24_CD
The_DT
cost_NN
of_PIN
defined_VBN
benefit_NN
plan_NN
pensions_NN
in_PIN
a_DT
year_NN
can_POMD [SPAU]
notionally_RB
be_VB [PASS]
divided_VBN
into_PIN
the_DT
regular_JJ
cost_NN
and_PHC
variations_NOMZ
from_PIN
the_DT
regular_JJ
cost_NN
._.
Under_IN
SSAP_NN
24_CD
the_DT
regular_JJ
cost_NN
is_VPRT [PASS]
based_VBN
on_PIN
actuarial_JJ
assumptions_NOMZ
and_CC
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
year_NN
it_PIT
is_VPRT [PASS]
paid_VBN
whilst_OSUB
any_QUAN
variations_NOMZ
,_,
which_WDT [SERE]
arise_VPRT
where_RB
the_DT
experience_NN
of_PIN
the_DT
scheme_NN
varies_VPRT
from_PIN
the_DT
assumptions_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
actuary_NN
,_,
are_VPRT [PASS]
charged_VBN
or_CC
credited_VBN
over_IN
the_DT
estimated_VBN [PRIV]
remaining_VBG
service_NN
lives_NN
of_PIN
the_DT
employees_NN
._.
Costs_NN
of_PIN
defined_VBN
contribution_NOMZ
plan_NN
pensions_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
immediately_TIME
._.
On_PIN
these_DEMO
bases_NN
,_,
the_DT
total_JJ
pension_NN
cost_NN
for_PIN
the_DT
Group_NN
under_IN
SSAP_NN
24_CD
for_PIN
2002_CD
was_VBD
$_$
220m_CD
2001_CD
$_$
194m_CD
,_,
2000_CD
$_$
184m_CD
._.
In_PIN
the_DT
Group_NN
balance_NN
sheet_NN
at_PIN
31_CD
December_NN
2002_CD
,_,
accrued_VBN
pension_NN
costs_NN
included_VBD
in_PIN
other_JJ
creditors_NN
amounted_VBD
to_TO
$_$
53m_CD
2001_CD
$_$
76m_CD
:_:
prepaid_JJ
pension_NN
costs_NN
of_PIN
$_$
114m_CD
2001_CD
$_$
47m_CD
are_VPRT [PASS]
included_VBN
in_PIN
debtors_NN
._.
Provisions_NN
for_PIN
unfunded_JJ
pension_NN
obligations_NOMZ
,_,
included_VBD
in_PIN
provisions_NN
,_,
amounted_VBD
to_TO
$_$
235m_CD
2001_CD
$_$
357m_CD
._.
With_PIN
regard_NN
to_PIN
the_DT
Groups_NN
main_JJ
UK_NN
defined_VBD
benefit_NN
fund_NN
,_,
the_DT
latest_JJ
actuarial_JJ
valuation_NOMZ
was_VBD [PASS]
carried_VBN
out_PIN
at_PIN
31_CD
March_NN
2002_CD
and_CC
the_DT
pension_NN
cost_NN
assessed_VBN
using_VBG
the_DT
projected_VBN
unit_NN
credit_NN
method_NN
._.
The_DT
key_JJ
accounting_GER
assumptions_NOMZ
for_PIN
the_DT
purposes_NN
of_PIN
SSAP_NN
24_CD
were_VBD
that_DEMP
,_,
against_PIN
a_DT
background_NN
long_JJ
term_NN
UK_NN
price_NN
inflation_NOMZ
averaging_VBG [WZPRES]
2.5_CD
%_NN
pa_NN
,_,
investment_NOMZ
returns_NN
would_PRMD
average_VB
6.5_CD
%_NN
pa_NN
,_,
salary_NN
increases_NN
4.3_CD
%_NN
pa_NN
and_PHC
pension_NN
increases_NN
2.5_CD
%_NN
pa._NN
._.
The_DT
market_NN
value_NN
of_PIN
the_DT
funds_NN
assets_NN
at_PIN
the_DT
valuation_NOMZ
date_NN
was_VBD [BEMA]
2,161_CD
m_NN
$_$
3,477_CD
m_NN
equivalent_NN
,_,
representing_VBG [PRESP]
94.6_CD
%_NN
of_PIN
the_DT
liabilities_NOMZ
using_VBG [WZPRES]
these_DEMO
assumptions_NOMZ
._.
The_DT
regular_JJ
cost_NN
for_PIN
accounting_GER
purposes_NN
equates_VPRT
to_PIN
18.8_CD
%_NN
of_PIN
pensionable_JJ
salaries_NN
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
the_DT
valuation_NOMZ
was_VBD [PASS]
carried_VBN
out_PIN
for_PIN
ongoing_JJ
funding_GER
purposes_NN
,_,
with_PIN
assumptions_NOMZ
slightly_DWNT
more_EMPH
conservative_JJ
than_PIN
those_DEMP
used_VBN
for_PIN
SSAP_NN
24_CD
purposes_NN
._.
The_DT
market_NN
value_NN
of_PIN
the_DT
funds_NN
assets_NN
at_PIN
the_DT
valuation_NOMZ
date_NN
represent_VPRT
90.1_CD
%_NN
of_PIN
the_DT
liabilities_NOMZ
on_PIN
a_DT
funding_GER
basis_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
indicated_VBN [PRIV]
to_PIN
the_DT
trustee_NN
of_PIN
the_DT
UK_NN
fund_NN
its_PIT
intention_NOMZ
to_TO
target_VB
a_DT
solvency_NN
ratio_NN
of_PIN
91_CD
%_NN
following_VBG [WZPRES]
the_DT
2003_CD
actuarial_JJ
valuation_NOMZ
,_,
with_PIN
a_DT
longer_JJ
term_NN
aim_NN
of_PIN
restoring_VBG
solvency_NN
over_IN
a_DT
period_NN
of_PIN
around_PLACE
15_CD
years_NN
._.
Any_QUAN
cash_NN
contributions_NOMZ
made_VBD
to_PIN
the_DT
fund_NN
would_PRMD
be_VB [PASS]
treated_VBN
as_IN
a_DT
prepayment_NOMZ
and_CC
taken_VBN
into_PIN
account_NN
in_PIN
the_DT
actuarially_RB
assessed_VBN
contributions_NOMZ
to_PIN
the_DT
fund_NN
charged_VBN [WZPAST]
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
US_FPP1
defined_VBD
benefits_NN
program_NN
was_VBD [SPAU] [PASS]
actuarially_RB
revalued_VBN
at_PIN
31_CD
December_NN
2002_CD
when_RB
plan_NN
obligations_NOMZ
were_VBD [PASS]
estimated_VBN [PRIV]
to_TO
amount_VB
to_TO
$_$
812m_CD
and_CC
plan_NN
assets_NN
were_VBD
$_$
665m_CD
._.
The_DT
US_FPP1
typically_RB
makes_VPRT
contributions_NOMZ
to_TO
provide_VB
for_PIN
plan_NN
benefit_VPRT
deficits_NN
on_PIN
a_DT
regular_JJ
basis_NN
._.
PRI_NN
Pensionstjnst_NN
AB_NN
,_,
a_DT
joint_JJ
company_NN
for_PIN
Swedish_JJ
industry_NN
,_,
administers_VPRT
the_DT
Swedish_JJ
plan_NN
for_PIN
salaried_JJ
employees_NN
and_PHC
Alecta_NN
establishes_VPRT [PRIV]
benefit_NN
levels_NN
and_CC
actuarial_JJ
assumptions_NOMZ
._.
During_PIN
2002_CD
AstraZeneca_NN
AB_NN
has_VPRT [PEAS]
established_VBN [PRIV] [THATD]
separate_JJ
trustee_NN
administered_VBN
funds_NN
to_TO
support_VB
its_PIT
pension_NN
liabilities_NOMZ
:_:
prior_RB
to_PIN
2002_CD
the_DT
plan_NN
was_VBD [BEMA]
unfunded_PRED
._.
Post-retirement_NOMZ
benefits_NN
other_JJ
than_PIN
pensions_NN
In_PIN
the_DT
US_FPP1
,_,
and_ANDC
to_PIN
a_DT
lesser_JJ
extent_NN
in_PIN
some_QUAN
other_JJ
countries_NN
,_,
AstraZenecas_NN
employment_NOMZ
practices_NN
include_VPRT
the_DT
provision_NN
of_PIN
healthcare_NN
and_PHC
life_NN
insurance_NN
benefits_NN
for_PIN
retired_VBN
employees_NN
._.
Some_QUAN
6,920_CD
retired_VBN
employees_NN
and_CC
covered_VBD
dependants_NN
currently_RB
benefit_VPRT
from_PIN
these_DEMO
provisions_NN
and_CC
some_QUAN
13,383_CD
current_JJ
employees_NN
will_PRMD
be_VB [BEMA]
eligible_PRED
on_PIN
retirement_NOMZ
._.
AstraZeneca_NN
accrues_VPRT
for_PIN
the_DT
present_JJ
value_NN
of_PIN
such_JJ
retiree_NN
obligations_NOMZ
over_IN
the_DT
working_VBG
life_NN
of_PIN
the_DT
employee_NN
._.
The_DT
cost_NN
of_PIN
post-retirement_JJ
benefits_NN
other_JJ
than_PIN
pensions_NN
for_PIN
the_DT
Group_NN
in_PIN
2002_CD
was_VBD
$_$
22m_CD
2001_CD
$_$
16m_CD
,_,
2000_CD
$_$
25m_CD
._.
Provisions_NN
and_PHC
creditors_NN
set_VBN [WZPAST]
aside_RB
for_PIN
the_DT
benefit_NN
obligations_NOMZ
at_PIN
31_CD
December_NN
2002_CD
amounted_VBD
to_TO
$_$
32m_CD
2001_CD
$_$
248m_CD
,_,
2000_CD
$_$
233m_CD
._.
Other_JJ
than_PIN
this_DEMO
provision_NN
there_EX
were_VBD
plan_NN
assets_NN
amounting_VBG [WZPRES]
to_TO
$_$
133m_CD
in_PIN
the_DT
US_FPP1
at_PIN
31_CD
December_NN
2002_CD
._.
These_DEMO
benefit_NN
plans_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
disclosure_NN
of_PIN
post-retirement_JJ
benefits_NN
under_IN
FRS17_NN
._.
com_NN
94_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
32_CD
Post-retirement_NOMZ
benefits_NN
continued_VBD
FRS_NN
17_CD
Full_NN
implementation_NOMZ
of_PIN
FRS_NN
17_CD
had_VBD [SPAU] [PEAS]
originally_TIME
been_VBN [PASS]
intended_VBN [SUAV]
for_PIN
accounting_GER
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
after_IN
22_CD
June_NN
2003_CD
but_CC
has_VPRT [PEAS]
been_VBN [BYPA]
deferred_VBN
by_PIN
the_DT
Accounting_GER
Standards_NN
Board_NN
until_IN
accounting_GER
periods_NN
commencing_VBG [WZPRES]
on_PIN
or_CC
after_IN
1_CD
January_NN
2005_CD
._.
However_CONJ
,_,
the_DT
requirements_NOMZ
for_PIN
disclosure_NN
under_IN
FRS_NN
17_CD
between_PIN
its_PIT
issue_NN
and_CC
full_JJ
implementation_NOMZ
dates_NN
remain_VPRT
and_CC
this_DEMO
information_NOMZ
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
When_RB
fully_AMP
adopted_VBN
,_,
the_DT
objective_NN
of_PIN
FRS_NN
17_CD
is_VPRT
to_TO
reflect_VB [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
post-retirement_JJ
plan_NN
assets_NN
and_PHC
liabilities_NOMZ
and_CC
associated_VBN
charges_NN
in_PIN
the_DT
Financial_NN
Statements_NOMZ
._.
FRS_NN
17_CD
specifies_VPRT
how_RB
key_JJ
assumptions_NOMZ
should_NEMD
be_VB [PASS]
formulated_VBN
and_PHC
applied_VBN
:_:
these_DEMO
assumptions_NOMZ
are_VPRT [BEMA]
often_RB
different_PRED
to_PIN
the_DT
funding_GER
bases_NN
established_VBN [PRIV] [WZPAST]
by_PIN
the_DT
pension_NN
funds_NN
trustees_NN
or_CC
actuaries_NN
._.
The_DT
accounting_GER
requirements_NOMZ
of_PIN
FRS_NN
17_CD
are_VPRT
broadly_RB
as_IN
follows_VPRT
:_:
Post-retirement_NOMZ
scheme_NN
assets_NN
are_VPRT [PASS]
valued_VBN
at_PIN
market_NN
values_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
:_:
Post-retirement_NOMZ
scheme_NN
liabilities_NOMZ
are_VPRT [PASS]
measured_VBN
using_VBG
a_DT
projected_VBN
unit_NN
method_NN
and_CC
discounted_VBN
at_PIN
the_DT
current_JJ
rate_NN
of_PIN
return_NN
on_PIN
high_JJ
quality_NOMZ
corporate_JJ
bonds_NN
of_PIN
equivalent_JJ
term_NN
and_PHC
currency_NN
to_PIN
the_DT
liability_NOMZ
:_:
and_ANDC
The_DT
movement_NOMZ
in_PIN
the_DT
scheme_NN
surplus_NN
deficit_NN
will_PRMD
be_VB [PASS]
split_VBN
between_PIN
operating_GER
charges_NN
and_PHC
financing_GER
items_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
and_CC
,_,
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
,_,
actuarial_JJ
gains_NN
and_PHC
losses_NN
._.
Financial_NN
assumptions_NOMZ
Qualified_VBN
independent_JJ
actuaries_NN
have_VPRT [PEAS]
updated_VBN
the_DT
actuarial_JJ
valuations_NOMZ
of_PIN
the_DT
major_JJ
defined_VBN
benefit_NN
schemes_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
to_PIN
31_CD
December_NN
2002_CD
._.
The_DT
assumptions_NOMZ
used_VBN [WZPAST]
by_PIN
the_DT
actuaries_NN
are_VPRT [BEMA]
the_DT
best_JJ
estimates_NN
chosen_VBN [WZPAST]
from_PIN
a_DT
range_NN
of_PIN
possible_JJ
actuarial_JJ
assumptions_NOMZ
which_WDT [WHOBJ]
,_,
due_JJ
to_PIN
the_DT
long_JJ
term_NN
nature_NN
of_PIN
the_DT
scheme_NN
,_,
may_POMD
not_XX0
necessarily_RB
be_VB [PASS]
borne_VBN
out_PIN
in_PIN
practice_NN
._.
These_DEMO
assumptions_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Rest_VB
of_PIN
Rest_VB
of_PIN
UK_NN
Group_NN
UK_NN
Group_NN
Inflation_NOMZ
assumption_NOMZ
2.2_CD
%_NN
2.1_CD
%_NN
2.5_CD
%_NN
2.7_CD
%_NN
Rate_NN
of_PIN
increase_NN
in_PIN
salaries_NN
4.0_CD
%_NN
4.0_CD
%_NN
4.3_CD
%_NN
4.6_CD
%_NN
Rate_NN
of_PIN
increase_NN
in_PIN
pensions_NN
in_PIN
payment_NOMZ
2.2_CD
%_NN
0.5_CD
%_NN
2.5_CD
%_NN
0.5_CD
%_NN
Discount_NN
rate_NN
5.6_CD
%_NN
5.8_CD
%_NN
5.8_CD
%_NN
6.2_CD
%_NN
Long_JJ
term_NN
rate_NN
of_PIN
return_NN
expected_VBN [PRIV] [WZPAST]
at_PIN
31_CD
December_NN
Equities_NOMZ
8.3_CD
%_NN
8.4_CD
%_NN
7.6_CD
%_NN
9.7_CD
%_NN
Bonds_NN
4.9_CD
%_NN
6.1_CD
%_NN
5.3_CD
%_NN
6.1_CD
%_NN
Others_NN
3.7_CD
%_NN
3.6_CD
%_NN
4.0_CD
%_NN
8.7_CD
%_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
95_CD
32_CD
Post-retirement_NOMZ
benefits_NN
continued_VBD
Post-retirement_JJ
scheme_NN
deficit_NN
The_DT
post-retirement_JJ
scheme_NN
deficit_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
under_IN
FRS_NN
17_CD
is_VPRT
as_IN
if_COND
this_DEMO
standard_NN
were_VBD [SPAU] [PASS]
fully_AMP
applied_VBN
._.
However_CONJ
,_,
under_IN
the_DT
current_JJ
accounting_GER
methodology_NN
SSAP_NN
24_CD
there_EX
are_VPRT
prepayments_NOMZ
and_PHC
provisions_NN
including_VBG [WZPRES]
deferred_JJ
tax_NN
within_PIN
the_DT
balance_NN
sheet_NN
at_PIN
31_CD
December_NN
2002_CD
that_DEMP
would_PRMD
offset_VB
the_DT
effect_NN
on_PIN
net_JJ
assets_NN
of_PIN
this_DEMO
deficit_NN
in_PIN
the_DT
event_NN
of_PIN
a_DT
restatement_NOMZ
under_IN
FRS_NN
17_CD
._.
The_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
major_JJ
defined_VBN
benefit_NN
schemes_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
at_PIN
31_CD
December_NN
2002_CD
as_IN
calculated_VBN [PRIV]
in_PIN
accordance_NN
with_PIN
FRS_NN
17_CD
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
._.
The_DT
fair_JJ
values_NN
of_PIN
the_DT
schemes_NN
assets_NN
are_VPRT [PASS]
not_XX0
intended_VBN [SUAV]
to_TO
be_VB [PASS]
realized_VBN [PRIV]
in_PIN
the_DT
short_JJ
term_NN
and_CC
may_POMD
be_VB [BEMA]
subject_PRED
to_PIN
significant_JJ
change_NN
before_IN
they_TPP3
are_VPRT [PASS]
realized_VBN [PRIV]
._.
The_DT
present_JJ
value_NN
of_PIN
the_DT
schemes_NN
liabilities_NOMZ
is_VPRT [PASS]
derived_VBN
from_PIN
cash_NN
flow_NN
projections_NOMZ
over_IN
long_JJ
periods_NN
and_CC
are_VPRT
thus_CONJ
inherently_RB
uncertain_JJ
._.
If_COND
FRS_NN
17_CD
had_VBD [PEAS]
been_VBN [PASS]
adopted_VBN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
the_DT
Groups_NN
reported_VBD [PUBV] [THATD]
net_JJ
assets_NN
see_VPRT [PRIV]
page_NN
60_CD
would_PRMD
be_VB [BYPA]
reduced_VBN
by_PIN
$_$
637m_CD
5.7_CD
%_NN
to_TO
$_$
10,589_CD
m._NN
Further_JJ
explanation_NOMZ
of_PIN
this_DEMO
adjustment_NOMZ
is_VPRT [PASS]
included_VBN
below_PLACE
:_:
Value_NN
at_PIN
31_CD
December_NN
2002_CD
Value_NN
at_PIN
31_CD
December_NN
2001_CD
Rest_VB
of_PIN
Rest_VB
of_PIN
UK_NN
Group_NN
Total_NN
UK_NN
Group_NN
Total_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Scheme_NN
assets_NN
Equities_NOMZ
1,186_CD
708_CD
1,894_CD
1,255_CD
409_CD
1,664_CD
Bonds_NN
2,097_CD
464_CD
2,561_CD
1,831_CD
214_CD
2,045_CD
Others_NN
75 102 177_CD
59 131 190_CD
Total_JJ
fair_JJ
value_NN
of_PIN
assets_NN
3,358_CD
1,274_CD
4,632_CD
3,145_CD
754_CD
3,899_CD
Present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
4,200_CD
1,665_CD
5,865_CD
3,569_CD
1,472_CD
5,041_CD
Deficit_NN
in_PIN
the_DT
scheme_NN
842_CD
391_CD
1,233_CD
424_CD
718_CD
1,142_CD
Related_VBN
deferred_VBN
tax_NN
asset_NN
253 151 404 127_CD
248_CD
375_CD
Net_JJ
post-retirement_JJ
deficit_NN
under_IN
FRS_NN
17 589 240 829_CD
297 470 767_CD
Adjustments_NOMZ
for_PIN
assets_NN
and_PHC
provisions_NN
under_IN
SSAP_NN
24_CD
Prepayment_NOMZ
,_,
net_NN
of_PIN
related_JJ
deferred_JJ
tax_NN
177_CD
56_CD
Accrual_NN
,_,
net_NN
of_PIN
deferred_JJ
tax_NN
36_CD
143_CD
Provision_NN
,_,
net_NN
of_PIN
deferred_JJ
tax_NN
333_CD
296_CD
Adjusted_VBN
post-retirement_JJ
deficit_NN
,_,
net_NN
of_PIN
related_JJ
deferred_JJ
tax_NN
637_CD
384_CD
Net_JJ
assets_NN
as_IN
currently_RB
disclosed_VBN [PUBV]
restated_VBN
see_VPRT [PRIV]
page_NN
60_CD
11,226_CD
9,629_CD
Net_JJ
assets_NN
as_IN
adjusted_VBN
if_COND
FRS_NN
17_CD
were_VBD [SPAU] [PASS]
fully_AMP
adopted_VBN
10,589_CD
9,245_CD
Profit_NN
and_PHC
loss_NN
account_NN
disclosures_NN
On_PIN
full_JJ
compliance_NN
with_PIN
FRS_NN
17_CD
,_,
on_PIN
the_DT
basis_NN
of_PIN
the_DT
above_PLACE
assumptions_NOMZ
,_,
the_DT
amounts_NN
that_TSUB
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
charged_VBN
to_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
and_PHC
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
in_PIN
respect_NN
of_PIN
defined_VBN
benefit_NN
schemes_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
Rest_VB
of_PIN
UK_NN
Group_NN
Total_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Operating_GER
profit_NN
Current_JJ
service_NN
cost_NN
100_CD
69_CD
169_CD
Past_JJ
service_NN
costs_NN
2_CD
8_CD
6_CD
Settlement_NOMZ
and_PHC
curtailment_NOMZ
24_CD
24_CD
Total_JJ
operating_VBG
charge_NN
102_CD
37_CD
139_CD
Finance_NN
expense_NN
Expected_VBN [PRIV]
return_NN
on_PIN
post-retirement_JJ
scheme_NN
assets_NN
197_CD
52_CD
249_CD
Interest_NN
on_PIN
post-retirement_JJ
scheme_NN
liabilities_NOMZ
210_CD
98_CD
308_CD
Net_JJ
return_NN
13_CD
46_CD
59_CD
Loss_NN
before_IN
taxation_NOMZ
115_CD
83_CD
198_CD
Consolidated_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Actual_JJ
return_NN
less_RB
expected_JJ
return_NN
on_PIN
the_DT
post-retirement_JJ
schemes_NN
assets_NN
301_CD
91_CD
392_CD
Experience_NN
losses_NN
gains_VPRT
arising_VBG
on_PIN
the_DT
post-retirement_JJ
schemes_NN
liabilities_NOMZ
108_CD
8_CD
100_CD
Changes_NN
in_PIN
assumptions_NOMZ
underlying_VBG [WZPRES]
the_DT
present_JJ
value_NN
of_PIN
the_DT
post-retirement_JJ
schemes_NN
liabilities_NOMZ
58_CD
27_CD
31_CD
Actuarial_JJ
loss_NN
recognized_VBN [PRIV]
351 110 461_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
96_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
32_CD
Post-retirement_NOMZ
benefits_NN
continued_VBD
Additional_JJ
disclosures_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
Rest_VB
of_PIN
UK_NN
Group_NN
Total_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Difference_NN
between_PIN
the_DT
expected_VBN [PRIV]
and_CC
actual_JJ
return_NN
on_PIN
scheme_NN
assets_NN
:_:
Amount_NN
301_CD
91_CD
392_CD
Percentage_NN
of_PIN
scheme_NN
assets_NN
9.0_CD
%_NN
7.1_CD
%_NN
8.5_CD
%_NN
Experience_NN
gains_NN
and_PHC
losses_NN
on_PIN
scheme_NN
liabilities_NOMZ
:_:
Amount_NN
108_CD
8_CD
100_CD
Percentage_NN
of_PIN
the_DT
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
2.6_CD
%_NN
0.5_CD
%_NN
1.7_CD
%_NN
Total_JJ
amount_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
:_:
Amount_NN
351 110 461_CD
Percentage_NN
of_PIN
the_DT
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
8.4_CD
%_NN
6.6_CD
%_NN
7.9_CD
%_NN
Movement_NOMZ
in_PIN
post-retirement_JJ
deficit_NN
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
Rest_VB
of_PIN
UK_NN
Group_NN
Total_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Deficits_NN
in_PIN
schemes_NN
at_PIN
beginning_GER
of_PIN
the_DT
year_NN
424_CD
718_CD
1,142_CD
Current_JJ
service_NN
cost_NN
100_CD
69_CD
169_CD
Contributions_NOMZ
125 567 692_CD
Past_JJ
service_NN
costs_NN
2_CD
8_CD
6_CD
Settlement_NOMZ
and_PHC
curtailment_NOMZ
24_CD
24_CD
Other_JJ
finance_NN
income_NN
13_CD
46_CD
59_CD
Actuarial_JJ
loss_NN
351 110 461_CD
Exchange_NN
77_CD
47_CD
124_CD
Deficits_NN
in_PIN
schemes_NN
at_PIN
end_NN
of_PIN
the_DT
year_NN
842_CD
391_CD
1,233_CD
Adjusted_VBN
post-retirement_JJ
deficit_NN
,_,
net_NN
of_PIN
deferred_JJ
tax_NN
637_CD
The_DT
increase_NN
in_PIN
the_DT
deficit_NN
during_PIN
2002_CD
is_VPRT [BEMA]
due_JJ
principally_RB
to_PIN
shortfalls_NN
on_PIN
returns_NN
of_PIN
post-retirement_JJ
scheme_NN
assets_NN
and_PHC
exchange_NN
,_,
offset_VBN [PASTP]
by_PIN
funding_GER
of_PIN
Swedens_NN
pension_NN
scheme_NN
and_CC
the_DT
USs_NN
non-pension_JJ
post-retirement_NOMZ
schemes_NN
for_PIN
the_DT
first_JJ
time_NN
in_PIN
2002_CD
._.
Reserves_NN
note_VPRT [PRIV]
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
Total_JJ
$_$
m_CD
Profit_NN
and_PHC
loss_NN
reserve_NN
excluding_VBG [WZPRES]
post-retirement_JJ
liability_NOMZ
8,451_CD
Post-retirement_NOMZ
reserve_NN
637_CD
Profit_NN
and_PHC
loss_NN
reserve_NN
under_IN
FRS17_NN
7,814_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
97_CD
33_CD
Employee_NN
costs_NN
and_PHC
share_NN
option_NOMZ
plans_NN
for_PIN
employees_NN
Employee_NN
costs_VPRT
The_DT
average_JJ
number_NN
of_PIN
people_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
in_PIN
2002_CD
was_VBD [BEMA]
57,500_CD
2001_CD
52,600_CD
,_,
2000_CD
57,000_CD
and_CC
the_DT
costs_NN
incurred_VBN [WZPAST]
during_PIN
the_DT
year_NN
in_PIN
respect_NN
of_PIN
these_DEMO
employees_NN
were_VBD
:_:
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Salaries_NN
3,049_CD
2,701_CD
2,862_CD
Social_NN
security_NOMZ
costs_NN
505 465 464_CD
Pension_NN
costs_NN
193 194 184_CD
Other_JJ
employment_NOMZ
costs_NN
246 182 170_CD
3,993_CD
3,542_CD
3,680_CD
Employee_NN
costs_NN
above_PLACE
do_VPRT
not_XX0
include_VB
severance_NN
costs_NN
._.
The_DT
Directors_NN
believe_VPRT [PRIV] [THATD]
that_DEMP
,_,
together_RB
with_PIN
the_DT
basic_JJ
salary_NN
system_NN
,_,
the_DT
Groups_NN
employee_NN
incentive_NN
schemes_NN
provide_VPRT
competitive_JJ
and_PHC
marketrelated_JJ
packages_NN
to_TO
motivate_VB
employees_NN
._.
They_TPP3
should_NEMD [SPAU]
also_RB
align_VB
the_DT
interests_NN
of_PIN
employees_NN
with_PIN
those_DEMO
of_PIN
shareholders_NN
,_,
as_IN
a_DT
whole_JJ
,_,
through_PIN
long_JJ
term_NN
share_NN
ownership_NN
in_PIN
the_DT
Company_NN
._.
The_DT
Groups_NN
current_JJ
UK_NN
,_,
Swedish_NN
and_PHC
US_FPP1
schemes_NN
are_VPRT [PASS]
described_VBN
below_PLACE
:_:
other_JJ
arrangements_NOMZ
apply_VPRT
elsewhere_RB
._.
The_DT
AstraZeneca_NN
UK_NN
Performance_NN
Bonus_NN
Plan_NN
Employees_NN
of_PIN
participating_VBG
AstraZeneca_NN
UK_NN
companies_NN
are_VPRT [PASS]
invited_VBN
to_TO
participate_VB
in_PIN
this_DEMO
bonus_NN
plan_NN
which_WDT [WHSUB]
rewards_VPRT
good_JJ
performance_NN
at_PIN
corporate_JJ
,_,
function_NOMZ
business_NOMZ
and_CC
individual_JJ
team_NN
levels_NN
._.
Depending_VBG [PRESP]
upon_PIN
performance_NN
and_CC
upon_PIN
which_WDT [PIRE]
level_NN
it_PIT
is_VPRT [PASS]
measured_VBN
,_,
bonuses_NN
may_POMD
be_VB [PASS]
paid_VBN
partly_DWNT
in_PIN
the_DT
form_NN
of_PIN
free_JJ
Ordinary_NN
Shares_NN
in_PIN
the_DT
Company_NN
under_IN
the_DT
Inland_NN
Revenue_NN
approved_VBD
AstraZeneca_NN
All-Employee_NN
Share_NN
Plan_NN
and_CC
up_RB
to_PIN
a_DT
maximum_JJ
annual_JJ
value_NN
of_PIN
3,000_CD
and_CC
partly_DWNT
in_PIN
cash_NN
._.
A_DT
tax_NN
efficient_JJ
share_NN
retention_NOMZ
scheme_NN
,_,
under_IN
which_WDT
employees_NN
leave_VPRT
their_TPP3
bonus_NN
shares_NN
in_PIN
trust_NN
for_PIN
three_CD
to_PIN
five_CD
years_NN
,_,
forms_NN
part_NN
of_PIN
the_DT
All-Employee_NN
Share_NN
Plan_NN
._.
In_PIN
2002_CD
,_,
for_PIN
the_DT
first_JJ
time_NN
the_DT
Company_NN
offered_VBD
UK_NN
employees_NN
the_DT
opportunity_NOMZ
to_TO
buy_VB
Partnership_NN
Shares_NN
Ordinary_NN
Shares_NN
under_IN
the_DT
All-Employee_NN
Share_NN
Plan_NN
._.
Employees_NN
may_POMD
invest_VB
up_RP
to_PIN
125_CD
per_PIN
month_NN
over_IN
a_DT
12_CD
month_NN
accumulation_NOMZ
period_NN
and_PHC
purchase_NN
Partnership_NN
Shares_NN
in_PIN
the_DT
Company_NN
with_PIN
the_DT
total_JJ
proceeds_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
period_NN
._.
The_DT
purchase_NN
price_NN
for_PIN
the_DT
shares_NN
is_VPRT [BEMA]
the_DT
lower_JJ
of_PIN
the_DT
price_NN
at_PIN
the_DT
beginning_GER
or_CC
the_DT
end_NN
of_PIN
the_DT
12_CD
month_NN
period_NN
._.
A_DT
tax_NN
efficient_JJ
share_NN
retention_NOMZ
scheme_NN
is_VPRT [BEMA]
also_RB
available_PRED
in_PIN
respect_NN
of_PIN
Partnership_NN
Shares_NN
._.
At_PIN
the_DT
Companys_NN
AGM_NN
in_PIN
2002_CD
,_,
shareholders_NN
approved_VBD
the_DT
issue_NN
of_PIN
new_JJ
shares_NN
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
All-Employee_NN
Share_NN
Plan_NN
._.
The_DT
AstraZeneca_NN
Executive_NN
Annual_JJ
Bonus_NN
Scheme_NN
This_DEMO
scheme_NN
is_VPRT [BEMA]
a_DT
performance_NN
bonus_NN
scheme_NN
for_PIN
Directors_NN
and_CC
senior_JJ
employees_NN
who_WP [WHSUB]
do_VPRT
not_XX0
participate_VB
in_PIN
the_DT
AstraZeneca_NN
UK_NN
Performance_NN
Bonus_NN
Plan_NN
._.
Annual_JJ
bonuses_NN
are_VPRT [PASS]
paid_VBN
in_PIN
cash_NN
and_CC
reflect_VB [PRIV]
both_DT
corporate_JJ
and_PHC
individual_JJ
performance_NN
measures_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
has_VPRT
discretion_NOMZ
to_TO
reduce_VB
or_CC
withhold_VB
bonuses_NN
if_COND
business_NOMZ
performance_NN
falls_VPRT
sufficiently_RB
short_JJ
of_PIN
expectations_NOMZ
in_PIN
any_QUAN
year_NN
such_JJ
as_IN
to_TO
make_VB
the_DT
payment_NOMZ
of_PIN
bonuses_NN
inappropriate_JJ
._.
The_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
UK_NN
employees_NN
may_POMD
make_VB
regular_JJ
monthly_JJ
savings_GER
contributions_NOMZ
over_IN
a_DT
three_CD
or_CC
five_CD
year_NN
period_NN
and_CC
may_POMD
apply_VB
for_PIN
options_NOMZ
to_TO
acquire_VB
AstraZeneca_NN
shares_NN
._.
Further_JJ
details_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
The_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
This_DEMP
is_VPRT [BEMA]
a_DT
share_NN
option_NOMZ
plan_NN
for_PIN
employees_NN
of_PIN
participating_VBG
AstraZeneca_NN
Group_NN
companies_NN
which_WDT [WHSUB]
was_VBD [BYPA]
approved_VBN
by_PIN
shareholders_NN
at_PIN
the_DT
Companys_NN
AGM_NN
in_PIN
2000_CD
._.
The_DT
first_JJ
grant_NN
of_PIN
options_NOMZ
occurred_VBD
in_PIN
August_NN
2000_CD
._.
The_DT
main_JJ
grant_NN
of_PIN
options_NOMZ
in_PIN
2002_CD
under_IN
the_DT
plan_NN
was_VBD [BEMA]
in_PIN
March_NN
,_,
with_PIN
a_DT
further_RB
,_,
smaller_JJ
grant_NN
in_PIN
August_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
sets_VPRT
the_DT
policy_NN
for_PIN
the_DT
Companys_NN
operation_NOMZ
of_PIN
the_DT
plan_NN
._.
Sweden_NN
In_PIN
Sweden_NN
an_DT
all_QUAN
employee_NN
performance_NN
bonus_NN
plan_NN
is_VPRT [BEMA]
in_PIN
operation_NOMZ
._.
The_DT
plan_NN
rewards_VPRT
good_JJ
performance_NN
at_PIN
corporate_JJ
,_,
function_NOMZ
and_CC
individual_JJ
team_NN
level_NN
._.
Bonuses_NN
for_PIN
corporate_JJ
and_CC
function_NOMZ
performance_NN
are_VPRT [SPAU] [PASS]
always_RB
paid_VBN
in_PIN
the_DT
form_NN
of_PIN
AstraZeneca_NN
Ordinary_NN
Shares_NN
._.
Bonuses_NN
for_PIN
individual_JJ
team_NN
performance_NN
may_POMD
be_VB [PASS]
paid_VBN
in_PIN
Ordinary_NN
Shares_NN
or_CC
in_PIN
cash_NN
,_,
at_PIN
the_DT
employees_NN
discretion_NOMZ
._.
Existing_VBG
Ordinary_NN
Shares_NN
are_VPRT [PASS]
used_VBN
to_TO
pay_VB
bonuses_NN
awarded_VBN
under_IN
the_DT
plan_NN
._.
These_DEMP
are_VPRT [PASS]
purchased_VBN
in_PIN
the_DT
market_NN
._.
They_TPP3
must_NEMD
be_VB [PASS]
left_VBN
in_PIN
trust_NN
for_PIN
three_CD
years_NN
._.
The_DT
AstraZeneca_NN
Executive_NN
Annual_JJ
Bonus_NN
Scheme_NN
and_CC
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
both_DT
operate_VPRT
in_PIN
respect_NN
of_PIN
relevant_JJ
AstraZeneca_NN
employees_NN
in_PIN
Sweden_NN
._.
US_FPP1
In_PIN
the_DT
US_FPP1
,_,
there_EX
are_VPRT
four_CD
senior_JJ
staff_NN
incentive_NN
schemes_NN
,_,
under_IN
which_WDT
either_CC
AstraZeneca_NN
ADSs_NN
or_CC
stock_NN
appreciation_NOMZ
rights_NN
related_VBN [WZPAST]
to_PIN
AstraZeneca_NN
ADSs_NN
are_VPRT [PASS]
awarded_VBN
to_PIN
participants_NN
._.
There_EX
are_VPRT
currently_RB
approximately_RB
146_CD
participants_NN
in_PIN
these_DEMO
schemes_NN
._.
AstraZeneca_NN
ADSs_NN
necessary_JJ
to_TO
satisfy_VB
the_DT
awards_NN
under_IN
these_DEMO
schemes_NN
are_VPRT [PASS]
purchased_VBN
in_PIN
the_DT
market_NN
and_CC
no_SYNE
subscriptions_NOMZ
for_PIN
new_JJ
Ordinary_NN
Shares_NN
have_VPRT [PEAS]
been_VBN [PASS]
involved_VBN
._.
The_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
operates_VPRT
in_PIN
respect_NN
of_PIN
relevant_JJ
AstraZeneca_NN
employees_NN
in_PIN
the_DT
US_FPP1
._.
com_NN
98_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
33_CD
Employee_NN
costs_NN
and_PHC
share_NN
option_NOMZ
plans_NN
for_PIN
employees_NN
continued_VBD
Share_NN
Option_NOMZ
Plans_NN
At_PIN
31_CD
December_NN
2002_CD
,_,
there_EX
were_VBD
options_NOMZ
outstanding_JJ
under_IN
the_DT
Zeneca_NN
1993_CD
Senior_JJ
Staff_NN
Share_NN
Option_NOMZ
Scheme_NN
,_,
the_DT
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
,_,
the_DT
Astra_NN
Shareholder_NN
Value_NN
Incentive_NN
Plan_NN
,_,
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
and_CC
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
._.
1_CD
Summary_NN
of_PIN
the_DT
Zeneca_NN
1993_CD
Senior_JJ
Staff_NN
Share_NN
Option_NOMZ
Scheme_NN
The_NN
Zeneca_NN
1993_CD
Senior_JJ
Staff_NN
Share_NN
Option_NOMZ
Scheme_NN
was_VBD [PASS]
introduced_VBN
at_PIN
the_DT
time_NN
of_PIN
the_DT
demerger_NN
of_PIN
Zeneca_NN
from_PIN
ICI_NN
in_PIN
1993_CD
._.
The_DT
last_JJ
date_NN
for_PIN
the_DT
grant_NN
of_PIN
options_NOMZ
was_VBD [BEMA]
19_CD
May_POMD
1994_CD
and_CC
the_DT
scheme_NN
was_VBD [BYPA]
replaced_VBN
by_PIN
the_DT
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
._.
2_CD
Summary_NN
of_PIN
the_DT
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
The_NN
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
was_VBD [PASS]
introduced_VBN
in_PIN
1994_CD
._.
The_DT
last_JJ
date_NN
for_PIN
the_DT
grant_NN
of_PIN
options_NOMZ
was_VBD [BEMA]
16_CD
March_NN
2000_CD
and_CC
the_DT
scheme_NN
has_VPRT [PEAS]
been_VBN [BYPA]
replaced_VBN
by_PIN
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
._.
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
1994_CD
scheme_NN
will_PRMD [SPAU]
normally_RB
be_VB [BEMA]
exercisable_PRED
between_PIN
three_CD
and_CC
10_CD
years_NN
following_VBG [WZPRES]
grant_NN
,_,
provided_VBD
the_DT
relevant_JJ
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
satisfied_VBN
._.
Options_NOMZ
may_POMD
be_VB [BYPA]
satisfied_VBN
by_PIN
the_DT
issue_NN
of_PIN
new_JJ
shares_NN
or_CC
by_PIN
existing_VBG
shares_NN
purchased_VBN [WZPAST]
in_PIN
the_DT
market_NN
._.
Options_NOMZ
will_PRMD
not_XX0
normally_RB
be_VB [BEMA]
exercisable_PRED
unless_COND
a_DT
performance_NN
condition_NOMZ
set_VBN [WZPAST]
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT [PEAS]
been_VBN [PASS]
satisfied_VBN
._.
The_DT
performance_NN
condition_NOMZ
is_VPRT
that_DEMO
earnings_GER
per_PIN
share_NN
must_NEMD
grow_VB
by_PIN
at_PIN
least_JJ
the_DT
increase_NN
in_PIN
the_DT
UK_NN
Retail_NN
Price_NN
Index_NN
over_IN
three_CD
years_NN
plus_PIN
3_CD
%_NN
per_PIN
annum_NN
._.
Satisfaction_NOMZ
of_PIN
this_DEMO
condition_NOMZ
is_VPRT [PASS]
tested_VBN
annually_RB
by_PIN
reference_NN
to_PIN
the_DT
audited_JJ
financial_JJ
statements_NOMZ
._.
Once_TIME
the_DT
condition_NOMZ
is_VPRT [PASS]
satisfied_VBN
in_PIN
respect_NN
of_PIN
any_QUAN
rolling_VBG
three_CD
year_NN
period_NN
beginning_VBG [WZPRES]
no_SYNE
earlier_TIME
than_PIN
the_DT
end_NN
of_PIN
the_DT
financial_JJ
year_NN
prior_RB
to_PIN
the_DT
grant_NN
of_PIN
the_DT
option_NOMZ
,_,
then_RB
it_PIT
need_MD
not_XX0
be_VB [PASS]
satisfied_VBN
again_TIME
in_PIN
respect_NN
of_PIN
that_DEMO
option_NOMZ
._.
The_DT
Remuneration_NOMZ
Committee_NN
reviews_VPRT
the_DT
performance_NN
conditions_NOMZ
at_PIN
intervals_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
they_TPP3
continue_VPRT
to_TO
be_VB [BEMA]
appropriate_PRED
._.
3_CD
Summary_NN
of_PIN
the_DT
Astra_NN
Shareholder_NN
Value_NN
Incentive_NN
Plan_NN
In_PIN
1996_CD
,_,
Astra_NN
established_VBD [PRIV]
a_DT
stock_NN
option_NOMZ
plan_NN
for_PIN
some_QUAN
100_CD
Astra_NN
employees_NN
in_PIN
key_JJ
senior_JJ
positions_NOMZ
._.
The_DT
plan_NN
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
used_VBN
for_PIN
the_DT
grant_NN
of_PIN
options_NOMZ
and_CC
has_VPRT [PEAS]
been_VBN [BYPA]
superseded_VBN
by_PIN
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
._.
On_PIN
completion_NOMZ
of_PIN
the_DT
merger_NN
with_PIN
Zeneca_NN
,_,
options_NOMZ
in_PIN
Astra_NN
shares_NN
granted_VBN [SUAV]
under_IN
the_DT
plan_NN
were_VBD [BYPA]
replaced_VBN
by_PIN
options_NOMZ
to_TO
acquire_VB
a_DT
number_NN
of_PIN
AstraZeneca_NN
shares_NN
based_VBN [WZPAST]
on_PIN
the_DT
exchange_NN
ratio_NN
used_VBN [WZPAST]
in_PIN
the_DT
exchange_NN
offers_VPRT
used_VBN
to_TO
effect_VB
the_DT
AstraZeneca_NN
merger_NN
._.
The_DT
ratio_NN
of_PIN
AstraZeneca_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
respect_NN
of_PIN
former_JJ
Astra_NN
options_NOMZ
was_VBD [BEMA]
0.5045_CD
AstraZeneca_NN
options_NOMZ
for_PIN
each_QUAN
Astra_NN
option_NOMZ
held_VBD [PRIV]
and_CC
the_DT
table_NN
shown_VBN [PRIV] [WZPAST]
on_PIN
page_NN
100_CD
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
throughout_PIN
accordingly_RB
._.
4_CD
Summary_NN
of_PIN
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
Eligibility_NOMZ
UK_NN
resident_NN
employees_NN
of_PIN
participating_VBG
AstraZeneca_NN
companies_NN
are_VPRT [BEMA]
automatically_RB
eligible_PRED
to_TO
participate_VB
._.
Grant_NN
of_PIN
options_NOMZ
Invitations_NOMZ
to_TO
apply_VB
for_PIN
options_NOMZ
may_POMD
be_VB [PASS]
issued_VBN
within_PIN
six_CD
weeks_NN
after_IN
the_DT
announcement_NOMZ
by_PIN
the_DT
Company_NN
of_PIN
its_PIT
results_NN
for_PIN
any_QUAN
period_NN
and_CC
at_PIN
other_JJ
times_NN
in_PIN
circumstances_NN
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
exceptional_PRED
by_PIN
the_DT
Directors_NN
._.
No_SYNE
invitations_NOMZ
may_POMD
be_VB [PASS]
issued_VBN
later_TIME
than_PIN
10_CD
years_NN
after_IN
the_DT
approval_NN
of_PIN
the_DT
scheme_NN
by_PIN
shareholders_NN
._.
Options_NOMZ
may_POMD [SPAU]
only_DWNT
be_VB [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
who_WP [WHSUB]
enter_VPRT
into_PIN
UK_NN
Inland_NN
Revenue_NN
approved_VBD
savings_GER
contracts_NN
with_PIN
the_DT
savings_GER
body_NN
nominated_VBN [WZPAST]
by_PIN
the_DT
Company_NN
,_,
under_IN
which_WDT
monthly_JJ
savings_GER
of_PIN
a_DT
fixed_VBN
amount_NN
currently_RB
not_XX0
less_JJ
than_PIN
5_CD
nor_SYNE
more_EMPH
than_PIN
250_CD
are_VPRT [PASS]
made_VBN
over_RP
a_DT
period_NN
of_PIN
three_CD
or_CC
five_CD
years_NN
._.
The_DT
number_NN
of_PIN
shares_NN
over_IN
which_WDT
an_DT
option_NOMZ
is_VPRT [PASS]
granted_VBN [SUAV]
will_PRMD
be_VB [BEMA]
such_OSUB
that_NULL
the_DT
total_JJ
amount_NN
payable_JJ
on_PIN
its_PIT
exercise_NN
will_PRMD
be_VB [BEMA]
the_DT
proceeds_NN
on_PIN
maturity_NOMZ
of_PIN
the_DT
related_JJ
savings_GER
contract_NN
._.
No_SYNE
payment_NOMZ
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
for_PIN
the_DT
grant_NN
of_PIN
an_DT
option_NOMZ
._.
Individual_JJ
participation_NOMZ
Monthly_JJ
savings_GER
by_PIN
an_DT
employee_NN
under_IN
all_QUAN
savings_GER
contracts_NN
linked_VBN [WZPAST]
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
any_QUAN
SAYE_NN
scheme_NN
may_POMD
not_XX0
exceed_VB
250_CD
or_CC
such_JJ
lower_JJ
amounts_NN
as_IN
may_POMD
be_VB [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Directors_NN
._.
com_NN
99_CD
33_CD
Employee_NN
costs_NN
and_PHC
share_NN
option_NOMZ
plans_NN
for_PIN
employees_NN
continued_VBD
Acquisition_NOMZ
price_NN
The_DT
price_NN
per_PIN
Ordinary_NN
Share_NN
payable_JJ
upon_PIN
the_DT
exercise_NN
of_PIN
an_DT
option_NOMZ
will_PRMD
not_XX0
normally_RB
be_VB [BEMA]
less_PRED
than_PIN
the_DT
higher_JJ
of_PIN
:_:
a_DT
90_CD
%_NN
of_PIN
the_DT
arithmetical_JJ
average_NN
of_PIN
the_DT
middle-market_JJ
quotations_NOMZ
for_PIN
an_DT
Ordinary_NN
Share_NN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
on_PIN
three_CD
consecutive_JJ
dealing_VBG
days_NN
shortly_TIME
before_IN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
invitations_NOMZ
to_TO
apply_VB
for_PIN
options_NOMZ
are_VPRT [PASS]
issued_VBN
provided_VBN
that_DEMO
no_SYNE
such_JJ
day_NN
may_POMD
fall_VB
before_IN
the_DT
Company_NN
last_JJ
announced_VBD [PUBV]
its_PIT
results_NN
for_PIN
any_QUAN
period_NN
or_CC
such_JJ
other_JJ
dealing_VBG
day_NN
or_CC
days_NN
falling_VBG [WZPRES]
within_PIN
the_DT
six_CD
week_NN
period_NN
for_PIN
the_DT
issue_NN
of_PIN
invitations_NOMZ
as_IN
the_DT
Directors_NN
may_POMD
decide_VB [SUAV] [PRIV]
:_:
and_ANDC
b_NN
the_DT
nominal_JJ
value_NN
of_PIN
an_DT
Ordinary_NN
Share_NN
unless_COND
the_DT
option_NOMZ
is_VPRT [PASS]
expressed_VBN
to_TO
relate_VB
only_DWNT
to_TO
existing_VBG
shares_NN
._.
Exercise_NN
of_PIN
options_NOMZ
An_DT
option_NOMZ
will_PRMD [SPAU]
normally_RB
be_VB [BEMA]
exercisable_JJ
only_DWNT
for_PIN
six_CD
months_NN
commencing_VBG [WZPRES]
on_PIN
the_DT
third_JJ
or_CC
fifth_JJ
anniversary_NN
of_PIN
the_DT
commencement_NOMZ
of_PIN
the_DT
related_JJ
savings_GER
contract_NN
._.
Options_NOMZ
normally_RB
lapse_NN
on_PIN
cessation_NOMZ
of_PIN
employment_NOMZ
._.
Exercise_NN
is_VPRT
,_,
however_CONJ
,_,
permitted_VBD
for_PIN
a_DT
limited_JJ
period_NN
irrespective_RB
of_PIN
the_DT
period_NN
during_PIN
which_WDT [PIRE]
the_DT
option_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
held_VBN [PRIV]
following_VBG
cessation_NOMZ
of_PIN
employment_NOMZ
in_PIN
certain_JJ
compassionate_JJ
circumstances_NN
or_CC
where_RB
an_DT
option_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
held_VBN [PRIV]
for_PIN
more_EMPH
than_PIN
three_CD
years_NN
except_PIN
on_PIN
dismissal_NN
for_PIN
misconduct_NN
and_CC
on_PIN
an_DT
amalgamation_NOMZ
,_,
take-over_NN
or_CC
winding-up_NN
of_PIN
the_DT
Company_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
chosen_VBN
to_PIN
avail_NN
itself_PIT
of_PIN
the_DT
exemption_NOMZ
to_PIN
application_NOMZ
of_PIN
UITF17_NN
revised_VBD
to_PIN
its_PIT
SAYE_NN
scheme_NN
._.
5_CD
Summary_NN
of_PIN
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
Eligibility_NOMZ
Any_QUAN
AstraZeneca_NN
employee_NN
may_POMD
be_VB [PASS]
recommended_VBN [SUAV]
from_PIN
time_NN
to_PIN
time_NN
for_PIN
the_DT
grant_NN
of_PIN
an_DT
option_NOMZ
._.
The_DT
Remuneration_NOMZ
Committee_NN
sets_VPRT
the_DT
policy_NN
for_PIN
the_DT
Companys_NN
operation_NOMZ
of_PIN
the_DT
plan_NN
including_VBG [WZPRES]
as_IN
regards_VPRT
which_WDT
employees_NN
will_PRMD
be_VB [BEMA]
eligible_PRED
to_TO
participate_VB
._.
Grant_NN
of_PIN
options_NOMZ
Options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
at_PIN
any_QUAN
time_NN
other_JJ
than_PIN
during_PIN
a_DT
close_JJ
period_NN
._.
No_SYNE
options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
after_IN
the_DT
fifth_JJ
anniversary_NN
of_PIN
the_DT
approval_NN
of_PIN
the_DT
plan_NN
by_PIN
shareholders_NN
until_IN
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT [PEAS]
reviewed_VBN
the_DT
plan_NN
._.
The_DT
grant_NN
of_PIN
options_NOMZ
is_VPRT [BYPA]
supervised_VBN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
which_WDT [WHSUB]
is_VPRT [PASS]
comprised_VBN
wholly_RB
of_PIN
Non-Executive_JJ
Directors_NN
._.
No_SYNE
payment_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
for_PIN
the_DT
grant_NN
of_PIN
an_DT
option_NOMZ
._.
Options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
over_IN
Ordinary_NN
Shares_NN
in_PIN
AstraZeneca_NN
PLC_NN
or_CC
over_IN
the_DT
Companys_NN
ADSs_NN
._.
Acquisition_NOMZ
price_NN
The_DT
price_NN
per_PIN
Ordinary_NN
Share_NN
payable_JJ
upon_PIN
the_DT
exercise_NN
of_PIN
an_DT
option_NOMZ
will_PRMD
not_XX0
be_VB [BEMA]
less_PRED
than_PIN
an_DT
amount_NN
equal_JJ
to_PIN
the_DT
average_NN
of_PIN
the_DT
middle-market_JJ
closing_GER
price_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
for_PIN
an_DT
Ordinary_NN
Share_NN
of_PIN
the_DT
Company_NN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
on_PIN
the_DT
three_CD
consecutive_JJ
dealing_VBG
days_NN
immediately_TIME
before_IN
the_DT
date_NN
of_PIN
grant_NN
or_CC
as_IN
otherwise_CONJ
agreed_VBN [SUAV] [PUBV]
with_PIN
the_DT
Inland_NN
Revenue_NN
._.
Where_RB
the_DT
option_NOMZ
is_VPRT [BEMA]
an_DT
option_NOMZ
to_TO
subscribe_VB
,_,
the_DT
price_NN
payable_JJ
upon_PIN
exercise_NN
can_POMD
not_XX0
be_VB [BEMA]
less_PRED
than_PIN
the_DT
nominal_JJ
value_NN
of_PIN
an_DT
Ordinary_NN
Share_NN
of_PIN
the_DT
Company_NN
._.
Exercise_NN
of_PIN
options_NOMZ
An_DT
option_NOMZ
will_PRMD [SPAU]
normally_RB
be_VB [BEMA]
exercisable_PRED
between_PIN
three_CD
and_CC
10_CD
years_NN
following_VBG [WZPRES]
its_PIT
grant_NN
provided_VBD
any_QUAN
relevant_JJ
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
satisfied_VBN
._.
The_DT
Remuneration_NOMZ
Committee_NN
sets_VPRT
the_DT
policy_NN
for_PIN
the_DT
Companys_NN
operation_NOMZ
of_PIN
the_DT
plan_NN
including_VBG [WZPRES]
as_IN
regards_VPRT
whether_IN
any_QUAN
performance_NN
target_NN
s_PRP
will_PRMD
apply_VB
to_PIN
the_DT
grant_NN
and_CC
or_CC
exercise_NN
of_PIN
each_QUAN
eligible_JJ
employees_NN
option_NOMZ
._.
Exercise_NN
is_VPRT
,_,
however_CONJ
,_,
permitted_VBD
for_PIN
a_DT
limited_JJ
period_NN
following_VBG [WZPRES]
cessation_NOMZ
of_PIN
employment_NOMZ
either_CC
for_PIN
reasons_NN
of_PIN
injury_NN
or_CC
disability_NOMZ
,_,
redundancy_NN
or_CC
retirement_NOMZ
,_,
or_CC
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
and_ANDC
on_PIN
an_DT
amalgamation_NOMZ
,_,
take-over_NN
or_CC
winding-up_NN
of_PIN
the_DT
Company_NN
._.
com_NN
100_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
33_CD
Employee_NN
costs_NN
and_PHC
share_NN
option_NOMZ
plans_NN
for_PIN
employees_NN
continued_VBD
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
1994_CD
Scheme_NN
SAYE_NN
Scheme_NN
ASVIP_NN
Shares_NN
under_IN
Options_NOMZ
WAEP_NN
Options_NOMZ
WAEP_NN
Options_NOMZ
WAEP_NN
option_NOMZ
WAEP_NN
000_CD
pence_NN
000_CD
pence_NN
000_CD
pence_NN
000_CD
SEK_NN
At_PIN
1_CD
January_NN
2000_CD
Options_NOMZ
outstanding_JJ
Nil_NN
Nil_NN
3,001_CD
1934_CD
4,388_CD
1708_CD
1,249_CD
361_CD
Movements_NOMZ
during_PIN
2000_CD
Options_NOMZ
granted_VBN [SUAV]
712_CD
3093_CD
8,885_CD
2714 723 2806_CD
Nil_NN
Options_NOMZ
exercised_VBD
Nil_NN
Nil_NN
800_CD
1525_CD
1,078_CD
1117 159 303_CD
Options_NOMZ
forfeited_VBD
Nil_NN
Nil_NN
99 2675 207 1843_CD
Nil_NN
Options_NOMZ
lapsed_VBD
Nil_NN
Nil_NN
Nil_NN
Nil_NN
Nil_NN
Weighted_NN
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
during_PIN
the_DT
year_NN
809 712 396_CD
At_PIN
31_CD
December_NN
2000_CD
Options_NOMZ
outstanding_JJ
712_CD
3093_CD
10,987_CD
2588_CD
3,826_CD
2074_CD
1,090_CD
370_CD
Movements_NOMZ
during_PIN
2001_CD
Options_NOMZ
granted_VBN [SUAV]
10,984_CD
3245 649 2971_CD
Options_NOMZ
exercised_VBN
1_CD
3093 592 1687_CD
1,125_CD
1583 117 328_CD
Options_NOMZ
forfeited_VBD
296 3231 457 2709_CD
551_CD
2181_CD
8_CD
306_CD
Options_NOMZ
lapsed_VBD
Weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
during_PIN
the_DT
year_NN
653_CD
495_CD
At_PIN
31_CD
December_NN
2001_CD
Options_NOMZ
outstanding_JJ
11,399_CD
3236_CD
9,938_CD
2636_CD
2,799_CD
2459 965 375_CD
Movements_NOMZ
during_PIN
2002_CD
Options_NOMZ
granted_VBN [SUAV]
10,658_CD
3462_CD
2,721_CD
1756_CD
Options_NOMZ
exercised_VBN
22 3214 243 2175_CD
469 1888 206 317_CD
Options_NOMZ
forfeited_VBD
637 3298 406 2654_CD
986_CD
2735_CD
Options_NOMZ
lapsed_VBD
Weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
during_PIN
the_DT
year_NN
1186_CD
559_CD
At_PIN
31_CD
December_NN
2002_CD
Options_NOMZ
outstanding_JJ
21,398_CD
3347_CD
9,289_CD
2647_CD
4,065_CD
1987 759 391_CD
Range_NN
of_PIN
exercise_NN
prices_NN
1913p_VPRT
to_TO
826p_VB
to_TO
1756p_VB
to_PIN
298SEK_CD
to_PIN
3487p_CD
2749p_CD
2971p_JJ
442SEK_NN
Weighted_NN
average_JJ
remaining_VBG
contractual_JJ
life_NN
3,183_CD
days_NN
2,542_CD
days_NN
1,439_CD
days_NN
746_CD
days_NN
Options_NOMZ
exercisable_JJ
351 3303 1786 2367_CD
130 2070 759 391_CD
Weighted_NN
Average_NN
Exercise_NN
Price_NN
In_CONJ
addition_NULL
to_PIN
the_DT
schemes_NN
disclosed_VBN [PUBV]
above_PLACE
at_PIN
31_CD
December_NN
2002_CD
there_EX
were_VBD
5,000_CD
options_NOMZ
outstanding_JJ
issued_VBN
under_IN
the_DT
Zeneca_NN
1993_CD
Senior_JJ
Staff_NN
Share_NN
Option_NOMZ
Scheme_NN
with_PIN
a_DT
weighted_JJ
average_JJ
exercise_NN
price_NN
of_PIN
717p_CD
._.
com_NN
101_CD
34_CD
Assets_NN
pledged_VBN [SUAV]
,_,
commitments_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Assets_NN
pledged_VBD [SUAV]
Mortgages_NN
and_CC
other_JJ
assets_NN
pledged_VBD [SUAV]
90_CD
118_CD
51_CD
Commitments_NOMZ
Contracts_NN
placed_VBN [WZPAST]
for_PIN
future_JJ
capital_NN
expenditure_NN
not_XX0
provided_VBN
for_PIN
in_PIN
these_DEMO
accounts_NN
500 515 604_CD
Included_VBN
in_PIN
the_DT
above_PLACE
total_NN
are_VPRT [PASS]
contracts_NN
related_VBN [WZPAST]
to_PIN
certain_JJ
product_NN
purchase_NN
and_PHC
licence_NN
agreements_NOMZ
with_PIN
deferred_JJ
consideration_NOMZ
obligations_NOMZ
,_,
the_DT
amounts_NN
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
variable_PRED
depending_VBG
upon_PIN
particular_JJ
milestone_NN
achievements_NOMZ
._.
Sales_NN
of_PIN
the_DT
products_NN
to_PIN
which_WDT [PIRE]
these_DEMO
milestones_NN
relate_VPRT
could_POMD
give_VB
rise_VB
to_PIN
additional_JJ
payments_NOMZ
,_,
contingent_NN
upon_PIN
the_DT
sales_NN
levels_NN
achieved_VBN
._.
Guarantees_NN
and_PHC
contingencies_NN
arising_VBG [WZPRES]
in_PIN
the_DT
ordinary_JJ
course_NN
of_PIN
business_NOMZ
,_,
for_PIN
which_WDT [PIRE]
no_SYNE
security_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
given_VBN
,_,
are_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
result_VB
in_PIN
any_QUAN
material_NN
financial_JJ
loss_NN
._.
Commitments_NOMZ
AstraZeneca_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
pay_VB
approximately_RB
$_$
800m_CD
over_IN
at_PIN
least_JJ
a_DT
five-year_JJ
period_NN
which_WDT [WHSUB]
commenced_VBD
in_PIN
1999_CD
,_,
under_IN
the_DT
terms_NN
of_PIN
an_DT
agreement_NOMZ
with_PIN
Schering-Plough_NN
._.
With_PIN
effect_NN
from_PIN
1_CD
January_NN
1999_CD
,_,
in_PIN
connection_NOMZ
with_PIN
this_DEMO
agreement_NOMZ
,_,
AstraZeneca_NN
obtained_VBD
a_DT
stand-by_PIN
letter_NN
of_PIN
credit_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
608m_CD
._.
This_DEMO
letter_NN
of_PIN
credit_NN
is_VPRT [BYPA]
collateralised_VBN
by_PIN
high-grade_JJ
government_NOMZ
securities_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
available_PRED
to_PIN
AstraZeneca_NN
to_PIN
the_DT
extent_NN
of_PIN
the_DT
outstanding_JJ
balance_NN
of_PIN
the_DT
letter_NN
of_PIN
credit_NN
._.
The_DT
amount_NN
outstanding_JJ
under_IN
the_DT
letter_NN
of_PIN
credit_NN
is_VPRT [SPAU] [PASS]
automatically_RB
reduced_VBN
with_PIN
each_QUAN
payment_NOMZ
made_VBN [WZPAST]
by_PIN
AstraZeneca_NN
to_PIN
Schering-Plough_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
this_DEMO
agreement_NOMZ
AstraZeneca_NN
reacquired_VBD
the_DT
rights_NN
to_PIN
market_NN
omeprazole_NN
under_IN
the_DT
Losec_NN
trade_NN
mark_NN
and_PHC
felodipine_NN
under_IN
the_DT
Prevex_NN
and_PHC
Perfudal_NN
trade_NN
marks_NN
in_PIN
Italy_NN
and_PHC
Spain_NN
._.
The_DT
total_JJ
discounted_JJ
liability_NOMZ
and_CC
associated_VBN
asset_NN
were_VBD [PASS]
recognized_VBN [PRIV]
in_PIN
1999_CD
._.
Payments_NOMZ
under_IN
this_DEMO
agreement_NOMZ
in_PIN
2002_CD
totalled_VBD
approximately_RB
$_$
146m_CD
._.
The_DT
final_JJ
payment_NOMZ
will_PRMD
be_VB [PASS]
made_VBN
in_PIN
2003_CD
._.
In_PIN
1998_CD
,_,
Astra_NN
and_PHC
Merck_NN
&_CC
Co._NN
._.
Inc_NN
restructured_VBD
their_TPP3
joint_JJ
venture_NN
the_DT
restructuring_GER
which_WDT [WHSUB]
had_VBD [PEAS]
been_VBN [PASS]
established_VBN [PRIV]
some_QUAN
years_NN
earlier_TIME
for_PIN
the_DT
purpose_NN
of_PIN
selling_GER
and_PHC
marketing_GER
certain_JJ
Astra_NN
products_NN
in_PIN
the_DT
US_FPP1
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
1998_CD
restructuring_GER
,_,
the_DT
merger_NN
between_PIN
Astra_NN
and_PHC
Zeneca_NN
in_PIN
1999_CD
triggered_VBD
two_CD
one-time_JJ
payments_NOMZ
from_PIN
AstraZeneca_NN
to_PIN
Merck_NN
:_:
a_DT
Lump_NN
Sum_NN
Payment_NOMZ
of_PIN
$_$
809m_CD
,_,
which_WDT [SERE]
was_VBD [PASS]
charged_VBN
to_TO
profit_VB
and_CC
loss_NN
account_NN
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
which_WDT [PIRE]
Merck_NN
relinquished_VBD
any_QUAN
rights_NN
to_PIN
Zeneca_NN
products_NN
:_:
and_ANDC
an_DT
Advance_NN
Payment_NOMZ
of_PIN
$_$
967m_CD
._.
This_DEMO
Advance_NN
Payment_NOMZ
was_VBD [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
then_RB
net_JJ
present_JJ
value_NN
of_PIN
$_$
2.8_CD
bn_NN
discounted_VBN [WZPAST]
from_PIN
2008_CD
to_PIN
the_DT
date_NN
of_PIN
payment_NOMZ
at_PIN
a_DT
rate_NN
of_PIN
13_CD
%_NN
per_PIN
annum_NN
and_CC
led_VBD
Merck_NN
to_TO
relinquish_VB
any_QUAN
rights_NN
to_PIN
future_JJ
Astra_NN
products_NN
with_PIN
no_DT
existing_VBG
or_CC
pending_VBG
US_FPP1
patents_NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
merger_NN
._.
AstraZeneca_NN
makes_VPRT
ongoing_JJ
payments_NOMZ
to_PIN
Merck_NN
based_VBN [WZPAST]
on_PIN
sales_NN
of_PIN
certain_JJ
AstraZeneca_NN
products_NN
in_PIN
the_DT
US_FPP1
the_DT
contingent_JJ
payments_NOMZ
on_PIN
the_DT
agreement_NOMZ
products_NN
as_RB
well_RB
as_IN
certain_JJ
other_JJ
partnership_NN
distributions_NOMZ
,_,
the_DT
latter_NN
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
not_XX0
material_PRED
to_PIN
the_DT
Group_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
1999_CD
merger_NN
,_,
these_DEMO
contingent_JJ
payments_NOMZ
excluding_VBG [WZPRES]
those_DEMO
in_PIN
respect_NN
of_PIN
Prilosec_NN
and_PHC
Nexium_NN
are_VPRT [BEMA]
subject_PRED
to_TO
defined_VBN
minimum_JJ
amounts_NN
ranging_VBG [WZPRES]
from_PIN
$_$
125m_CD
to_TO
$_$
225m_CD
between_PIN
2002_CD
and_CC
2007_CD
._.
Payments_NOMZ
under_IN
these_DEMO
arrangements_NOMZ
have_VPRT [PEAS]
exceeded_VBN
the_DT
minimum_JJ
level_NN
in_PIN
2002_CD
._.
The_DT
terms_NN
of_PIN
the_DT
1998_CD
restructuring_GER
also_RB
provide_VB
for_PIN
the_DT
following_VBG
events_NN
:_:
Partial_NN
Redemption_NOMZ
First_NN
Option_NOMZ
Second_JJ
Option_NOMZ
Partial_NN
Redemption_NOMZ
In_PIN
2008_CD
,_,
there_EX
will_PRMD
be_VB
a_DT
partial_JJ
redemption_NOMZ
of_PIN
Mercks_NN
limited_JJ
partnership_NN
interest_NN
which_WDT [WHSUB]
will_PRMD
end_VB
Mercks_NN
rights_NN
to_PIN
contingent_JJ
payments_NOMZ
in_PIN
respect_NN
of_PIN
certain_JJ
of_PIN
the_DT
agreement_NOMZ
products_NN
by_PIN
distribution_NOMZ
to_PIN
Merck_NN
of_PIN
an_DT
amount_NN
calculated_VBN [PRIV]
as_IN
a_DT
multiple_NN
of_PIN
the_DT
previous_JJ
three_CD
years_NN
contingent_JJ
payments_NOMZ
on_PIN
the_DT
relevant_JJ
products_NN
,_,
plus_PIN
$_$
750m_CD
._.
First_NN
Option_NOMZ
In_PIN
2008_CD
a_DT
calculation_NOMZ
will_PRMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
Appraised_NN
Value_NN
,_,
being_VBG [PRESP] [BEMA]
the_DT
net_JJ
present_JJ
value_NN
of_PIN
the_DT
future_JJ
contingent_JJ
payments_NOMZ
in_PIN
respect_NN
of_PIN
all_QUAN
other_JJ
agreement_NOMZ
products_NN
not_XX0
covered_VBN
by_PIN
the_DT
Partial_NN
Redemption_NOMZ
other_JJ
than_PIN
Prilosec_NN
and_PHC
Nexium_NN
._.
Payment_NOMZ
of_PIN
this_DEMO
amount_NN
to_PIN
Merck_NN
in_PIN
2008_CD
is_VPRT
,_,
however_CONJ
,_,
contingent_NN
on_PIN
Mercks_NN
exercise_NN
of_PIN
the_DT
First_NN
Option_NOMZ
._.
Exercise_NN
of_PIN
the_DT
First_NN
Option_NOMZ
will_PRMD
require_VB [SUAV]
AstraZeneca_NN
to_TO
re-purchase_VB
Mercks_NN
interest_NN
in_PIN
these_DEMO
products_NN
._.
Should_NEMD
Merck_NN
not_XX0
exercise_VB
this_DEMO
option_NOMZ
in_PIN
2008_CD
,_,
AstraZeneca_NN
may_POMD
exercise_VB
it_PIT
in_PIN
2010_CD
for_PIN
a_DT
sum_NN
equal_JJ
to_PIN
the_DT
2008_CD
Appraised_NN
Value_NN
._.
If_COND
neither_SYNE
Merck_NN
nor_SYNE
AstraZeneca_NN
exercise_VPRT
the_DT
option_NOMZ
,_,
the_DT
contingent_JJ
payment_NOMZ
arrangements_NOMZ
in_PIN
respect_NN
of_PIN
these_DEMO
agreement_NOMZ
products_NN
will_PRMD
continue_VB
and_CC
the_DT
Appraised_NN
Value_NN
will_PRMD
not_XX0
be_VB [PASS]
paid_VBN
._.
com_NN
102_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
34_CD
Assets_NN
pledged_VBN [SUAV]
,_,
commitments_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
continued_VBD
In_CONJ
addition_NULL
,_,
in_PIN
2008_CD
there_EX
will_PRMD
be_VB
a_DT
true_JJ
up_RB
of_PIN
the_DT
Advance_NN
Payment_NOMZ
._.
The_DT
calculation_NOMZ
of_PIN
this_DEMP
will_PRMD
be_VB [PASS]
based_VBN
on_PIN
a_DT
multiple_NN
of_PIN
the_DT
previous_JJ
three_CD
years_NN
contingent_JJ
payments_NOMZ
in_PIN
respect_NN
of_PIN
all_QUAN
the_DT
agreement_NOMZ
products_NN
with_PIN
the_DT
exception_NOMZ
of_PIN
Prilosec_NN
and_PHC
Nexium_NN
,_,
plus_PIN
other_JJ
defined_VBN
amounts_NN
,_,
which_WDT [SERE]
are_VPRT [SPAU] [BYPA]
then_RB
reduced_VBN
by_PIN
the_DT
Appraised_NN
Value_NN
whether_IN
paid_VBN
or_CC
not_XX0
,_,
the_DT
Partial_NN
Redemption_NOMZ
and_CC
the_DT
Advance_NN
Payment_NOMZ
._.
This_DEMP
could_POMD
result_VB
in_PIN
a_DT
further_JJ
payment_NOMZ
by_PIN
AstraZeneca_NN
to_PIN
Merck_NN
or_CC
a_DT
payment_NOMZ
by_PIN
Merck_NN
to_PIN
AstraZeneca_NN
._.
The_DT
precise_JJ
amount_NN
of_PIN
settlements_NOMZ
with_PIN
Merck_NN
under_IN
the_DT
Partial_NN
Redemption_NOMZ
and_CC
the_DT
First_NN
Option_NOMZ
can_POMD
not_XX0
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
at_PIN
this_DEMO
time_NN
,_,
as_IN
some_QUAN
of_PIN
the_DT
payments_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
calculations_NOMZ
based_VBN [WZPAST]
on_PIN
sales_NN
between_PIN
2005_CD
and_CC
2007_CD
,_,
and_ANDC
another_DT
is_VPRT [BEMA]
contingent_PRED
upon_PIN
Merck_NN
exercising_VBG [WZPRES]
the_DT
First_NN
Option_NOMZ
._.
However_CONJ
,_,
if_COND
Merck_NN
does_EMPH
exercise_VB
this_DEMO
option_NOMZ
,_,
the_DT
combined_VBN
effect_NN
will_PRMD
involve_VB
a_DT
minimum_NN
amount_NN
payable_JJ
to_PIN
Merck_NN
in_PIN
2008_CD
of_PIN
approximately_RB
$_$
4.7_CD
bn_NN
._.
If_COND
AstraZeneca_NN
exercises_VPRT
this_DEMO
option_NOMZ
in_PIN
2010_CD
,_,
the_DT
combined_VBN
effect_NN
will_PRMD
involve_VB
a_DT
minimum_JJ
aggregate_JJ
payable_JJ
to_PIN
Merck_NN
in_PIN
2008_CD
and_CC
2010_CD
of_PIN
approximately_RB
$_$
4.7_CD
bn_NN
._.
Finally_RB
,_,
in_PIN
2008_CD
Merck_NN
will_PRMD
repay_VB
to_PIN
AstraZeneca_NN
a_DT
loan_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
1.4_CD
bn_NN
made_VBN [WZPAST]
at_PIN
the_DT
time_NN
of_PIN
the_DT
restructuring_GER
._.
Second_JJ
Option_NOMZ
A_DT
Second_JJ
Option_NOMZ
exists_VPRT
whereby_OSUB
AstraZeneca_NN
has_VPRT
the_DT
option_NOMZ
to_TO
re-purchase_VB
Mercks_NN
interests_NN
in_PIN
Prilosec_NN
and_PHC
Nexium_NN
in_PIN
the_DT
US_FPP1
._.
This_DEMO
option_NOMZ
is_VPRT [BEMA]
exercisable_PRED
by_PIN
AstraZeneca_NN
two_CD
years_NN
after_IN
the_DT
exercise_NN
of_PIN
the_DT
First_NN
Option_NOMZ
in_PIN
either_CC
2008_CD
or_CC
2010_CD
._.
Exercise_NN
of_PIN
the_DT
Second_JJ
Option_NOMZ
by_PIN
AstraZeneca_NN
at_PIN
a_DT
later_TIME
date_NN
is_VPRT [SPAU] [PASS]
also_RB
provided_VBN
for_PIN
in_PIN
2017_CD
or_CC
if_COND
combined_VBN
annual_JJ
sales_NN
of_PIN
the_DT
two_CD
products_NN
fall_VPRT
below_PLACE
a_DT
minimum_JJ
amount_NN
provided_VBN
,_,
in_PIN
each_QUAN
case_NN
only_DWNT
so_RB
long_RB
as_IN
the_DT
First_NN
Option_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
exercised_VBN
._.
The_DT
exercise_NN
price_NN
for_PIN
the_DT
Second_JJ
Option_NOMZ
is_VPRT [BEMA]
the_DT
fair_JJ
value_NN
of_PIN
these_DEMO
product_NN
rights_NN
as_IN
determined_VBN [SUAV] [PRIV]
at_PIN
the_DT
time_NN
of_PIN
exercise_NN
._.
If_COND
the_DT
Second_JJ
Option_NOMZ
is_VPRT [PASS]
exercised_VBN
,_,
Merck_NN
will_PRMD
have_VB
no_SYNE
further_JJ
rights_NN
to_PIN
contingent_JJ
payments_NOMZ
from_PIN
AstraZeneca_NN
._.
Environmental_JJ
costs_NN
and_PHC
liabilities_NOMZ
The_DT
Groups_NN
expenditure_NN
on_PIN
environmental_JJ
protection_NOMZ
,_,
including_VBG [PRESP]
both_DT
capital_NN
and_PHC
revenue_NN
items_NN
,_,
relates_VPRT
to_PIN
costs_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
necessary_PRED
for_PIN
meeting_VBG
current_JJ
good_JJ
practice_NN
standards_NN
and_CC
regulatory_JJ
requirements_NOMZ
for_PIN
processes_NN
and_PHC
products_NN
._.
They_TPP3
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
normal_JJ
ongoing_JJ
expenditure_NN
for_PIN
maintaining_VBG [PUBV] [THATD]
the_DT
Groups_NN
manufacturing_VBG [WZPRES]
capacity_NOMZ
and_PHC
product_NN
ranges_NN
and_CC
are_VPRT [PASS]
not_XX0
separated_VBN
from_PIN
overall_JJ
operating_GER
and_PHC
development_NOMZ
costs_NN
._.
There_EX
are_VPRT
no_DT
known_VBN [PRIV]
changes_NN
in_PIN
environmental_JJ
,_,
regulatory_JJ
or_CC
other_JJ
requirements_NOMZ
resulting_VBG [WZPRES]
in_PIN
material_NN
changes_NN
to_PIN
the_DT
levels_NN
of_PIN
expenditure_NN
for_PIN
2000_CD
,_,
2001_CD
or_CC
2002_CD
._.
In_CONJ
addition_NULL
to_PIN
expenditure_NN
for_PIN
meeting_GER
current_JJ
and_CC
foreseen_VBN
environmental_JJ
protection_NOMZ
requirements_NOMZ
,_,
the_DT
Group_NN
incurs_VPRT
substantial_JJ
costs_NN
in_PIN
investigating_VBG
and_PHC
cleaning_VBG
up_RP
land_NN
and_PHC
groundwater_NN
contamination_NOMZ
._.
In_CONJ
particular_NULL
,_,
AstraZeneca_NN
has_VPRT
environmental_JJ
liabilities_NOMZ
at_PIN
some_QUAN
currently_RB
or_CC
formerly_TIME
owned_VBN
,_,
leased_VBN
and_CC
third_JJ
party_NN
sites_NN
in_PIN
the_DT
US_FPP1
and_PHC
Europe_NN
._.
AstraZeneca_NN
,_,
or_CC
its_PIT
indemnitees_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
under_IN
US_FPP1
legislation_NOMZ
the_DT
Comprehensive_NN
Environmental_NN
Response_NN
,_,
Compensation_NOMZ
and_PHC
Liability_NOMZ
Act_NN
of_PIN
1980_CD
,_,
as_IN
amended_VBN
as_IN
potentially_RB
responsible_JJ
parties_NN
PRPSNNP
in_PIN
respect_NN
of_PIN
32_CD
sites_NN
although_CONC
AstraZeneca_NN
expects_VPRT [PRIV]
to_TO
be_VB [PASS]
indemnified_VBN
against_PIN
liabilities_NOMZ
associated_VBN [WZPAST]
with_PIN
nine_CD
of_PIN
these_DEMO
sites_NN
by_PIN
the_DT
seller_NN
or_CC
owner_NN
of_PIN
the_DT
businesses_NOMZ
associated_VBN [WZPAST]
with_PIN
such_JJ
sites_NN
and_CC
,_,
where_RB
appropriate_JJ
,_,
actively_RB
participates_VPRT
in_PIN
or_CC
monitors_VPRT
the_DT
clean-up_JJ
activities_NOMZ
at_PIN
sites_NN
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [BEMA]
a_DT
PRPSNNP
._.
Stauffer_NN
Management_NOMZ
Company_NN
,_,
a_DT
subsidiary_NN
of_PIN
AstraZeneca_NN
established_VBN [PRIV] [WZPAST]
in_PIN
1987_CD
to_TO
own_VB
and_PHC
manage_VB
certain_JJ
assets_NN
of_PIN
Stauffer_NN
Chemical_NN
Company_NN
which_WDT [WHSUB]
was_VBD [PASS]
acquired_VBN
that_DEMO
year_NN
,_,
has_VPRT [PEAS]
identified_VBN
28_CD
sites_NN
including_VBG [WZPRES]
18_CD
for_PIN
which_WDT [PIRE]
an_DT
AstraZeneca_NN
indemnitee_NN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
a_DT
PRPSNNP
for_PIN
which_WDT [PIRE]
it_PIT
may_POMD
have_VB
responsibility_NOMZ
that_TSUB
will_PRMD
,_,
in_PIN
aggregate_NN
,_,
require_VPRT [SUAV]
significant_JJ
expenditure_NN
on_PIN
clean-up_JJ
and_CC
monitoring_GER
._.
Liabilities_NOMZ
are_VPRT
generally_RB
more_EMPH
likely_JJ
to_TO
crystallise_VB
where_RB
a_DT
contaminated_VBN
site_NN
is_VPRT
to_TO
be_VB [PASS]
sold_VBN
,_,
its_PIT
use_NN
changed_VBD
or_CC
where_RB
a_DT
regulatory_JJ
authority_NOMZ
imposes_VPRT
a_DT
particular_JJ
remedial_JJ
measure_NN
._.
Costs_NN
of_PIN
these_DEMO
liabilities_NOMZ
may_POMD
be_VB [BYPA]
offset_VBN
by_PIN
amounts_NN
recovered_VBD
from_PIN
third_JJ
parties_NN
,_,
such_JJ
as_IN
previous_JJ
owners_NN
of_PIN
the_DT
sites_NN
in_PIN
question_NOMZ
or_CC
through_PIN
insurance_NN
._.
The_DT
future_JJ
level_NN
of_PIN
investigation_NOMZ
and_CC
clean_VB
up_RP
costs_NN
will_PRMD
depend_VB
on_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
including_VBG [PRESP]
the_DT
nature_NN
and_PHC
extent_NN
of_PIN
any_QUAN
contamination_NOMZ
that_TSUB
may_POMD [SPAU]
ultimately_RB
be_VB [PASS]
found_VBN [PRIV]
to_TO
exist_VB
,_,
the_DT
need_NN
for_PIN
and_CC
type_NN
of_PIN
any_QUAN
remedial_JJ
work_NN
to_TO
be_VB [PASS]
undertaken_VBN
and_CC
the_DT
standards_NN
required_VBN [SUAV] [WZPAST]
by_PIN
applicable_JJ
current_JJ
and_PHC
future_JJ
environmental_JJ
laws_NN
and_PHC
regulations_NOMZ
and_CC
the_DT
number_NN
and_CC
financial_JJ
viability_NOMZ
of_PIN
other_JJ
PRPS_NN
._.
The_DT
relative_JJ
importance_NN
of_PIN
these_DEMO
factors_NN
varies_VPRT
significantly_RB
from_PIN
site_NN
to_PIN
site_NN
._.
Many_QUAN
sites_NN
are_VPRT [BEMA]
at_PIN
different_JJ
stages_NN
in_PIN
the_DT
regulatory_JJ
process_NN
or_CC
at_PIN
different_JJ
stages_NN
in_PIN
the_DT
process_NN
of_PIN
evaluating_VBG
environmental_JJ
damage_NN
or_CC
alternative_NN
remediation_NOMZ
methods_NN
._.
It_PIT
is_VPRT [BEMA]
therefore_CONJ
difficult_PRED
to_TO
form_VB
meaningful_JJ
ranges_NN
of_PIN
estimates_NN
for_PIN
such_JJ
costs_NN
._.
AstraZeneca_NN
had_VBD
provisions_NN
at_PIN
31_CD
December_NN
2002_CD
in_PIN
respect_NN
of_PIN
such_JJ
costs_NN
in_PIN
accordance_NN
with_PIN
the_DT
accounting_GER
policies_NN
on_PIN
page_NN
64_CD
._.
Although_CONC
there_EX
can_POMD
be_VB
no_SYNE
assurance_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
that_DEMP
,_,
taking_VBG
account_NN
of_PIN
these_DEMO
provisions_NN
,_,
the_DT
costs_NN
of_PIN
addressing_VBG
currently_RB
identified_VBN
environmental_JJ
obligations_NOMZ
,_,
as_IN
AstraZeneca_NN
currently_RB
views_VPRT
those_DEMO
obligations_NOMZ
,_,
is_VPRT [BEMA]
unlikely_PRED
to_TO
impair_VB
materially_RB
AstraZenecas_NN
financial_JJ
position_NOMZ
._.
Such_JJ
contingent_NN
costs_NN
,_,
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
exceed_VPRT
applicable_JJ
provisions_NN
,_,
could_POMD
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
AstraZenecas_NN
results_NN
of_PIN
operations_NOMZ
for_PIN
the_DT
relevant_JJ
period_NN
._.
com_NN
103_CD
Legal_NN
proceedings_GER
Losec_NN
Prilosec_NN
omeprazole_NN
In_PIN
June_NN
1997_CD
,_,
the_DT
German_NN
Federal_NN
Patent_NN
Court_NN
declared_VBD [PUBV]
invalid_JJ
a_DT
previously_TIME
granted_VBN [SUAV]
supplementary_JJ
protection_NOMZ
certificate_NN
which_WDT [WHSUB]
extended_VBD
protection_NOMZ
for_PIN
omeprazole_NN
,_,
the_DT
active_JJ
ingredient_NN
contained_VBN [WZPAST]
in_PIN
Losec_NN
,_,
from_PIN
1999_CD
to_PIN
2003_CD
._.
The_DT
decision_NN
was_VBD [PASS]
appealed_VBN
and_CC
on_PIN
1_CD
February_NN
2000_CD
,_,
at_PIN
AstraZenecas_NN
request_NN
,_,
the_DT
German_NN
Supreme_NN
Court_NN
decided_VBD [SUAV] [PRIV]
to_TO
refer_VB
the_DT
case_NN
to_PIN
the_DT
European_NN
Court_NN
of_PIN
Justice_NN
for_PIN
a_DT
preliminary_JJ
ruling_NN
._.
The_DT
court_NN
heard_VBD [PRIV]
the_DT
case_NN
on_PIN
8_CD
November_NN
2001_CD
and_CC
its_PIT
decision_NN
is_VPRT
pending_VBG
._.
The_DT
case_NN
does_VPRT
not_XX0
involve_VB
any_QUAN
financial_JJ
claims_NN
._.
In_PIN
March_NN
2000_CD
,_,
the_DT
German_NN
Federal_NN
Patent_NN
Court_NN
declared_VBD [PUBV]
that_THVC
AstraZenecas_NN
formulation_NOMZ
patent_NN
for_PIN
omeprazole_NN
was_VBD [BEMA]
invalid_PRED
._.
The_DT
decision_NN
has_VPRT [PEAS]
been_VBN [PASS]
appealed_VBN
to_PIN
the_DT
German_JJ
Supreme_NN
Court_NN
._.
As_CONJ
a_NULL
consequence_NULL
,_,
all_QUAN
pending_VBG
infringement_NOMZ
actions_NOMZ
in_PIN
Germany_NN
have_VPRT [PEAS]
been_VBN [PASS]
stayed_VBN
awaiting_VBG
the_DT
outcome_NN
of_PIN
the_DT
appeal_NN
._.
There_EX
is_VPRT
one_CD
interlocutory_NN
injunction_NOMZ
in_PIN
force_NN
against_PIN
ratiopharm_JJ
GmbH_NN
based_VBN [WZPAST]
on_PIN
the_DT
formulation_NOMZ
patent_NN
._.
If_COND
the_DT
final_JJ
decision_NN
on_PIN
the_DT
validity_NOMZ
of_PIN
the_DT
formulation_NOMZ
patent_NN
goes_VPRT
against_PIN
AstraZeneca_NN
,_,
ratiopharm_NN
may_POMD
claim_VB [PUBV]
damages_NN
for_PIN
lost_VBN
sales_NN
due_JJ
to_PIN
the_DT
interlocutory_JJ
injunction_NOMZ
._.
In_PIN
1998_CD
,_,
Astra_NN
filed_VBD
suits_NN
in_PIN
the_DT
US_FPP1
against_PIN
Andrx_NN
Pharmaceuticals_NN
,_,
Inc._NN
and_PHC
Genpharm_NN
,_,
Inc._NN
._.
This_DEMP
followed_VBD
the_DT
filing_NN
of_PIN
abbreviated_JJ
new_JJ
drug_NN
applications_NOMZ
by_PIN
Andrx_NN
and_PHC
Genpharm_NN
with_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
FDA_NN
concerning_VBG [WZPRES]
the_DT
two_CD
companies_NN
intention_NOMZ
to_PIN
market_NN
generic_JJ
omeprazole_NN
products_NN
in_PIN
the_DT
US_FPP1
._.
During_PIN
1999_CD
,_,
Astra_NN
also_RB
filed_VBD
suits_NN
against_PIN
Kremers_NN
Urban_NN
Development_NOMZ
Company_NN
and_PHC
Schwarz_NN
Pharma_NN
,_,
Inc._NN
and_CC
against_PIN
Cheminor_NN
Drugs_NN
Ltd._NN
._.
Reddy-Cheminor_NN
Inc._NN
and_PHC
Schein_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
During_PIN
2000_CD
,_,
AstraZeneca_NN
filed_VBD
further_JJ
suits_NN
against_PIN
Lek_NN
Pharmaceutical_NN
and_PHC
Chemical_NN
Company_NN
d._FW
d_LS
,_,
Impax_NN
Laboratories_NN
Inc._NN
._.
Eon_NN
Labs_NN
Manufacturing_GER
Inc._NN
and_PHC
Mylan_NN
Pharmaceuticals_NN
Inc._NN
._.
During_PIN
2001_CD
,_,
AstraZeneca_NN
filed_VBD
further_JJ
suits_NN
against_PIN
Torpharm_NN
,_,
Inc._NN
and_PHC
Zenith_NN
Goldline_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Ivax_NN
._.
The_DT
basis_NN
for_PIN
the_DT
proceedings_GER
is_VPRT
that_DEMO
the_DT
actions_NOMZ
of_PIN
all_QUAN
the_DT
companies_NN
infringe_VPRT
several_QUAN
patents_NN
relating_VBG [WZPRES]
to_TO
omeprazole_VB
Prilosec_NN
in_PIN
the_DT
US_FPP1
._.
The_DT
cases_NN
are_VPRT
proceeding_VBG
under_IN
the_DT
US_FPP1
Hatch-Waxman_NN
legislation_NOMZ
._.
AstraZeneca_NN
filed_VBD
additional_JJ
patent_NN
infringement_NOMZ
suits_NN
during_PIN
2001_CD
against_PIN
Andrx_NN
and_PHC
Genpharm_NN
in_PIN
respect_NN
of_PIN
one_CD
other_JJ
omeprazole_JJ
patent_NN
outside_PLACE
the_DT
Hatch-Waxman_NN
legislation_NOMZ
._.
The_DT
trial_NN
against_PIN
Andrx_NN
,_,
Genpharm_NN
,_,
Kremers_NN
Urban_NN
Development_NOMZ
Company_NN
and_PHC
Cheminor_NN
started_VBD
in_PIN
December_NN
2001_CD
and_CC
ended_VBN
in_PIN
July_NN
2002_CD
._.
In_PIN
October_NN
2002_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
ruled_VBD [SUAV]
that_THVC
two_CD
AstraZeneca_NN
patents_NN
230_CD
and_CC
505_CD
relating_VBG
to_PIN
the_DT
formulation_NOMZ
of_PIN
omeprazole_NN
are_VPRT [BEMA]
valid_PRED
until_IN
2007_CD
,_,
that_THVC
Andrx_NN
,_,
Genpharm_NN
and_PHC
Cheminor_NN
all_QUAN
infringed_VBN
both_DT
patents_NN
but_CC
that_THVC
Kremers_NN
Urban_NN
Development_NOMZ
Company_NN
did_VBD
not_XX0
infringe_VB
either_DT
patent_NN
._.
The_DT
court_NN
did_VBD
not_XX0
rule_NN
on_PIN
the_DT
281_CD
patent_NN
relating_VBG [WZPRES]
to_PIN
a_DT
manufacturing_GER
process_NN
for_PIN
omeprazole_JJ
formulations_NOMZ
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
AstraZeneca_NN
has_VPRT [PEAS]
sued_VBN
Andrx_NN
only_DWNT
._.
AstraZeneca_NN
has_VPRT [PEAS]
appealed_VBN
the_DT
judgement_NOMZ
with_PIN
regard_NN
to_PIN
non-infringement_JJ
and_CC
Kremers_NN
Urban_NN
Development_NOMZ
Company_NN
._.
Andrx_NN
,_,
Genpharm_NN
and_PHC
Cheminor_NN
have_VPRT [PEAS]
appealed_VBN
the_DT
decision_NN
with_PIN
regard_NN
to_PIN
infringement_NOMZ
and_PHC
validity_NOMZ
of_PIN
the_DT
patents_NN
._.
In_PIN
April_NN
2001_CD
,_,
Andrx_NN
filed_VBD
a_DT
case_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
against_PIN
AstraZeneca_NN
,_,
Merck_NN
&_CC
Co._NN
._.
Inc._NN
and_CC
the_DT
FDA_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
listing_GER
of_PIN
certain_JJ
patents_NN
in_PIN
the_DT
FDAs_NN
Orange_NN
Book_NN
was_VBD [BEMA]
improper_PRED
and_CC
constituted_VBD
violations_NOMZ
of_PIN
certain_JJ
provisions_NN
of_PIN
the_DT
Sherman_NN
Act_NN
,_,
the_DT
US_FPP1
federal_JJ
anti-trust_JJ
legislation_NOMZ
,_,
and_ANDC
a_DT
state_NN
statute_NN
analogous_JJ
to_PIN
the_DT
federal_JJ
anti-trust_JJ
laws_NN
._.
Andrx_NN
seeks_VPRT
injunctive_JJ
relief_NN
compelling_JJ
the_DT
parties_NN
to_TO
delist_VB
omeprazole-related_JJ
patents_NN
it_PIT
claims_VPRT [PUBV]
were_VBN [SPAU] [PASS]
improperly_RB
listed_VBN
in_PIN
the_DT
Orange_NN
Book_NN
and_CC
prohibiting_VBG
the_DT
defendants_NN
from_PIN
using_VBG
patents_NN
to_TO
delay_VB
the_DT
effective_JJ
date_NN
of_PIN
the_DT
FDAs_NN
approval_NN
of_PIN
Andrxs_NN
ANDA_NN
for_PIN
omeprazole_NN
._.
AstraZeneca_NN
and_PHC
Merck_NN
have_VPRT [PEAS]
filed_VBN
motions_NOMZ
to_TO
dismiss_VB
the_DT
case_NN
,_,
which_WDT [SERE]
are_VPRT
pending_VBG
._.
AstraZeneca_NN
and_PHC
Merck_NN
&_CC
Co._NN
._.
Inc._NN
were_VBD [PASS]
named_VBN
as_IN
defendants_NN
in_PIN
three_CD
class_NN
actions_NOMZ
:_:
two_CD
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
and_CC
one_CD
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
._.
The_DT
plaintiffs_NN
are_VPRT
consumers_NN
and_CC
third_JJ
party_NN
payers_NN
who_WP [WHSUB]
have_VPRT [PEAS]
alleged_VBN [PUBV]
that_THVC
they_TPP3
and_CC
others_NN
who_WP [WHSUB]
are_VPRT [SPAU] [PASS]
similarly_CONJ
situated_VBN
have_VPRT [PEAS]
been_VBN [PASS]
forced_VBN
to_TO
pay_VB
higher_JJ
prices_NN
for_PIN
omeprazole_NN
as_CONJ
a_NULL
result_NULL
of_PIN
agreements_NOMZ
that_TOBJ
AstraZeneca_NN
and_PHC
Merck_NN
entered_VBD
into_PIN
that_DEMP
resulted_VBD
in_PIN
unreasonable_JJ
restraints_NN
of_PIN
trade_NN
and_PHC
competition_NOMZ
._.
Furthermore_CONJ
,_,
the_DT
plaintiffs_NN
have_VPRT [PEAS]
alleged_VBN [PUBV]
that_THVC
AstraZeneca_NN
and_PHC
Merck_NN
engaged_VBD
in_PIN
conduct_NN
designed_VBN
to_TO
extend_VB
their_TPP3
monopoly_NN
power_NN
beyond_IN
the_DT
lawful_JJ
boundaries_NN
of_PIN
their_TPP3
patents_NN
._.
The_DT
plaintiffs_NN
are_VPRT
seeking_VBG
declarative_NN
,_,
equitable_JJ
and_PHC
injunctive_JJ
relief_NN
enjoining_VBG [SUAV] [WZPRES]
AstraZeneca_NN
and_PHC
Merck_NN
from_PIN
continuing_VBG
their_TPP3
alleged_VBN [PUBV]
illegal_JJ
activities_NOMZ
,_,
costs_NN
of_PIN
suit_NN
,_,
reasonable_JJ
attorneys_NN
fees_NN
and_PHC
expenses_NN
and_CC
any_QUAN
other_JJ
relief_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
by_PIN
the_DT
court_NN
._.
AstraZeneca_NN
filed_VBD
a_DT
motion_NOMZ
in_PIN
March_NN
2002_CD
to_TO
dismiss_VB
the_DT
two_CD
class_NN
actions_NOMZ
before_IN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
June_NN
2002_CD
._.
The_DT
plaintiffs_NN
did_VBD
not_XX0
appeal_NN
._.
The_DT
plaintiffs_NN
voluntarily_RB
dismissed_VBD
the_DT
New_NN
Jersey_NN
case_NN
also_RB
in_PIN
June_NN
2002_CD
._.
In_PIN
October_NN
2000_CD
,_,
the_DT
Federal_NN
Court_NN
of_PIN
Australia_NN
Full_NN
Court_NN
handed_VBD
down_RP
a_DT
patent_NN
ruling_NN
pertaining_VBG [WZPRES]
to_TO
omeprazole_VB
in_PIN
connection_NOMZ
with_PIN
a_DT
dispute_NN
between_PIN
AstraZeneca_NN
and_CC
the_DT
generic_JJ
company_NN
,_,
Alphapharm_NN
Pty_NN
Ltd._NN
._.
The_DT
court_NN
declared_VBD [PUBV]
that_THVC
AstraZenecas_NN
formulation_NOMZ
patent_NN
was_VBD [BEMA]
invalid_PRED
._.
In_PIN
November_NN
2001_CD
,_,
AstraZeneca_NN
applied_VBD
for_PIN
special_JJ
leave_NN
to_TO
appeal_VB
the_DT
decision_NN
to_PIN
the_DT
High_NN
Court_NN
of_PIN
Australia_NN
and_CC
this_DEMO
application_NOMZ
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
December_NN
2001_CD
._.
The_DT
appeal_NN
was_VBD [BYPA]
heard_VBN [PRIV]
by_PIN
the_DT
High_NN
Court_NN
in_PIN
May_POMD
2002_CD
and_CC
in_PIN
December_NN
2002_CD
the_DT
High_NN
Court_NN
reversed_VBD
the_DT
judgement_NOMZ
of_PIN
the_DT
lower_JJ
court_NN
._.
The_DT
High_NN
Court_NN
ruled_VBD [SUAV]
that_THVC
AstraZenecas_NN
formulation_NOMZ
patent_NN
is_VPRT [BEMA]
valid_PRED
and_CC
that_THVC
the_DT
case_NN
should_NEMD
be_VB [PASS]
returned_VBN
to_PIN
the_DT
lower_JJ
court_NN
for_PIN
determination_NOMZ
of_PIN
the_DT
remaining_VBG
issues_NN
._.
During_PIN
2000_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
granted_VBN [SUAV] [THATD]
interlocutory_JJ
injunctions_NOMZ
based_VBN [WZPAST]
on_PIN
certain_JJ
of_PIN
AstraZenecas_NN
omeprazole_NN
patents_NN
and_CC
supplementary_JJ
protection_NOMZ
certificates_NN
against_PIN
the_DT
generic_JJ
company_NN
,_,
Scandinavian_NN
AB_NN
Scand_NN
Pharm_NN
,_,
in_PIN
Sweden_NN
,_,
Denmark_NN
and_PHC
Norway_NN
._.
In_PIN
October_NN
2000_CD
,_,
the_DT
District_NN
Court_NN
of_PIN
Stockholm_NN
ruled_VBD [SUAV]
that_THVC
Scand_NN
Pharm_NN
had_VBD [PEAS]
infringed_VBN
one_CD
of_PIN
AstraZenecas_NN
supplementary_JJ
protection_NOMZ
certificates_NN
for_PIN
omeprazole_NN
._.
Scand_NN
Pharm_NN
has_VPRT [PEAS]
appealed_VBN
this_DEMO
decision_NN
._.
In_PIN
October_NN
2001_CD
,_,
Oslo_NN
City_NOMZ
Court_NN
in_PIN
Norway_NN
found_VBD [PRIV]
that_THVC
Scand_NN
Pharm_NN
had_VBD [PEAS]
infringed_VBN
AstraZenecas_NN
formulation_NOMZ
patent_NN
for_PIN
omeprazole_NN
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
the_DT
court_NN
declared_VBD [PUBV]
AstraZenecas_NN
formulation_NOMZ
patent_NN
valid_JJ
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
Norwegian_JJ
case_NN
,_,
Scand_NN
Pharm_NN
can_POMD
not_XX0
sell_VB
its_PIT
omeprazole_JJ
product_NN
in_PIN
Norway_NN
,_,
nor_SYNE
can_POMD
it_PIT
do_VB
so_RB
in_PIN
Sweden_NN
or_CC
Denmark_NN
pending_VBG [WZPRES]
the_DT
outcome_NN
of_PIN
the_DT
main_JJ
actions_NOMZ
in_PIN
the_DT
cases_NN
in_PIN
these_DEMO
countries_NN
._.
If_COND
the_DT
final_JJ
decisions_NN
in_PIN
these_DEMO
cases_NN
are_VPRT [BEMA]
against_PIN
AstraZeneca_NN
,_,
Scand_NN
Pharm_NN
may_POMD
claim_VB [PUBV]
damages_NN
for_PIN
lost_VBN
sales_NN
due_JJ
to_PIN
the_DT
interlocutory_JJ
injunctions_NOMZ
._.
com_NN
104_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
34_CD
Assets_NN
pledged_VBN [SUAV]
,_,
commitments_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
continued_VBD
In_PIN
March_NN
2002_CD
,_,
the_DT
Patents_NN
Court_NN
in_PIN
the_DT
UK_NN
handed_VBD
down_RP
a_DT
ruling_NN
invalidating_VBG [WZPRES]
certain_JJ
of_PIN
AstraZenecas_NN
formulation_NOMZ
patents_NN
for_PIN
omeprazole_NN
._.
AstraZeneca_NN
applied_VBD
for_PIN
leave_NN
to_TO
appeal_VB
the_DT
decision_NN
to_PIN
the_DT
Court_NN
of_PIN
Appeal_NN
and_CC
this_DEMO
application_NOMZ
was_VBD [PASS]
granted_VBN [SUAV]
._.
The_DT
appeal_NN
was_VBD [BYPA]
heard_VBN [PRIV]
by_PIN
the_DT
Court_NN
of_PIN
Appeal_NN
in_PIN
October_NN
2002_CD
and_CC
the_DT
court_NN
affirmed_VBD [PUBV]
the_DT
original_JJ
decision_NN
of_PIN
the_DT
Patents_NN
Court_NN
invalidating_VBG [WZPRES]
the_DT
formulation_NOMZ
patents_NN
._.
In_PIN
the_DT
Netherlands_NN
,_,
Pharmachemie_NN
BV_NN
has_VPRT [PEAS]
filed_VBN
a_DT
claim_NN
against_PIN
two_CD
AstraZeneca_NN
companies_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
AstraZeneca_NN
has_VPRT [PEAS]
misused_VBN
its_PIT
exclusive_JJ
rights_NN
in_PIN
the_DT
Netherlands_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
expiration_NOMZ
date_NN
for_PIN
AstraZenecas_NN
supplementary_JJ
protection_NOMZ
certificate_NN
for_PIN
omeprazole_NN
._.
AstraZeneca_NN
denies_VPRT [PUBV]
the_DT
allegations_NOMZ
and_CC
is_VPRT
defending_VBG
the_DT
case_NN
._.
Other_JJ
court_NN
cases_NN
relating_VBG [WZPRES]
to_TO
omeprazole_VB
patents_NN
are_VPRT
pending_VBG
worldwide_NN
._.
However_CONJ
,_,
the_DT
financial_JJ
impact_NN
if_COND
AstraZeneca_NN
loses_VPRT
is_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB
material_NN
._.
In_PIN
February_NN
2000_CD
,_,
the_DT
European_JJ
Commission_NN
commenced_VBD
an_DT
investigation_NOMZ
relating_VBG [WZPRES]
to_PIN
certain_JJ
omeprazole_NN
intellectual_JJ
property_NN
rights_NN
,_,
and_ANDC
associated_VBN
regulatory_JJ
and_CC
patent_NN
infringement_NOMZ
litigation_NOMZ
._.
The_DT
investigation_NOMZ
is_VPRT [BEMA]
pursuant_PRED
to_PIN
Article_NN
82_CD
of_PIN
the_DT
EC_NN
Treaty_NN
,_,
which_WDT [SERE]
prohibits_VPRT
an_DT
abuse_NN
of_PIN
a_DT
dominant_JJ
position_NOMZ
._.
The_DT
investigation_NOMZ
was_VBD [BYPA]
precipitated_VBN
by_PIN
a_DT
complaint_NN
by_PIN
a_DT
party_NN
to_PIN
a_DT
number_NN
of_PIN
patent_NN
and_CC
other_JJ
proceedings_GER
involving_VBG [WZPRES]
AstraZeneca_NN
and_CC
relates_VPRT
to_PIN
a_DT
limited_JJ
number_NN
of_PIN
European_JJ
countries_NN
._.
AstraZeneca_NN
has_VPRT
,_,
in_PIN
accordance_NN
with_PIN
its_PIT
corporate_JJ
policy_NN
,_,
co-operated_JJ
with_PIN
the_DT
Commission_NN
._.
AstraZeneca_NN
remains_VPRT
of_PIN
the_DT
view_NN
that_TOBJ
the_DT
complaint_NN
is_VPRT [BEMA]
unfounded_PRED
and_CC
that_THVC
it_PIT
has_VPRT [PEAS]
complied_VBN
with_PIN
all_QUAN
relevant_JJ
competition_NOMZ
laws_NN
._.
In_CONJ
particular_NULL
,_,
it_PIT
considers_VPRT [PRIV]
that_THVC
the_DT
matters_NN
raised_VBN [WZPAST]
by_PIN
the_DT
complaint_NN
are_VPRT [SPAU] [PASS]
more_EMPH
properly_RB
dealt_VBN
with_PIN
by_PIN
the_DT
courts_NN
in_PIN
the_DT
context_NN
of_PIN
the_DT
litigation_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
complainant_NN
is_VPRT [PASS]
involved_VBN
._.
The_DT
Commission_NN
has_VPRT [SPAU] [PEAS]
recently_TIME
requested_VBN [SUAV]
certain_JJ
factual_JJ
patent_NN
and_CC
regulatory_JJ
information_NOMZ
from_PIN
AstraZeneca_NN
and_PHC
AstraZeneca_NN
will_PRMD
continue_VB
to_TO
co-operate_VB
with_PIN
the_DT
Commission_NN
._.
Zoladex_NN
goserelin_NN
acetate_NN
implant_VPRT
investigation_NOMZ
The_DT
US_FPP1
Department_NOMZ
of_PIN
Justice_NN
has_VPRT [PEAS]
been_VBN
conducting_VBG
a_DT
civil_JJ
and_PHC
criminal_JJ
investigation_NOMZ
into_PIN
the_DT
sale_NN
and_PHC
marketing_GER
of_PIN
Zoladex_NN
goserelin_NN
acetate_NN
implant_VPRT
._.
The_DT
investigation_NOMZ
was_VBD [BYPA]
prompted_VBN
by_PIN
the_DT
filing_NN
of_PIN
a_DT
qui_FW
tam_FW
complaint_NN
by_PIN
a_DT
private_JJ
party_NN
in_PIN
1997_CD
and_CC
involves_VPRT
allegations_NOMZ
of_PIN
improper_JJ
submissions_NN
of_PIN
claims_NN
to_PIN
the_DT
Medicare_NN
and_PHC
Medicaid_NN
programs_NN
._.
Plendil_NN
felodipine_NN
In_PIN
August_NN
2000_CD
,_,
AstraZeneca_NN
LP_NN
received_VBD
a_DT
letter_NN
from_PIN
Mutual_JJ
Pharmaceutical_NN
Co._NN
._.
Inc._NN
informing_VBG [WZPRES]
AstraZeneca_NN
of_PIN
Mutuals_NN
intention_NOMZ
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
AstraZenecas_NN
felodipine_NN
extended_VBD
release_NN
tablets_NN
Plendil_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patent_NN
covering_VBG [WZPRES]
the_DT
extended_JJ
release_NN
formulation_NOMZ
._.
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
Mutual_JJ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
._.
Mutual_JJ
responded_VBD
and_PHC
filed_VBD
counterclaims_NN
alleging_VBG [PUBV] [WZPRES]
non-infringement_JJ
and_CC
invalidity_NOMZ
._.
Expert_NN
discovery_NN
is_VPRT [BEMA]
due_PRED
to_TO
close_VB
in_PIN
March_NN
2003_CD
._.
A_DT
trial_NN
date_NN
has_VPRT [PEAS]
not_XX0
yet_RB
been_VBN [PASS]
set_VBN
._.
In_PIN
May_POMD
2001_CD
,_,
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
received_VBD
a_DT
similar_JJ
letter_NN
from_PIN
Zenith_NN
Goldline_NN
Pharmaceuticals_NN
,_,
Inc._NN
and_CC
in_PIN
July_NN
2001_CD
,_,
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
Zenith_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
._.
Zenith_NN
responded_VBD
and_PHC
filed_VBD
counterclaims_NN
alleging_VBG [PUBV] [WZPRES]
non-infringement_JJ
._.
Fact_NN
discovery_NN
is_VPRT [BEMA]
due_PRED
to_TO
close_VB
in_PIN
May_POMD
2003_CD
._.
Nolvadex_NN
tamoxifen_NN
AstraZeneca_NN
is_VPRT [BEMA]
a_DT
co-defendant_NN
with_PIN
Barr_NN
Laboratories_NN
,_,
Inc._NN
in_PIN
numerous_JJ
purported_JJ
class_NN
actions_NOMZ
filed_VBN [WZPAST]
in_PIN
federal_JJ
and_CC
state_NN
courts_NN
throughout_PIN
the_DT
US_FPP1
._.
All_QUAN
of_PIN
the_DT
state_NN
court_NN
actions_NOMZ
were_VBD [PASS]
removed_VBN
to_PIN
federal_JJ
court_NN
and_CC
have_VPRT [PEAS]
been_VBN [BEMA]
consolidated_PRED
,_,
along_IN
with_PIN
all_QUAN
of_PIN
the_DT
cases_NN
originally_TIME
filed_VBN
in_PIN
federal_JJ
court_NN
,_,
in_PIN
a_DT
federal_JJ
multi-district_JJ
litigation_NOMZ
proceeding_VBG [WZPRES]
pending_VBG
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
New_NN
York_NN
._.
Some_QUAN
of_PIN
the_DT
cases_NN
were_VBD [BYPA]
filed_VBN
by_PIN
plaintiffs_NN
representing_VBG [WZPRES]
a_DT
putative_JJ
class_NN
of_PIN
consumers_NN
who_WP [WHSUB]
purchased_VBD
tamoxifen_NN
._.
The_DT
other_JJ
cases_NN
were_VBD [PASS]
filed_VBN
on_PIN
behalf_NN
of_PIN
a_DT
putative_JJ
class_NN
of_PIN
third_JJ
party_NN
payers_NN
including_VBG [WZPRES]
health_NN
maintenance_NN
organizations_NOMZ
,_,
insurers_NN
and_CC
other_JJ
managed_VBN
care_NN
providers_NN
and_PHC
health_NN
plans_NN
that_TSUB
have_VPRT [PEAS]
reimbursed_VBN
or_CC
otherwise_CONJ
paid_VBN
for_PIN
prescriptions_NOMZ
of_PIN
tamoxifen_NN
._.
The_DT
plaintiffs_NN
allege_VPRT [PUBV]
that_THVC
they_TPP3
paid_VBD
supra-competitive_JJ
and_PHC
monopolistic_JJ
prices_NN
for_PIN
tamoxifen_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
settlement_NOMZ
of_PIN
patent_NN
litigation_NOMZ
between_PIN
Zeneca_NN
and_PHC
Barr_NN
in_PIN
1993_CD
._.
The_DT
plaintiffs_NN
seek_VPRT
injunctive_JJ
relief_NN
,_,
treble_JJ
damages_NN
under_IN
the_DT
anti-trust_JJ
laws_NN
,_,
disgorgement_NOMZ
and_PHC
restitution_NOMZ
._.
In_PIN
April_NN
2002_CD
,_,
AstraZeneca_NN
filed_VBD
a_DT
motion_NOMZ
to_TO
dismiss_VB
the_DT
cases_NN
for_PIN
failure_NN
to_TO
state_VB [PUBV]
a_DT
cause_NN
of_PIN
action_NOMZ
._.
The_DT
courts_NN
decision_NN
is_VPRT [PASS]
awaited_VBN
._.
In_PIN
August_NN
2002_CD
,_,
AstraZenecas_NN
US_FPP1
distribution_NOMZ
agreement_NOMZ
with_PIN
Barr_NN
Laboratories_NN
,_,
Inc._NN
for_PIN
non-branded_JJ
tamoxifen_NN
expired_VBD
,_,
as_IN
did_VBD [PROD]
AstraZenecas_NN
patent_NN
for_PIN
Nolvadex_NN
tamoxifen_NN
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
a_DT
six_CD
month_NN
period_NN
of_PIN
market_NN
exclusivity_NOMZ
,_,
awarded_VBN [PASTP]
by_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
in_PIN
connection_NOMZ
with_PIN
the_DT
successful_JJ
completion_NOMZ
of_PIN
certain_JJ
paediatric_JJ
testing_GER
with_PIN
the_DT
product_NN
,_,
commenced_VBN
._.
Barr_NN
thereafter_RB
commenced_VBD
litigation_NOMZ
against_PIN
the_DT
FDA_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Columbia_NN
,_,
challenging_VBG [PRESP]
the_DT
FDAs_NN
refusal_NN
to_TO
grant_VB [SUAV]
Barr_NN
final_JJ
approval_NN
for_PIN
its_PIT
own_JJ
generic_JJ
tamoxifen_NN
prior_RB
to_PIN
expiration_NOMZ
of_PIN
AstraZenecas_NN
exclusivity_NOMZ
period_NN
._.
Barr_NN
also_RB
declined_VBD
AstraZenecas_NN
offer_NN
to_TO
extend_VB
the_DT
distribution_NOMZ
agreement_NOMZ
through_PIN
the_DT
end_NN
of_PIN
the_DT
exclusivity_NOMZ
period_NN
._.
Therefore_CONJ
,_,
in_PIN
October_NN
2002_CD
,_,
AstraZeneca_NN
began_VBD
shipping_VBG
its_PIT
own_JJ
non-branded_JJ
tamoxifen_NN
to_PIN
customers_NN
to_TO
ensure_VB [SUAV] [PRIV]
an_DT
uninterrupted_JJ
supply_NN
to_PIN
patients_NN
._.
In_PIN
December_NN
2002_CD
,_,
the_DT
Court_NN
held_VBD [PRIV]
that_THVC
Barr_NN
could_POMD
not_XX0
obtain_VB
final_JJ
FDA_NN
approval_NN
for_PIN
its_PIT
own_JJ
generic_JJ
tamoxifen_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
paediatric_JJ
exclusivity_NOMZ
for_PIN
Nolvadex_NN
._.
In_PIN
January_NN
2003_CD
,_,
Barr_NN
made_VBD
a_DT
claim_NN
that_TOBJ
AstraZeneca_NN
improperly_RB
thwarted_VBD
Barrs_NN
entry_NN
into_PIN
the_DT
tamoxifen_JJ
market_NN
and_CC
caused_VBD
Barr_NN
monetary_JJ
damages_NN
._.
com_NN
105_CD
Zestril_NN
lisinopril_NN
In_PIN
1986_CD
,_,
AstraZenecas_NN
predecessor_NN
company_NN
and_PHC
Merck_NN
&_CC
Co._NN
._.
Inc._NN
entered_VBD
into_PIN
licence_NN
agreements_NOMZ
under_IN
which_WDT
AstraZeneca_NN
was_VBD [PASS]
granted_VBN [SUAV]
the_DT
right_NN
to_TO
make_VB
,_,
use_VB
and_PHC
sell_VB
lisinopril_NN
Zestril_NN
,_,
in_PIN
return_NN
for_PIN
which_WDT [PIRE]
AstraZeneca_NN
agreed_VBD [SUAV] [PUBV]
to_TO
pay_VB
royalties_NN
to_PIN
Merck_NN
._.
In_PIN
April_NN
2002_CD
,_,
AstraZeneca_NN
commenced_VBD
arbitration_NOMZ
proceedings_GER
against_PIN
Merck_NN
under_IN
one_CD
of_PIN
the_DT
licence_NN
agreements_NOMZ
._.
In_PIN
the_DT
arbitration_NOMZ
,_,
AstraZeneca_NN
is_VPRT
seeking_VBG
repayment_NOMZ
of_PIN
approximately_RB
$_$
38m_CD
of_PIN
prior_JJ
royalty_NN
amounts_NN
and_CC
a_DT
prospective_JJ
reduction_NOMZ
in_PIN
the_DT
royalty_NN
rate_NN
going_VBG [WZPRES]
forward_RB
,_,
based_VBN [PASTP]
on_PIN
a_DT
provision_NN
of_PIN
the_DT
licence_NN
agreement_NOMZ
which_WDT [WHSUB]
reduces_VPRT
the_DT
royalty_NN
rate_NN
if_COND
sales_NN
of_PIN
lisinopril_NN
by_PIN
third_JJ
parties_NN
exceed_VPRT
a_DT
certain_JJ
level_NN
._.
The_DT
case_NN
is_VPRT [SPAU]
currently_RB
progressing_VBG
under_IN
the_DT
arbitration_NOMZ
rules_NN
of_PIN
the_DT
International_NN
Chamber_NN
of_PIN
Commerce_NN
._.
Retail_JJ
pharmacies_NN
drug_NN
purchasers_NN
actions_NOMZ
Since_OSUB
October_NN
1993_CD
,_,
several_QUAN
thousand_CD
retail_JJ
pharmacies_NN
and_CC
certain_JJ
retail_JJ
drug_NN
purchasers_NN
have_VPRT [PEAS]
commenced_VBN
purported_JJ
class_NN
actions_NOMZ
and_CC
individual_JJ
actions_NOMZ
in_PIN
various_JJ
federal_JJ
and_CC
state_NN
courts_NN
throughout_PIN
the_DT
US_FPP1
alleging_VBG [PUBV] [THATD] [WZPRES]
that_DEMP
,_,
with_PIN
respect_NN
to_PIN
brand_NN
name_NN
prescription_NOMZ
drugs_NN
,_,
manufacturers_NN
and_PHC
wholesalers_NN
engaged_VBN [WZPAST]
in_PIN
discriminatory_JJ
pricing_GER
practices_NN
,_,
discriminatory_JJ
discounting_GER
and_PHC
rebate_NN
practices_NN
,_,
and_ANDC
or_CC
conspired_VBN
with_PIN
one_CD
another_DT
to_TO
fix_VB
prices_NN
and_CC
artificially_RB
maintain_VPRT [PUBV]
high_JJ
prices_NN
to_PIN
the_DT
plaintiffs_NN
in_PIN
restraint_NN
of_PIN
trade_NN
and_PHC
commerce_NN
._.
More_EMPH
than_PIN
20_CD
brand_NN
name_NN
prescription_NOMZ
drug_NN
manufacturers_NN
and_CC
eight_CD
wholesalers_NN
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
defendants_NN
in_PIN
some_QUAN
or_CC
all_QUAN
of_PIN
these_DEMO
suits_NN
._.
AstraZeneca_NN
entered_VBD
into_PIN
a_DT
settlement_NOMZ
agreement_NOMZ
with_PIN
the_DT
retail_JJ
class_NN
plaintiffs_NN
whose_WPS [WHOBJ]
anti-trust_JJ
claims_NN
were_VBD [PASS]
consolidated_VBN
in_PIN
a_DT
federal_JJ
multidistrict_JJ
litigation_NOMZ
proceeding_VBG [WZPRES]
pending_VBG
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Northern_NN
District_NN
of_PIN
Illinois_NN
._.
AstraZeneca_NN
also_RB
reached_VBD
settlements_NOMZ
with_PIN
numerous_JJ
independent_JJ
and_CC
chain_NN
pharmacies_NN
that_TSUB
opted_VBD
out_PIN
of_PIN
the_DT
federal_JJ
class_NN
action_NOMZ
,_,
although_CONC
there_EX
are_VPRT
still_RB
actions_NOMZ
brought_VBN [WZPAST]
by_PIN
certain_JJ
chain_NN
and_CC
independent_JJ
pharmacies_NN
pending_VBG [WZPRES]
in_PIN
federal_JJ
court_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
settled_VBN
or_CC
been_VBN [PASS]
dismissed_VBN
from_PIN
all_QUAN
of_PIN
the_DT
state_NN
cases_NN
except_PIN
for_PIN
a_DT
consumer_NN
case_NN
pending_VBG [WZPRES]
in_PIN
state_NN
court_NN
in_PIN
Alabama_NN
._.
AstraZeneca_NN
has_VPRT [SPAU] [PEAS]
consistently_RB
denied_VBN [PUBV]
liability_NOMZ
and_CC
continues_VPRT
to_TO
believe_VB [PRIV] [THATD]
it_PIT
has_VPRT
meritorious_JJ
defences_NN
to_PIN
all_QUAN
of_PIN
these_DEMO
claims_NN
._.
However_CONJ
,_,
it_PIT
believes_VPRT [PRIV] [THATD]
that_DEMP
entering_VBG
into_PIN
these_DEMO
settlements_NOMZ
is_VPRT [BEMA]
the_DT
prudent_JJ
course_NN
of_PIN
action_NOMZ
given_VBN
the_DT
inherent_JJ
risks_NN
and_PHC
costs_NN
of_PIN
litigation_NOMZ
and_CC
to_TO
avoid_VB
further_JJ
business_NOMZ
disruption_NOMZ
._.
Average_JJ
wholesale_JJ
price_NN
class_NN
action_NOMZ
litigation_NOMZ
In_PIN
January_NN
2002_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
named_VBN
as_IN
a_DT
defendant_NN
along_IN
with_PIN
24_CD
other_JJ
pharmaceutical_JJ
manufacturers_NN
in_PIN
a_DT
class_NN
action_NOMZ
suit_NN
,_,
in_PIN
Massachusetts_NN
,_,
brought_VBD
on_PIN
behalf_NN
of_PIN
a_DT
putative_JJ
class_NN
of_PIN
plaintiffs_NN
alleged_VBN [PUBV]
to_TO
have_VB [PEAS]
overpaid_VBN
for_PIN
prescription_NOMZ
drugs_NN
as_CONJ
a_NULL
result_NULL
of_PIN
inflated_JJ
wholesale_JJ
list_NN
prices_NN
._.
The_DT
suit_NN
seeks_VPRT
to_TO
recover_VB
unspecified_JJ
damages_NN
._.
AstraZeneca_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
named_VBN
as_IN
a_DT
co-defendant_NN
with_PIN
various_JJ
other_JJ
pharmaceutical_JJ
manufacturers_NN
in_PIN
similar_JJ
class_NN
action_NOMZ
suits_NN
filed_VBN [WZPAST]
in_PIN
five_CD
other_JJ
states_NN
._.
Most_EMPH
of_PIN
these_DEMO
suits_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
with_PIN
the_DT
Massachusetts_NN
action_NOMZ
for_PIN
pre-trial_JJ
purposes_NN
pursuant_JJ
to_PIN
federal_JJ
multi-district_JJ
litigation_NOMZ
procedures_NN
._.
AstraZeneca_NN
believes_VPRT [PRIV]
that_THVC
it_PIT
has_VPRT
meritorious_JJ
defences_NN
to_PIN
all_QUAN
of_PIN
these_DEMO
claims_NN
._.
Additional_JJ
government_NOMZ
investigations_NOMZ
into_PIN
drug_NN
marketing_GER
practices_NN
As_IN
is_VPRT [BEMA]
true_PRED
for_PIN
most_EMPH
,_,
if_COND
not_XX0
all_QUAN
,_,
major_JJ
prescription_NOMZ
pharmaceutical_JJ
companies_NN
operating_VBG [WZPRES]
in_PIN
the_DT
US_FPP1
,_,
AstraZeneca_NN
is_VPRT [SPAU] [PASS]
currently_RB
involved_VBN
in_PIN
multiple_JJ
additional_JJ
US_FPP1
federal_JJ
and_CC
state_NN
criminal_JJ
and_PHC
civil_JJ
investigations_NOMZ
into_PIN
drug_NN
marketing_GER
and_PHC
pricing_GER
practices_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
received_VBN
subpoenas_NN
from_PIN
the_DT
US_FPP1
Attorneys_NN
Office_NN
in_PIN
Boston_NN
requesting_VBG [SUAV] [WZPRES]
production_NOMZ
of_PIN
documents_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
sale_NN
and_PHC
promotion_NOMZ
of_PIN
Prilosec_NN
to_PIN
the_DT
New_NN
England_NN
Medical_NN
Center_NN
in_PIN
Boston_NN
._.
A_DT
separate_JJ
subpoena_NN
from_PIN
the_DT
same_JJ
office_NN
requests_NN
documents_NOMZ
relating_VBG [WZPRES]
to_PIN
Prilosec_NN
purchasing_GER
and_PHC
services_NN
agreements_NOMZ
with_PIN
AdvancePCS_NN
,_,
the_DT
pharmacy_NN
benefits_NN
management_NOMZ
company_NN
._.
AstraZeneca_NN
has_VPRT [SPAU] [PEAS]
also_RB
received_VBN
a_DT
subpoena_NN
from_PIN
the_DT
Massachusetts_NN
Attorney_NN
Generals_NN
Office_NN
seeking_VBG [WZPRES]
documents_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
sale_NN
and_PHC
promotion_NOMZ
of_PIN
five_CD
products_NN
Prilosec_NN
,_,
Seroquel_NN
,_,
Rhinocort_NN
Aqua_NN
,_,
Toprol-XL_NN
and_PHC
Zestril_NN
within_PIN
Massachusetts_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
received_VBN
an_DT
investigative_JJ
demand_NN
from_PIN
the_DT
Missouri_NN
Attorney_NN
Generals_NN
Office_NN
seeking_VBG [WZPRES]
documents_NOMZ
and_PHC
information_NOMZ
relating_VBG [WZPRES]
to_PIN
agreements_NOMZ
with_PIN
drug_NN
retailers_NN
doing_VBG [WZPRES] [PROD]
business_NOMZ
within_PIN
Missouri_NN
._.
Most_EMPH
recently_TIME
,_,
AstraZeneca_NN
has_VPRT [PEAS]
received_VBN
a_DT
Civil_JJ
Investigative_NN
Demand_NN
from_PIN
the_DT
US_FPP1
Federal_NN
Trade_NN
Commission_NN
for_PIN
certain_JJ
information_NOMZ
concerning_VBG [WZPRES]
AstraZenecas_NN
advertising_GER
and_PHC
marketing_GER
of_PIN
Nexium_NN
._.
AstraZeneca_NN
is_VPRT
cooperating_VBG
with_PIN
these_DEMO
investigations_NOMZ
._.
It_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
to_TO
predict_VB [PUBV]
the_DT
outcome_NN
of_PIN
any_QUAN
of_PIN
these_DEMO
investigations_NOMZ
,_,
which_WDT [SERE]
could_POMD
include_VB
the_DT
payment_NOMZ
of_PIN
damages_NN
and_CC
the_DT
imposition_NOMZ
of_PIN
fines_NN
,_,
penalties_NN
and_CC
administrative_JJ
remedies_NN
._.
General_NN
AstraZeneca_NN
is_VPRT [SPAU] [PASS]
also_RB
involved_VBN
in_PIN
various_JJ
other_JJ
legal_JJ
proceedings_GER
considered_VBN [PRIV]
typical_JJ
to_PIN
its_PIT
businesses_NOMZ
,_,
including_VBG [PRESP]
some_QUAN
remaining_VBG
US_FPP1
retail_JJ
pharmacy_NN
anti-trust_JJ
class_NN
and_CC
individual_JJ
actions_NOMZ
outside_PLACE
the_DT
scope_NN
of_PIN
the_DT
settlements_NOMZ
described_VBN
above_PLACE
and_CC
litigation_NOMZ
relating_VBG [WZPRES]
to_PIN
employment_NOMZ
,_,
product_NN
liability_NOMZ
,_,
commercial_JJ
disputes_NN
,_,
infringement_NOMZ
of_PIN
intellectual_JJ
property_NN
rights_NN
and_CC
the_DT
validity_NOMZ
of_PIN
certain_JJ
patents_NN
._.
Although_CONC
there_EX
can_POMD
be_VB
no_SYNE
assurance_NN
regarding_VBG [WZPRES]
the_DT
outcome_NN
of_PIN
any_QUAN
of_PIN
the_DT
legal_JJ
proceedings_GER
or_CC
investigations_NOMZ
referred_VBD
to_PIN
in_PIN
this_DEMO
Note_NN
34_CD
to_PIN
the_DT
Financial_NN
Statements_NOMZ
,_,
AstraZeneca_NN
does_VPRT
not_XX0
expect_VB [PRIV]
them_TPP3
to_TO
have_VB
a_DT
materially_RB
adverse_JJ
effect_NN
on_PIN
AstraZenecas_NN
financial_JJ
position_NOMZ
or_CC
profitability_NOMZ
._.
com_NN
106_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
35_CD
Leases_NN
Total_NN
rentals_NN
under_IN
operating_VBG
leases_NN
charged_VBN
to_TO
profit_VB
and_CC
loss_NN
account_NN
were_VBD
as_IN
follows_VPRT
:_:
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Hire_NN
of_PIN
plant_NN
and_PHC
machinery_NN
23_CD
25_CD
15_CD
Other_JJ
96_CD
76 74 119 101_CD
89_CD
Commitments_NOMZ
under_IN
operating_VBG
leases_NN
to_TO
pay_VB
rentals_NN
during_PIN
the_DT
year_NN
following_VBG [WZPRES]
the_DT
year_NN
of_PIN
these_DEMO
Financial_NN
Statements_NOMZ
analyzed_VBD
according_VBG
to_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
each_QUAN
lease_NN
expires_VPRT
were_VBD
as_IN
follows_VPRT
:_:
Land_NN
and_PHC
buildings_GER
Other_JJ
assets_NN
2002 2001 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Expiring_GER
within_PIN
one_CD
year_NN
5_CD
5_CD
11_CD
12_CD
Expiring_GER
in_PIN
years_NN
two_CD
to_PIN
five_CD
25_CD
37_CD
15_CD
13_CD
Expiring_VBG
thereafter_RB
32_CD
25_CD
2_CD
2_CD
62_CD
67_CD
28_CD
27_CD
The_DT
future_NN
minimum_NN
lease_NN
payments_NOMZ
under_IN
operating_VBG
leases_NN
that_TSUB
have_VPRT
initial_JJ
or_CC
remaining_VBG
terms_NN
in_PIN
excess_NN
of_PIN
one_CD
year_NN
at_PIN
31_CD
December_NN
2002_CD
were_VBD
as_IN
follows_VPRT
:_:
Operating_VBG
leases_NN
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD
Obligations_NOMZ
under_IN
leases_NN
comprise_VPRT
Rentals_NN
due_JJ
within_PIN
one_CD
year_NN
90_CD
94_CD
Rentals_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
After_IN
five_CD
years_NN
from_PIN
balance_NN
sheet_NN
date_NN
94_CD
97_CD
From_PIN
four_CD
to_PIN
five_CD
years_NN
21_CD
20_CD
From_PIN
three_CD
to_PIN
four_CD
years_NN
27_CD
21_CD
From_PIN
two_CD
to_PIN
three_CD
years_NN
38_CD
25_CD
From_PIN
one_CD
to_PIN
two_CD
years_NN
47 35 227 198_CD
317_CD
292_CD
The_DT
Group_NN
had_VBD
no_SYNE
commitments_NOMZ
2001_CD
$_$
nil_JJ
under_IN
finance_NN
leases_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
which_WDT [WHSUB]
were_VBD [BEMA]
due_PRED
to_TO
commence_VB
thereafter_RB
._.
com_NN
107_CD
36_CD
Statutory_NN
and_CC
other_JJ
information_NOMZ
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Statutory_JJ
audit_NN
fees_NN
KPMG_NN
Audit_NN
Plc_NN
3.5_CD
2.5_CD
3.2_CD
Others_NN
0.1_CD
0.1_CD
3.6_CD
2.6_CD
3.2_CD
Fees_NN
for_PIN
other_JJ
services_NN
KPMG_NN
Audit_NN
Plc_NN
and_PHC
associates_NN
UK_NN
0.4_CD
3.2_CD
8.9_CD
Worldwide_NN
3.1_CD
2.0_CD
5.0_CD
3.5_CD
5.2_CD
13.9_CD
Non_NN
statutory_JJ
audit_NN
fees_NN
paid_VBN [WZPAST]
to_PIN
KPMG_NN
Audit_NN
Plc_NN
and_CC
its_PIT
associates_NN
were_VBD [BEMA]
in_PIN
relation_NOMZ
to_PIN
other_JJ
assurance_NN
services_NN
$_$
1.5_CD
m_NN [BEMA]
2001_CD
$_$
1.8_CD
m_NN
:_:
taxation_NOMZ
$_$
1.8_CD
m_NN [BEMA]
2001_CD
$_$
2.1_CD
m_NN
:_:
and_ANDC
other_JJ
non_NN
audit_NN
services_NN
$_$
0.2_CD
m_NN [BEMA]
2001_CD
$_$
1.3_CD
m._NN
In_CONJ
addition_NULL
to_PIN
the_DT
above_PLACE
,_,
in_PIN
2000_CD
KPMG_NN
Audit_NN
Plc_NN
and_CC
its_PIT
associates_NN
charged_VBN
fees_NN
for_PIN
other_JJ
services_NN
of_PIN
$_$
8.0_CD
m_NN
that_TSUB
were_VBD [BYPA]
borne_VBN
by_PIN
Syngenta_NN
AG_NN
in_PIN
relation_NOMZ
to_PIN
its_PIT
demerger_NN
from_PIN
AstraZeneca_NN
._.
The_DT
charge_NN
for_PIN
the_DT
statutory_JJ
audit_NN
of_PIN
the_DT
Company_NN
,_,
AstraZeneca_NN
PLC_NN
,_,
was_VBD
$_$
1,600_CD
2001_CD
$_$
1,600_CD
,_,
2000_CD
$_$
1,600_CD
._.
KPMG_NN
Audit_NN
Plc_NN
were_VBD [BEMA]
sole_JJ
auditors_NN
to_PIN
AstraZeneca_NN
in_PIN
2002_CD
and_CC
2001_CD
._.
The_DT
bulk_NN
of_PIN
fees_NN
for_PIN
other_JJ
services_NN
charged_VBN [WZPAST]
by_PIN
KPMG_NN
Audit_NN
Plc_NN
and_CC
its_PIT
associates_NN
aside_RB
from_PIN
the_DT
Zeneca_NN
Agrochemicals_NN
demerger_NN
and_CC
associated_VBN
restructuring_GER
work_NN
were_VBD [PASS]
incurred_VBN
in_PIN
the_DT
early_TIME
months_NN
of_PIN
2000_CD
,_,
completing_VBG [PRESP]
1999_CD
integration_NOMZ
projects_NN
._.
Related_VBN
party_NN
transactions_NOMZ
The_DT
Group_NN
had_VBD
no_SYNE
material_NN
related_VBN
party_NN
transactions_NOMZ
which_WDT [WHSUB]
might_POMD [SPAU]
reasonably_RB
be_VB [PASS]
expected_VBN [PRIV]
to_TO
influence_VB
decisions_NN
made_VBN [WZPAST]
by_PIN
the_DT
users_NN
of_PIN
these_DEMO
Financial_NN
Statements_NOMZ
._.
Subsequent_JJ
events_NN
No_SYNE
significant_JJ
change_NN
has_VPRT [PEAS]
occurred_VBN
since_OSUB
the_DT
date_NN
of_PIN
the_DT
annual_JJ
Financial_NN
Statements_NOMZ
._.
com_NN
108_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
37_CD
Company_NN
information_NOMZ
Company_NN
Balance_NN
Sheet_NN
At_PIN
31_CD
December_NN
2002_CD
2001_CD
Notes_NN
$_$
m_CD
$_$
m_CD [PASS]
Fixed_VBN
assets_NN
Fixed_VBN
asset_NN
investments_NOMZ
37_CD
7,236_CD
6,736_CD
7,236_CD
6,736_CD
Current_JJ
assets_NN
Debtors_NN
amounts_NN
owed_VBN [WZPAST]
by_PIN
subsidiaries_NN
27,104_CD
27,998_CD
Total_JJ
assets_NN
34,340_CD
34,734_CD
Creditors_NN
due_JJ
within_PIN
one_CD
year_NN
Non-trade_JJ
creditors_NN
37_CD
2,961_CD
835_CD
2,961_CD
835_CD
Net_JJ
current_JJ
assets_NN
24,143_CD
27,163_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
31,379_CD
33,899_CD
Creditors_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Loans_NN
owed_VBD
to_PIN
subsidiaries_NN
37 295 590_CD
Net_JJ
assets_NN
31,084_CD
33,309_CD
Capital_NN
and_PHC
reserves_NN
Called-up_JJ
share_NN
capital_NN
38 429 436_CD
Share_NN
premium_NN
account_NN
37 403 334_CD
Capital_NN
redemption_NOMZ
reserve_NN
37_CD
16_CD
9_CD
Other_JJ
reserves_NN
37_CD
1,841_CD
2,239_CD
Profit_NN
and_PHC
loss_NN
account_NN
37_CD
28,395_CD
30,291_CD
Shareholders_NN
funds_NN
equity_NOMZ
interests_NN
31,084_CD
33,309_CD
The_DT
financial_JJ
statements_NOMZ
on_PIN
pages_NN
58_CD
to_PIN
122_CD
were_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
on_PIN
30_CD
January_NN
2003_CD
and_CC
were_VBD [PASS]
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
Sir_NN
Tom_NN
McKillop_NN
Jonathan_NN
Symonds_NN
Director_NN
Director_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
109_CD
37_CD
Company_NN
information_NOMZ
continued_VBD
Deferred_JJ
taxation_NOMZ
The_DT
parent_NN
company_NN
had_VBD
no_SYNE
deferred_JJ
tax_NN
assets_NN
or_CC
liabilities_NOMZ
actual_JJ
or_CC
potential_JJ
at_PIN
31_CD
December_NN
2002_CD
._.
Investments_NOMZ
in_PIN
subsidiaries_NN
Fixed_VBN
asset_NN
investments_NOMZ
Shares_NN
Loans_NN
Total_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cost_NN
at_PIN
beginning_GER
of_PIN
year_NN
6,145_CD
591_CD
6,736_CD
Additions_NOMZ
500_CD
500_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2002_CD
6,645_CD
591_CD
7,236_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2001_CD
6,145_CD
591_CD
6,736_CD
Non-trade_JJ
creditors_NN
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
Short_JJ
term_NN
borrowings_GER
unsecured_JJ
3_CD
3_CD
Other_JJ
creditors_NN
50_CD
4_CD
Amounts_NN
owed_VBN [WZPAST]
to_PIN
subsidiaries_NN
2,100_CD
8_CD
Dividends_NN
to_PIN
Shareholders_NN
808_CD
820_CD
2,961_CD
835_CD
Loans_NN
owed_VBD
to_PIN
subsidiaries_NN
Repayment_NOMZ
2002_CD
2001_CD
Dates_NN
$_$
m_CD
$_$
m_CD [BEMA]
Loans_JJ
unsecured_JJ
US_FPP1
dollars_NN
6.58_CD
%_NN
loan_NN
2003 295 295_CD
7.2_CD
%_NN
loan_NN
2023 295 295_CD
Total_JJ
loans_NN
590_CD
590_CD
Loans_NN
or_CC
instalments_NOMZ
thereof_RB
are_VPRT [BEMA]
repayable_PRED
After_IN
five_CD
years_NN
from_PIN
balance_NN
sheet_NN
date_NN
295_CD
295_CD
From_PIN
two_CD
to_PIN
five_CD
years_NN
From_PIN
one_CD
to_PIN
two_CD
years_NN
295_CD
Total_JJ
unsecured_JJ
295_CD
590_CD
Total_JJ
due_JJ
within_PIN
one_CD
year_NN
295_CD
Total_JJ
loans_NN
590_CD
590_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
110_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
37_CD
Company_NN
information_NOMZ
continued_VBD
Share_NN
Capital_NN
Profit_NN
premium_NN
redemption_NOMZ
Other_JJ
and_CC
loss_NN
2002_CD
2001_CD
Reserves_NN
account_VPRT
reserve_NN
reserves_NN
account_VPRT
Total_JJ
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
At_PIN
beginning_GER
of_PIN
year_NN
334_CD
9_CD
2,239_CD
30,291_CD
32,873_CD
32,759_CD
Net_JJ
profit_NN
for_PIN
the_DT
year_NN
102_CD
102_CD
2,314_CD
Dividends_NN
398_CD
808_CD
1,206_CD
1,225_CD
Share_NN
re-purchase_NN
7_CD
1,190_CD
1,183_CD
1,074_CD
Share_NN
premiums_NN
69_CD
69_CD
99_CD
At_PIN
end_NN
of_PIN
year_NN
403_CD
16_CD
1,841_CD
28,395_CD
30,655_CD
32,873_CD
Distributable_JJ
reserves_NN
at_PIN
end_NN
of_PIN
year_NN
443_CD
1,614_CD
2,057_CD
1,623_CD
As_IN
permitted_VBN
by_PIN
section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
the_DT
Company_NN
has_VPRT [PEAS]
not_XX0
presented_VBN
its_PIT
profit_NN
and_PHC
loss_NN
account_NN
._.
At_PIN
31_CD
December_NN
2002_CD
$_$
26,781_CD
m_NN [BEMA]
31_CD
December_NN
2001_CD
$_$
29,440_CD
m_NN [BEMA]
of_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
was_VBD [BEMA]
not_XX0
available_PRED
for_PIN
distribution_NOMZ
._.
The_DT
majority_NOMZ
of_PIN
this_DEMO
non-distributable_JJ
amount_NN
relates_VPRT
to_TO
profit_VB
arising_VBG
on_PIN
the_DT
sale_NN
of_PIN
Astra_NN
AB_NN
to_PIN
a_DT
subsidiary_NN
in_PIN
1999_CD
,_,
which_WDT [SERE]
becomes_VPRT
distributable_JJ
as_IN
the_DT
underlying_VBG
receivable_NN
is_VPRT [PASS]
settled_VBN
in_PIN
cash_NN
._.
During_PIN
2002_CD
,_,
$_$
2,659_CD
m_NN [BEMA]
of_PIN
the_DT
profit_NN
was_VBD [BYPA]
realized_VBN [PRIV]
by_PIN
repayment_NOMZ
._.
Subsequent_JJ
to_PIN
the_DT
year_NN
end_NN
a_DT
further_JJ
$_$
825m_CD
was_VBD [PASS]
repaid_VBN
on_PIN
23_CD
January_NN
2003_CD
resulting_VBG
in_PIN
additional_JJ
distributable_JJ
reserves_NN
not_XX0
included_VBD
in_PIN
the_DT
figures_NN
above_PLACE
._.
Included_VBN [PASTP]
in_PIN
other_JJ
reserves_NN
is_VPRT [BEMA]
a_DT
special_JJ
reserve_NN
of_PIN
$_$
157m_CD
,_,
arising_VBG [PRESP]
on_PIN
the_DT
redenomination_NOMZ
of_PIN
share_NN
capital_NN
in_PIN
1999_CD
._.
2002_CD
2001_CD
Reconciliation_NOMZ
of_PIN
movement_NOMZ
in_PIN
shareholders_NN
funds_NN
$_$
m_CD
$_$
m_CD
Shareholders_NN
funds_NN
at_PIN
beginning_GER
of_PIN
year_NN
33,309_CD
33,201_CD
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
102_CD
2,314_CD
Dividends_NN
1,206_CD
1,225_CD
Issues_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
69_CD
99_CD
Re-purchase_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
1,190_CD
1,080_CD
Net_JJ
reduction_NOMZ
in_CONJ
addition_NULL
to_PIN
shareholders_NN
funds_NN
2,225_CD
108_CD
Shareholders_NN
funds_NN
at_PIN
end_NN
of_PIN
year_NN
31,084_CD
33,309_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Financial_NN
Statements_NOMZ
www_NN
._.
com_NN
111_CD
38_CD
Called-up_JJ
share_NN
capital_NN
of_PIN
parent_NN
company_NN
Allotted_NN
,_,
called-up_JJ
Authorised_NN
and_CC
fully_AMP
paid_VBN
2002 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Ordinary_NN
Shares_NN
$_$
0.25_CD
each_QUAN
429 429 436_CD
Unissued_NN
Ordinary_NN
Shares_NN
$_$
0.25_CD
each_QUAN
171_CD
Redeemable_JJ
Preference_NN
Shares_NN
50,000_CD
600 429 436_CD
The_DT
Redeemable_JJ
Preference_NN
Shares_NN
carry_VPRT
limited_JJ
class_NN
voting_NN
rights_NN
and_CC
no_SYNE
dividend_NN
rights_NN
._.
This_DEMO
class_NN
of_PIN
shares_NN
is_VPRT [BEMA]
capable_PRED
of_PIN
redemption_NOMZ
at_PIN
par_NN
at_PIN
the_DT
option_NOMZ
of_PIN
the_DT
Company_NN
on_PIN
the_DT
giving_VBG
of_PIN
seven_CD
days_NN
written_VBN [PUBV]
notice_NN
to_PIN
the_DT
registered_VBN
holder_NN
of_PIN
the_DT
shares_NN
._.
The_DT
movements_NOMZ
in_PIN
share_NN
capital_NN
during_PIN
the_DT
year_NN
can_POMD
be_VB [PASS]
summarised_VBN
as_IN
follows_VPRT
:_:
No._NN
._.
of_PIN
shares_NN
million_CD
$_$
m_CD [BEMA]
At_PIN
beginning_GER
of_PIN
year_NN
1,745_CD
436_CD
Issues_NN
of_PIN
shares_NN
2_CD
Re-purchase_NN
of_PIN
shares_NN
28_CD
7_CD
At_PIN
31_CD
December_NN
2002_CD
1,719_CD
429_CD
Share_NN
buy-back_NN
During_PIN
the_DT
year_NN
the_DT
Company_NN
purchased_VBD
,_,
and_ANDC
subsequently_TIME
canceled_VBN
,_,
28,386,560_CD
Ordinary_NN
Shares_NN
at_PIN
an_DT
average_JJ
price_NN
of_PIN
2785_CD
pence_NN
per_PIN
share_NN
for_PIN
a_DT
consideration_NOMZ
,_,
including_VBG
expenses_NN
,_,
of_PIN
$_$
1,190_CD
m._FW
The_DT
excess_NN
of_PIN
the_DT
consideration_NOMZ
over_IN
the_DT
nominal_JJ
value_NN
has_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
against_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
._.
Share_NN
schemes_NN
A_DT
total_NN
of_PIN
1,737,401_CD
shares_NN
were_VBD [PASS]
issued_VBN
during_PIN
the_DT
year_NN
in_PIN
respect_NN
of_PIN
share_NN
schemes_NN
._.
Details_NN
of_PIN
movements_NOMZ
in_PIN
the_DT
number_NN
of_PIN
shares_NN
under_IN
option_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
Note_NN
33_CD
:_:
details_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
Directors_NN
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
._.
